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ABSTRACT:
Three decades into the HIV-I pandemic, it is increasingly apparent that generalized
immune activation is a key pathogenic determinant of AIDS. Studies of immune
activation, in the setting of HIV-I, have focused primarily on the adaptive immune
response despite the role of monocytes and macrophages as key regulators of inflammatory
responses. In this thesis, I focused on the relationships between mononuclear phagocyte
activation and HIV-I pathogenesis, both in vitro using model systems and in vivo in
African patients with AIDS. Using a monocyte-derived-macrophage (MOM) model of MI
and M2a polarization, I found that activation transiently altered the capacity of
macrophages to support productive HIV-I infection and that the level of viral inhibition
was dependant on the polarization phenotype. MI and M2a polarized MDM also differed
in the capacity to transmit virus to CD4+ T cells with M2a cells efficiently transmitting
HIV-I via a DC-SIGN dependant mechanism. In a cohort of treatment-naive AIDS
patients, in vivo activation of circulating monocytes and intestinal macrophages was
strongly associated with HIV-l pathogenesis. Monocyte activation in these patients was
differentially regulated by HIV-l and circulating LPS (marker of microbial translocation)
and was associated with two clearly distinct activation profiles. At the tissue level, HIV-I
..was associated with alterations in intestinal macrophage distribution, frequency and
phenotype. In the colon, macrophage activation was negatively correlated with viral load
and positively correlated with microbial translocation suggesting that, although
inflammatory macrophages in the intestine may contribute to the control viral replication,
they may also enhance microbial translocation and systemic activation. In summary,
current findings add to current knowledge by showing that monocytes and macrophages
are not only primary targets of HIV-1 but they also contribute to HIV-1 pathogenesis by
playing a pivotal role in interactions occurring at the interface between immune activation,
microbial translocation and the development of AIDS.
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1.0 OVERVIEWOF THE HIV-l/AIDS PANDEMIC
1.0.1 Magnitude and Regional Differences
As the world enters its fourth decade of the acquired immunodeficiency syndrome
(AIDS) pandemic, a cumulative total of more than 60 million people have been infected
with the human immunodeficiency virus type 1 (HN-l) (Figure 1.1). Of the
approximately 33 million people currently living with HN-I/AIDS, 30.8 million are adults
and 2.2 million are children under the age of 15 (1). Advances in antiretroviral therapy
(ART) have reduced transmission rates and provided clinical relief to many HIV-l-
infected patients living in Europe, North America and other regions of the developed world
but the costs and toxicities of these treatments are substantial (2). While ART is becoming
more universally available, the HN-I/AIDS epidemic continues to evolve and expand in
some low- and middle-income countries. New infections continue to occur at a rate of 2.7
million per year and each year 2 million people in the developing world die of AIDS (1).
The worst affected region, sub-Saharan Africa, currently accounts for 68% of persons
living with HNIAIDS worldwide and for 76% of all deaths due to AIDS (1). Eight
countries in southern Africa have exceeded an overall prevalence rate of 15% and in South
Africa alone, more than 5 million people are infected (1).
Perhaps one of the most perplexing aspects of HN IAIDS has been the unequal
worldwide spread of the virus. In the industrialized world, the HN -1 epidemic was
initially concentrated in high-risk populations (men who have sex with men, injecting drug
users, commercial sex workers). Between 1981 and 2005, three quarters of newly reported
infections in the United States were among men who have sex with men (3). In contrast, in
sub-Saharan Africa the HIV-l epidemic is more generalized. As of 2007, approximately
61% of infected Africans were women who acquired their HN-l through heterosexual
intercourse (1). Unlike transmission pathways that are confined to specific high-risk
groups, heterosexual transmission targets a large self-sustaining population. As a
13
consequence, the AIDS epidemic in the developing world is composed of many sub-
epidemics characterized by different behavioral and biological properties.
1.0.2 The Virus: Its Origins and Salient Characteristics
HIV, the pathogen responsible for AIDS, is a member of the lentivirus family of
retroviruses. Two distinct types of HIV, HIV-l and HIV-2, have been shown to infect and
cause disease in humans. Phylogenetic analyses have revealed the simian origins of both
viruses and provided an understanding of the factors contributing to their cross-species
transmission (4). Available evidence indicates that the simian counterparts of HIV-l and
HIV-2 were introduced into the human population on at least seven different occasions (4).
HIV-2 appears to have been transmitted by sooty mangabeys, whereas chimpanzees are the
most probable source HIV-l (5). It is generally accepted that the main (M) group of HfV-I
viruses originated through a single cross-species transmission (4, 5) that occurred
approximately 50-80 years ago (6, 7) in Central West Africa (8). While controversy still
surrounds the exact mode of transmission to humans, the progenitors were probably passed
to human hunters through blood-borne transmission (9). Unlike HIV-1 which is found
globally, HIV-2 has a restricted distribution that is confined primarily to West Africa and
India (10). HIV-2 is also associated with significantly slower progression to immune
deficiency and lower transmission rates compared to HIV-1 (11).
HIV-l, the primary determinant driving the current AIDS pandemic, is a rapidly
evolving RNA virus. Similar to other RNA viruses, such as hepatitis C (HCV), the ability
of HIV-1 to mutate and escape immune detection is an integral part of the pathogenic
process that results in viral persistence, uncontrolled transmission and the emergence of
devastating pandemics (12). Despite their extensive functional and structural diversity,
many RNA viruses, including HIV-l, share the following properties: 1) a small genome (3
to 30 kb) with relatively few genes; 2) high mutation rates due to an error prone reverse
transcriptase (or replicase); 3) high production rates, in excess of 109 virions per days, and
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4) long-term persistence of infection in large numbers of affected persons. These properties
provide tremendous scope for the diversification, expansion and spread of a range of viral
variants. In the case of HIV-I, a double-stranded RNA virus, the ability to generate escape
mutants is further enhanced by frequent recombination between the two strands of RNA.
This extreme plasticity, which is of unprecedented proportions in the case of HIV-l,
influences the virus' immunogenicity, transmissibility and infectivity, and is a major
impediment to the development of an efficacious AIDS vaccine (13).
1.0.3 HIV-l Subtypes and their Geographic Distribution
As a result of a high evolutionary rate, HIV-I group M, the viruses that dominate
the global pandemic, have evolved into nine major subtypes (A-D, F-H, J and K) and 43
circulating inter-SUbtype recombinant forms (CRFs) (14-16). Within the A and F SUbtypes,
separate sub-clusters have been given the designations AI, A2, A3 and A4, and FI and F2
(16). Subtype B, the first recognized and most studied variant of HIV-I, continues to
predominate in North America, Western and Central Europe, and Australia. This subtype
accounts for only a small fraction of the worldwide pandemic «15%) (16). On a global
scale, the most prevalent and frequently transmitted SUbtypes are C, A (sub-subtype AI)
and the AlG recombinant, CRF02_AG (Figure 1.2) (16). Subtype C viruses are
responsible for the explosive outbreaks of HIV-1 in southern Africa, India and China. CID
recombinants are common in Tanzania, and B/C recombinants are prevalent among
injecting drug users in China (17). Other subtypes are similarly restricted in their
geographic distribution. Subtype D is limited primarily to East and Central Africa with
sporadic cases being detected in Southern and Western Africa (18). Interestingly, E has
never materialized alone, but rather appears as an AlE recombinant that is present in Asia
and some parts of Africa (16). Subtypes H, J and K are relatively rare compared to other
subtypes and are typically localized to isolated areas. Although these general
classifications are still helpful, increasing immigration and globalization are having a
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dramatic impact on the distribution of HIV-1 subtypes (18). As a result, ongoing attempts
to organize and classify HIV-1' s genetic variants based on phylogeny are becoming
increasingly difficult (16). At present, >40% of all new infections in Europe are of the non-
B African and Asian subtypes (16, 19).
1.0.4 Functional Implications of Subtype Diversity
The genetic variation within a given HIV-1 subtype typically ranges from 15% to
20%, whereas variation between subtypes is in the order of 25% to 35% (15). In contrast to
HeV where there are clear-cut differences, not only in the geographic distribution of
different viral subtypes but also in their transmission routes and response to therapy, the
biological and functional significance ofHIV-l subtype diversity remains elusive.
The impact of subtype diversity on disease progression has been the subject of
several international studies. Although the results have been somewhat discrepant, these
studies have suggested there may be important differences between subtypes (20, 21). For
example, a study of 54 female sex workers in Senegal found that women infected with
subtypes e, D and G had increased rates of disease progression relative to those infected
with subtype A (22). A larger study from Uganda found faster progression to death among
patients infected with subtype D relative to A (23). Similarly, a Kenyan study found
patients infected with subtype D had a higher mortality rate and a faster CD4+ decline
relative to those with subtype A and e (24). It has also been suggested that this increased
mortality may be due to the higher prevalence of dual-tropic isolates among subtype D
viruses (25). While it is difficult to design a comparative study, preliminary data suggests
that there may also be subtype-specific differences in transmission efficiency. A recent
study of pregnant women in Kenya suggested that e viruses may be more transmissible
than subtypes A and D due to increased shedding of HIV-l-infected cells in the vaginal
mucosa (16). Another recent study found that subtype e (relative to subtype B) had higher
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rates of mother to child transmission (MTCT) compared to non-C viruses (26). Although
interesting, it is unclear if these findings are relevant on a global scale.
1.1 VIRUS STRUCTURE ANDLIFE CYCLE
1.1.1 Virion Structure and Composition
Lentiviruses are particularly skillful at evading the host immune system. They are
characterized by prolonged periods of disease progression, have high mutations rates, are
transmitted exclusively by the exchange of body fluids and most importantly, cannot be
easily eradicated from infected cells. Lentiviruses also differ from other viruses in their
ability to infect non-dividing cells (27). At the structural level, HIV-I virions are
composed of a nucleoprotein core surrounded by a proteolipid envelope containing surface
(gpI20) and transmembrane (gp4I) glycoproteins (28). The core of the virus contains an
electron dense conical p24 capsid containing two copies of viral genomic RNA held
together by RNA-binding proteins and multiple complementary nucleic acid regions (27).
The viral enzymes (reverse transcriptase, RNase Hand integrase), tRNA and the accessory
proteins required for viral infectivity, cDNA synthesis and virion assembly during budding
from the cell surface, are also found in the core of the viral particle (27).
In common with all viruses, the HIV-1 genome encodes three major genes; gag, pol
and env. The gag gene encodes a Pr55gagprecursor polyprotein which, when cleaved by
HIV-I protease, produces matrix (MA or pI7), capsid (CA or p24), nucleocapsid (Ne or
p7), p6 and two spacer proteins, pI and p2 (27). The viral enzymes are formed by cleavage
of PrI60gag-pol,a polyprotein derived by ribosomal frame-shifting (27). The envelope (Env)
glycoproteins, gp120 and gp4I, are also synthesized as a polyprotein precursor, gpI60.
However, unlike Gag and Pol, Env is processed by a cellular protease during trafficking to
the cell surface, a process that results in the generation of the surface gpI20 and trans-
membrane gp 41 proteins (27). In addition to enzymes and structural proteins, HIV-1 also
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encodes a number of regulatory and accessory proteins. Tat is a critical transcriptional
activator of the LTR region (29), whereas Rev plays a major role in the transport of viral
RNAs from the nucleus to the cytoplasm (30). Vpu, Vif, Vpr and Nef have been termed
"accessory" or "auxiliary" proteins to reflect the fact that they are not uniformly required
for virus replication. Interestingly Vpu promotes CD4 degradation, Vif overcomes the
inhibitory effects of host cell factors (namely APOBEC), Vpr promotes the infection of
macrophages and Nef promotes the down regulation of surface CD4 and class IMHC
expression, blocks apoptosis and enhances virion infectivity (31).
1.1.2 Membrane Fusion and Virus Entry
Entry of lentiviruses (including HIV-l) into host cells, closely resembles that of
other retroviruses and requires fusion of the viral envelope with the target cell membrane, a
process which allows the inner contents of the viral particle to gain access to the cytoplasm
(28). The first step in the entry process is initiated by the binding of HIV gp120 to CD4 on
the surface of target cells (32, 33). This interaction induces conformational changes in the
conserved core region of gp 120, leading to unmasking of the chemokine co-receptor
(CCRS or CXCR4) binding site (28, 34). Interaction with these chemokine co-receptors
promotes close apposition of the virus and cell membrane and results in further
conformational changes in the gpI20/gp41 complex, eventually activating gp41 (i.e.
allowing its exposure and insertion into the target cell membrane) (35). The gp41 protein
then experiences further structural re-organization into a six-helix bundle structure, a
process which changes the free energy state of the protein and provides the force required
for fusion, pore formation and entry of the viral capsid into the target cell (36, 37).
1.1.3 Tropism and Co-receptor Usage
HIV-l isolates vary in their co-receptor usage, and can use either CXCR4 (X4) or
CCR5 (R5) to enter cells. However, co-receptor use is not random and CCRS is the main
receptor used by the majority of isolates worldwide. Genetic differences in the V3 loop of
gpl20 are a major determinant of cellular tropism. Envelopes that interact with CCR5
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typically have a low number of positively charged V3 amino acids, whereas CXCR4-using
envelopes usually contain V3 sequences with an excess of positively charged amino acid
residues, most notably at positions 11 and/or 25 (38-41). Interestingly, R5X4 isolates have
a V3 charge pattern that is similar to X4 envelopes. The dual tropic properties of these
viruses are complex and involve multiple discontinuous regions of Env (42-44).
Historically, HN-l has been classified by its in vitro infection profile as either
monocyte-derived macrophage tropic (M-tropic)/non-syncytium inducing (NSI) or as T-
cell line tropic (T-tropic)/syncytium inducing (SI). M-tropiclNSI variants predominantly
use CCR5 for entry into macrophages and have been designated R5 viruses, whereas T-
tropic/SI variants predominantly use CXCR4 for entry into T-cell lines and have been
designated as X4 viruses (45). Dual tropic R5X4 viruses can infect both macrophages and
T-cells. This classification, however, is not completely accurate, as primary CD4+ T cells
can be infected by R5 viruses and some macrophages can be infected by some primary X4
isolates (46,47). In reality, the determinants of co-receptor usage are likely to be complex
and involve parameters of viral replication, host genetics and immune activation, in
addition to genetic changes in the HN-l envelope gene (48,49).
Interestingly, R5INSI viruses are preferentially transmitted to a new host, even
when the donor is infected with both R5 and X4 phenotypes (50). This phenomenon may
reflect the fact that macrophages are particularly abundant in mucosal membranes and that
they are less susceptible to CTL responses (51). As a result, R5 viruses can escape the
human immune system more efficiently than X4 viruses (51). In approximately 40-50% of
patients infected with subtype B, progression from asymptomatic to late-stage disease is
associated with a switch from R5 to X4, or R5X4 usage (52, 53). This switch in co-
receptor usage usually takes about 7 years to occur, involves amino acid changes in V3 and
is associated with a more rapid decline in CD4 T-cells and progression to AIDS. The
reason for the enhanced cytopathic effect of X4 viruses is not known, but may be due to
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altered replication kinetics and/or the ability of X4 strains to infect naive CD4+ T-cells in
addition of CD+CD45RO+ memory T-cells (54, 55). Accumulated evidence suggests the
conversion to an X4/SI phenotype occurs only once during the course of HIV-1 infection,
that the transition occurs abruptly and that R5X4 viruses may represent an intermediate in
the evolution between R5 and X4 viruses (56).
1.1.4 Uncoating and Viral Integration
HN -1 replication begins soon after fusion with the plasma membrane and the
release of the viral core into the cytoplasm of the target cell (Figure 1.3). During this
process, the viral capsid (CA) disassembles releasing the viral ribonucleoprotein complex
(RNP) (57, 58). This process, known as "uncoating", is critical for reverse transcription
and synthesis of the double-stranded viral DNA intermediate, as well as the formation of a
functional pre-integration complex (PIC). In the PIC, the reverse-transcribed HN -1 DNA
is present in a high molecular-weight nucleoprotein complex containing viral proteins
[integrase (IN), matrix protein (MA), reverse transcriptase (RT), nucleocapsid (NC), and
Vpr] (59-61). Although the structure of the PIC has not been well defined, it has been
suggested that the ends of the viral DNA are "tethered" by an assembly of proteins that
protect and prime the DNA for integration (62, 63). After entering the nucleus, integration
into the host genome is directed by cellular components of the PIC such as mobility group
protein HMO I(Y) (64, 65). Insertion of the viral genome occurs in genes that are highly
transcribed by RNA Pol II. This process is catalyzed by viral IN and involves both
terminal cleavage and ligation reactions (66, 67)
The ability of HN-I and other lentiviruses to infect non-dividing cells suggests
that their PIC can be actively transported into the nucleus. Current knowledge indicates
that nuclear import of the HN -1 PIC is an ATP-dependent process involving a nuclear
transport pathway and a viral nuclear localization signal (68). Other factors that may be
important for nuclear targeting of the PIC include the karyophilic IN, MA and Vpr proteins
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(69, 70), as well as a proviral structure known as the central DNA flap (71-73). Some
studies have suggested that CA protein may also play a role in the infection of non-
dividing cells, by serving as a link between uncoating and nuclear import of the PIC (74).
1.1.5 Viral Replication and Transcription
The transcription of HIV-1 proviral DNA is profoundly affected by the state of host
cell activation and is regulated by interactions between cellular transcription factors and
the HIV-l 5'-long terminal repeat (LTR) (75). This is due to the fact that a number of the
sequences present in the viral LTR closely resemble the promoter regions present in the
human genome. As a result of these similarities, HIV-1 is able to utilize the transcription
machinery of the host for viral gene expression and replication. The HIV-1 promoter is
divided into 3 distinct regions (76, 77). Two of these, the modulatory enhancer and core
promoter regions, are located upstream of the transcription start site. The third region, the
Trans-Activation Response region (TAR) lies downstream of the start point. The core
promoter region interacts with SPI and TATA binding proteins to mediate a basal level of
transcription (78). Enhancement of basal transcription can occur, either through
interactions between the virus-encoded Tat protein and TAR region of the viral LTR, or
through the binding of host transcriptional factors to the modulatory enhancer region (76,
77). The enhancer region contains at least 6 elements that bind different cellular factors,
the most studied being Nuclear-Factor-xls (NFKB) (75). The regulation of viral
transcription in cells of monocyte-macrophage lineage appears to be more complex than in
T cells. In monocytes and macrophages cellular activation can differentially affect viral
transcription depending on state of cellular differentiation (monocyte vs. macrophage) (79-
81). IL-4 and IL-13, for example, enhance viral replication in monocytes, but inhibit
replication in differentiated monocyte-derived macrophages (MDM) (260). Furthermore,
pro-inflammatory and immune modulating cytokines such as TNF-a., as well as gene
products of DNA viruses, can induce (or suppress) or HIV-l replication at both the
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transcriptional and post-transcriptional levels depending on whether stimulation occurs
before or after infection (78,82-84).
1.1.6 Assembly and Maturation of HIV-l Virions
The Gag polyprotein, Pr55Gag, directs the recruitment of all components required
for the efficient assembly and release of HN -1 virions (85, 86). All four domains of
Pr55Gag, matrix (MA), capsid (CA), nucleocapsid (NC) and p6, play an important role in
this process (87-90). The N-terminal myristic acid moiety of MA interacts with acid
phospholipids on the inner leaflet of the plasma membrane (89, 91); CA and NC promote
Gag-Gag interactions and the p6 domain of Gag stimulates virus release by interacting
with the endosomal sorting machinery (92, 93).
Although substantial progress has been made in understanding the viral and cellular
factors that are necessary for Pr55Gag membrane binding, multi-merization and virion
release, the intracellular site of HN-l assembly and the pathway of Gag-mediated
trafficking to the assembly site still remain controversial. Some studies have reported that
HN-l assembly occurs at the plasma membrane (94-96) whereas others have suggested
that virus assembly may take place in an endosomal compartment and that release of the
viral particles follows an exosomal pathway in which virus-containing endosomes fuse
with the plasma membrane releasing their contents (97-99). The endosomal model of virus
assembly has been of particular interest in the setting of HIV-I-infected macrophages.
Studies conducted in monocyte-derived macrophages (MDM) suggest that these cells
synthesize and accumulate virions in intracellular vacuoles that have the characteristics of
late endosomes or multivesicular bodies (MVB) [ie. they express markers for MHC II,
CD82 and the tetraspanins CD9, CD53, CD63 and CD81] that form part of large and
complex invaginated plasma membrane domain (100-104). HN-l particles stored in this
intracellular domain are protected from effector elements of the host immune system.
Other studies have shown these archived viruses remain infectious for prolonged periods
(ie. > 6 weeks) and can be subsequently transmitted across a transient adhesive contact, or
22
Virological Synapse (VS) (105). The VS is a multi-molecular complex that forms at the
interface between an HIV-I-infected macrophage (or dendritic cell) and an uninfected
CD4+ T cells (106-108). Formation of the synapse is driven by the interaction of HIV-I
gp120 on the donor cell and CD4/CCR5 or CD4/CXCR4 on the recipient cell and is
stabilized by cell-cell adhesion interactions (109).
1.2 HIVIMMUNOPATHOGENESIS
1.2.1 Changing Concepts in HIV-l Pathogenesis
Until recently, our understanding of HIV-l pathogenesis was based primarily on
changes in HIV-I viral load and CD4+ T cell numbers in the peripheral blood of patients
infected with SUbtypeB virus (110, 111). In this traditional view, acute HIV-I infection
was accompanied by a burst of plasma viremia and a transient but often unimpressive
decrease in CD4+ T cell counts. This was followed by a prolonged period of chronic
infection that typically lasts for 10 years. During this time there was a gradual but
profound loss of peripheral blood CD4+ T-cells (an average of 100 cells per J.LLof blood
per year) leading, ultimately, to collapse of the immune system. This prolonged disease
course, combined with studies showing high levels of HIV-I replication in CD4+ T cells in
lymph nodes, led to the "tap-drain" model of pathogenesis. In this model, CD4+ T cells
that were killed by the virus were continuously replaced by new cells generated in the
thymus, or through the homeostatic proliferation of peripheral CD4+ T cell pools (112,
113). Based on this model, progression to AIDS was attributed to a negative net balance in
cell death and replacement.
However, the question of whether HIV-I, on its own, could cause such a massive
loss of CD4+ T cells remained controversial. The main unresolved question related to
whether HIV-I replication directly killed CD4+ T cells or whether it acted indirectly by
inducing CD4+ T cell activation, with cell death being a normal consequence of this
process. Arguments against a direct cytolytic mechanism are that: 1) the number of
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productively infected CD4+ T cells in peripheral blood is very low (0.01-1 %); 2) HIV-l-
mediated destruction of CD4+ T cells rarely occurs in vivo and 3) high levels of SIV
replication in sooty mangabeys does not lead to CD4+ T cell depletion and AIDS (114).
Collectively, these data suggest that factors other than virus-induced cytolysis must
contribute to the high rates of CD4+ T cell death.
As a result of above ambiguities, investigators began to focus their attention on
immune activation as the cause rather than the consequence of CD4+ T cell death. This
view is supported by in vitro studies showing that cytokines can enhance viral replication
and that chronic infection is associated with increased T cell turnover, increased numbers
of activated T and B cells and increased levels of pro-inflammatory cytokines (112, 115).
However, as with the virus-driven model, the immune-activation theory is based almost
exclusively on the analysis of peripheral blood, a compartment that contains only 2% of
the body's total viral burden and a minority of its CD4+ T cells (114). Moreover, as we
now know, blood is not reflective of the dynamic events occurring in lymphoid and
mucosal tissues. The immune theory also does not explain why activation causes severe
CD4+ T cell depletion while sparing activated CD8+ cells (112).
Recent studies have provided critical new insights into the mechanisms driving
HIV-1 pathogenesis, as well as the timing and site of CD4+ depletion. These studies have
revealed that the bulk of the CD4+ T cell depletion occurs during the first few weeks of
infection and is localized primarily to the gastrointestinal tract (GIT) (Figure 1.4), a
unique immune environment that contains most of the body's lymphoid tissue (gut
associated lymphoid tissue (GALT» (112). Studies of acute SIV infection in rhesus
macaques, and of HIV -1 infection in humans, revealed that within 24 h of vaginal
exposure, virus production was detectable in the GALT (116). This was followed, on days
5 to 10, by an intense burst of viral replication and a massive 70-90% depletion of GALT's
memory CD4+CCR5 T cells (116, 117). In acute infection, the early loss of CD4+ T cells
appears to be a direct consequence of CD4+ target cell infection (118, 119) and virus
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induced Fas-mediated apoptosis (120). Based on these findings, it was proposed that this
massive destruction of CD4+ T cells in the GALT may lead to an early breach in mucosal
immunity, setting the stage for chronic progressive disease and further immunological
deterioration. It was also suggested that the level of immune activation and the rate of
progression to AIDS might be determined by the extent of CD4+ T cell depletion in the
GALT during acute infection (112). Inherent in the GIT model, is the concept that injury to
the immune component of the gut and the epithelial microenvironment may lead to
enhanced translocation of luminal pathogens and microbial products, systemic immune
activation and the exacerbation of HIV-l infection (121). The GALT serves as a constant
source of virus and because of its constant exposure to bacterial, viral and parasitic
pathogens, continues to playa key role in the recruitment, activation and infection of new
target cells throughout the course of HIV-I/AIDS (113).
In addition to CD4+ T cell depletion and chronic immune activation, other
parameters such as immune exhaustion and a limited regenerative capacity may also
contribute to AIDS pathogenesis. A model linking these three facets of HIV -1 disease -
massive CD4+ T cell depletion, exhaustion of T cell regenerative capacity and paradoxical
immune activation - was recently proposed by Appay and Sauce (122).
1.2.2 Mechanisms of HIV-1 Pathogenesis
a) CD4+ T cell Depletion
The main targets of HIV-l during both acute and chronic infection are activated
CCR5+CD4+ T cells that reside in lymph nodes and mucosal tissues, including the GIT
(116, 123-125). However, the reason(s) for the persistent decline in the functionality and
number of CD4+ T cells during the chronic phase of infection has been one of the most
debated topics in AIDS research. While viral replication and cytolysis may playa key role
in CD4+ T cell depletion during acute infection, other factors such as a limited
regenerative capacity may be of greater importance during the chronic phase of HIV-
lIAIDS (126).
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Immune activation accelerates both the production and destruction of CD4+ T cells
and poses a major burden on T cell renewal at the level of progenitor cells and thymic
differentiation (114, 127-129). HIV-l can also interfere with CD4+ T cell renewal through
direct infection of thymocytes and by inducing collagen deposition in the thymus,
damaging the thymic architecture and preventing normal T cell homeostasis (130, 131).
Another important pathway of CD4+ T cell depletion is programmed cell death
(PCD) triggered by cytokines or HIV-1 proteins. Three distinct but overlapping PCD
pathways have been described based on differences in the stimuli, the cytokine
environment and the death-inducing signaling cascades. Two pathways, apoptosis and
autophagy, have no affect the integrity of the plasma membrane and thus, do not induce an
inflammatory response (114). The third pathway, necrosis, involves mechanical rupture of
the membrane, the release of cellular organelles and the induction of a phagocytic
inflammatory response (114). Autophagy and necrosis have been studied in vitro, while
apoptosis has been extensively investigated both in vitro and in HIV-l-infected patients
(114).
The majority of CD4+ T cells undergoing cell death in peripheral blood and lymph
nodes are uninfected bystander cells that have a CD45RO+HLA-DR+CD2S· phenotype and
are killed by activation-induced cell death (AICD) resulting from repeated antigenic
stimulation (132, 133). Although this process is predominately driven by the interaction of
Fas and its ligand, FasL (134), it can also be triggered by interactions with the T Cell
Receptor (TCR) in the absence of a second signal (co-stimulatory molecules) (135). Over-
production of type-2 cytokines (IL-4 and IL-to) can increase susceptibility to AICD (114,
136). Interferon-a (lPN-a) produced in HIV-l-infected dendritic cells (DC) can also
induce CD4+ T cell apoptosis through the TRAIl1Death Receptor-5 pathway (137).
In addition, HIV-l proteins (Env, Tat, Vpr, Nef) can activate apoptotic cell death in
bystander CD4+ T cells through caspase-dependent extrinsic and (or) intrinsic pathways.
The extrinsic pathway involves members of the TNF family of proteins (TNF-Rl, Fas,
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Trail-Rl and Trail-R2) while, the -intrinsic pathway is regulated by the balance between
anti- and pro-apoptotic members of the Bcl-2 protein family. Interestingly, the binding of
R5 tropic Env to CCR5 on target cells triggers the extrinsic apoptotic pathway, while the
binding of X4 tropic Env to CXCR4 activates the intrinsic pathway, inducing
mitochondrial transmembrane depolarization, release of cytochrome-c from the
mitochondria into the cytosol, and activation of caspases-9 and -3 (138-140). Uptake of
extracellular Tat via clathrin-mediated endocytosis (141), activates the intrinsic pathway
(142, 143). Tat also upregulates FaslFasL on T cells (144) and TRAIL expression on
macrophages (145). Vpr induces apoptosis via a direct effect on mitochondrial
permeability (146), whereas Nef induces apoptosis through CXCR4 (147).
b) CD8+T Cell Exhaustion
HIV-l-specific CD8+ T lymphocytes are expanded during acute infection and play
an important role in clearing the infection (148) and determining the viral set point (149,
150). The earliest and most effective CTL responses are directed primarily agai~st the
regulatory proteins, Tat and Rev (150-152). The CTL response is initiated by an interaction
between the TCR on the CD8+ T cell and a peptide-MHC class I complex on an infected
target cell. Although this interaction leads to both cytolytic (cell-mediated) and non-
cytolytic (cytokine/chemokine) responses, these responses are only partially effective in
_controlling viral replication and spread. As would be expected, long-term non-progressors
(LTNP) typically exhibit a stronger more sustained CTL response and a more durable
suppression of HIV-1 viral load compared to patients with progressive disease (153).
The cytolytic response induced in HIV-l-specific CD8+ T cells involves the
secretion of granzymes and perforins and the induction of Fas-FasL interactions. Secretion
of the lytic granules occurs after activation of the TCR and involves their polarized
transport and release at an immunological synapse (IS) formed between the CTL and the
infected target cell (154). The lytic molecules released during this process cause the
formation of pores in the target cell membrane, activating the caspase cascade and the
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onset of apoptosis (154). Target cell apoptosis can also be triggered through a
TCRlpeptide-MHC-mediated upregulation of the Fas ligand (Fas-L) on the surface of the
CD8+ T cell (150). Subsequent interaction of these Fas ligands with the Fas receptor on
the infected target cell activates the caspase cascade of cell death (155, 156).
Non-cytolytic CD8+ T cell responses are mediated through the secretion of soluble
factors such as ~-chemokines (CCL3, CCrA and CCL5), cytokines (including lPN-y, TNF-
a and IL-2) and the CD8+ T Cell Antiviral Factor, CAP. ~-chemokines inhibit the entry of
R5 viruses by binding to their natural ligand, CCRS (157, 158). IFN-y upregulates MHC
class I expression and antigen processing (150, 159, 160), TNF-a activates apoptosis (160)
and interleukin-2 (IL-2) induces the proliferation of CD8+ memory T-cells (150, 161).
Soluble "CD8 antiviral factor (CAF)", a 27k, heat-stable soluble factor that has not yet
been biochemically characterized, is a potent inhibitor of HN-l LTR-driven transcription
(162-164).
However, the majority of HIV-l-infected patients are unable to maintain a durable
control over viral replication due to rapid genetic evolution of the viral genome and the
early generation of CTL and neutralizing antibody escape mutants (165-168). During the
chronic phase of infection, CD8+ T cell dysfunction is closely linked to viral replication
and is characterized by anergy and CD8+ T cell exhaustion. Anergy can be caused by
quantitative changes that alter the HIV-l-specific response including increased CD8+ T
cell apoptosis (via Fas-FasL), the loss of CD4+ T helper responses and (or) an increase in
the breadth of the CD8+ response and an associated loss in the reactivity against early
HIV-l genes (150). Qualitative changes in the CD8+ CTL response during chronic
infection include defects in IFN-yand perforin secretion, as well as a loss of proliferating
IL-2- and IFN-y-secreting CD8+ T cell subsets (162, 169, 170).
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Other factors that may contribute to the functional impairment of CD8+ T cells
include Nef-mediated the down-regulation of MHC class I molecules on HIV-l-infected
cells (171), the down-modulation of CD3-~ on CD8+ T cells (172) and differences in the
stage of cell differentiation (150). Although the mechanisms are not known, HIV-I
infection may also affect the differentiation of CD8+ T cells into memory subsets (122,
173, 174). At least four subsets of T cells have been proposed based on surface marker
expression: naive CD45RA+CCR7+; central memory, CD45RA-CCR7+ (TCM), effector
memory CD45RA-CCRT (TEM) and terminally differentiated effector CD45RA+CCRT
(TEMRA) cells. The TCM sub-population differentiates into cells that home to secondary
lymphoid tissues, while TEM cells produce high levels of perforin, IFN-y and IL-4 in
response to antigenic stimulation. TEMRA cells also produce high levels perforin and,
together with a subset of CD45RA + TEM cells, are known as rapid effectors. Infection with
HIV-1 has been shown to skew CD8+ T cell differentiation toward a disproportionate
increase in TEM cells with reduced proliferative capacity and reduced perforin expression
(150). These changes result in a major impairment/exhaustion of CD8+ T cell antiviral
activity.
Other studies have suggested the up-regulation of PD-l may mediate HIV -1-
specific CD8+ T cell exhaustion and that blocking of the PD-IIPDL-l pathway may
represent a new therapeutic strategy (175-177). This pathway is comprised of the PD-l
receptor and its two ligands, PD-LI and PD-L2, which are part of the B7-CD28 family.
PO-I, originally described during chronic lymphocytic choriomeningitis virus (LCMV)
infection, is highly expressed on exhausted T cells during chronic infection and its
engagement by PD-Ll and PD-L2 inhibits immune responses (Figure 1.5) (177). PD-l
expression is elevated on circulating HIV -specific CD8+ T cells and the level of
expression correlates with increased plasma viral loads and declining CD4+ T cell counts
(178). Interestingly, in vitro blocking of the PD-I-PD-Ll interactions in patient PBMC
leads to increased T cell proliferation and effector cytokine production (176-178). PD-I
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expression is down-regulated in HIV-l-infected patients who exhibit a successful response
to antiretroviral therapy (178). Further characterization of PD-IIPD-L interactions at the
tissue level will be critical to understand the contribution of this pathway to HIY-l
pathogenesis.
1.2.3 Characteristics of Pathogenic versus Non-Pathogenic Infection
Additional support for an immune-based theory of disease progression comes from
studies of non-human primates naturally infected with the closely related simian
immunodeficiency virus, SlY. In contrast to Rhesus macaques which display high levels of
immune activation, severe CD4+ T cell depletion and rapid SlY -associated disease
progression, natural (non-pathogenic) SIV infection in sooty mangabeys and African green
monkeys is characterized by sustained preservation of peripheral CD4+ T cells counts and
a lack of disease progression despite sustained high levels of plasma viremia that are
equivalent to, or greater than, those observed in HIY-l-infected persons with disease
progression (179-182). Other characteristic features of non-pathogenic SlY include low
levels of CD4+ and CD8+ T cell activation and proliferation in both blood and lymph
nodes (182-184), low levels of T cell apoptosis (184-186), preserved regenerative
functions in bone marrow, thymus and lymph nodes (187) and little or no cell-cycle
dysregulation (179, 188, 189). Interestingly, non-pathogenic (natural) SlY infection is also
associated with lower levels of peak immune activation and proliferation during primary
infection and a more pronounced post-peak decline in immune activation (Figure 1.6)
(179, 190, 191). Another interesting observation comes from studies of human
immunodeficiency virus type 2 (HIV-2). Most persons infected with HIV-2, a less
pathogenic strain of HIV, exhibit a relatively slow course of disease progression in
association with low viral loads and levels of immune activation (192). These data provide
compelling circumstantial evidence for a direct link between immune activation and
retroviral disease progression.
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1.3 INNATE IMMUNITY ANDHIV-l PATHOGENESIS
1.3.1 Role of Dendritic Cells (DC) in HIV-l Transmission and Dissemination
DC are professional antigen presenting cells that play a key role in adaptive
immune responses. They are a heterogeneous population of cells that exist in different
functional states. Immature DC are antigen-capturing cells that reside in mucosal
membranes. They have a high phagocytic and endocytic capacity, and continually sample
the environment for evidence of foreign antigens and invasive pathogens (193, 194).
Distinct subsets of mucosal DC express different pattern recognition receptors, such as
Toll-like receptors, C-type lectins and scavenger receptors that are involved in antigen
capture and the induction of immune responses (193). Depending on the receptor, these
responses can involve cell signaling, increased expression of adhesion molecules, DC
maturation and migration, and enhanced pathogen phagocytosis. Following activation of
Toll-like receptors, DC mature into antigen presenting cells and migrate from peripheral
tissues to secondary lymphoid sites where they stimulate naive CD4+ T cells and CD8+ T
cells, inducing them to develop into pathogen-specific helper and cytotoxic T cells,
respectively (193-195).
HIV-l has evolved a number of ways to exploit the biological properties of DC to
facilitate virus transmission and dissemination, and evade antiviral immunity (196).
Immature DC in mucosal membranes are among the first cells to be exposed to HIV-l
during heterosexual, homosexual and perinatal transmission. These DC are highly efficient
at capturing and transporting HIV-l virions to distal lymphoid tissues for transfer to
susceptible CD4+ T cell targets (197). A number of studies have shown that DC-mediated
transmission involves the capture of extracellular virions by DC-SIGN followed by
subsequent transfer of the virus to permissive CD4+ T cells (Figure 1.7) (197-200). Some
studies have suggested that DC-captured virions can also be internalized and stored in
intracellular vesicles where they remain infectious for several hours (198, 201, 202).
Although the exact nature of this storage compartment remains to be defined, it appears to
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be a low pH non-lysosomal compartment that lacks early and late endosomal markers
(197, 202, 203) but expresses markers that are characteristic of multivesicular bodies
(MVB), namely, tetraspanins CD81 and CD9 (197, 204).
Although C-type lectins DC-SIGN (209), Langerhin (CD207), Mannose Receptor
(CD206) and syndecans (heparin sulfate proteoglycans) can bind HIV-I, the ability to
capture and trans-transmit virus to CD4+ T cells has, thus far, been demonstrated only for
DC-SIGN (194, 197, 198, 205). Unlike classical interactions with entry receptors/co-
receptors (CD4/CCRS or CD4/CXCR4), the binding of HIV-l to DC-SIGN does not lead
to membrane fusion. Instead, DC-SIGN appears to function primarily as an attachment
factor that facilitates the trans-transmission of HIV-I. At least one recent study has
suggested that internalization is not essential for transmission and that DC-SIGN-mediated
transfer of HIV-I to T cells can occur with, or without, virus internalization (198, 200,
206). However, there are some controversies relating to the importance of DC-SIGN in the
transmission process (205, 207). Most of this controversy arises from differences in the
size of the viral inoculum used in tissue culture experiments. It now appears that DC-
SIGN-mediated transmission of HIV-I is most effective at low viral concentration and that
high levels of CD4+ co-expression on DC-SIGN+ donor cells can lead to internalization
and inefficient trans-transmission to T cells (for more details, see Chapter 4 in this thesis)
(2,08).
Although the mechanisms underlying DC-mediated transmission of HIV-I of T
cells are not fully understood, the process has been shown to involve the formation of a
tight intercellular junction or "Virological Synapse" (VS) between DC and CD4+ T cells
(200). This junction is similar to an "Immunological Synapse" and is most likely initiated
by a transient contact formed between a DC and T cell without a requirement for antigen
specificity (200). Before DC-T cell contact, HIV -1 is evenly distributed inside the DC.
However, within minutes after the initiation of cell-cell contact, viral particles concentrate
at the site of contact on the donor (DC) side of the interface (209). The HIV -1 receptor/co-
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receptors (CD4, CCR5 and/or CXCR4), and the adhesion molecule LFA-l are recruited to
the contact site on the recipient (T cell) side of the synapse (196, 200). This concentration
of HIV-1 and its receptors/co-receptors at DC-T cell interface, combined with the directed
release of HIV-l virions to this site, may help explain why cell-mediated transmission of
HIV-1 is several times more efficient than infection with cell-free viral particles (196,
209).
In addition, some strains of HIV-l may be able to infect distinct subsets of
langerhans, myeloid and plasmacytoid DC through a classical CD4/co-receptor-mediated
entry mechanism (210,211). However, this process is not particularly robust and seems to
require a high viral input (212). Further studies are needed to determine whether the HIV-l
virions synthesized in DC accumulate in MVB and whether MVB-archived virion promote
the long-term transmission of HIV-1 to T cells and serve as reservoirs of treatment-
refractory virus (211, 213).
1.3.2 Infection and Dysfunction of Mononuclear Phagocytes
Blood monocytes are the progenitors of all macrophage (and DC) subsets including
microglial cells, Kupffer cells and osteoclasts (214). Monocytes originate in the bone
marrow from a common myeloid progenitor that enters the peripheral blood and circulates
for a few days before migrating into peripheral tissues to differentiate into mature
macrophages (215, 216). Some tissue macrophages, such as those in the lamina propria of
the GIT, are thought to survive for few weeks before undergoing programmed cell death
(215, 217). Such cells are continually replenished by newly recruited blood monocytes.
Cells recruited to sites of inflammation typically have short half-life and exert potent pro-
inflammatory effects. Other macrophages appear to have more prolonged half-lives
ranging from several months (alveolar macrophages) to decades (microgial cells) (218) and
may be renewed, at least in part, by local proliferation (219, 220).
Circulating monocytes are a heterogeneous population of cells that can
phagocytose foreign material, present antigens to T cells and produce immunologically
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important cytokines in response to LPS stimulation through the CD14ffoll-like receptor 4
(TLR-4) complexes (221-224). LPS-induced ligation of the CD 14ffLR4+ receptor leads to
signal transduction, mobilization of transcription factors and enhanced expression of tumor
necrosis factor-a (TNF-a), a cytokine that induces cell proliferation and migration.
Although CDI4+ monocytes bind and support HIV-1 entry, accumulated evidence
suggests that viral replication is restricted at, or prior to, reverse transcription and
integration (225, 226) with some studies showing a block in virus entry that may be related
to low CCR5 expression (226, 227). Other studies have suggested that the presence of with
low molecular mass APOBEC3G may also contribute to the low susceptibility of CD14+
monocytes to HIV-1 infection (228).
Increasing evidence suggests that the subset of monocytes expressing CDl6
(FcyRIII) may be important mediators of HIV -1 pathogenesis. These cells express low
levels of CDI4 and high levels of CD16. Such cells represent only 5-10% of the blood
monocyte population in healthy persons (229) but can increase to levels of >40%,
especially in HIV-I-infected patients with advanced disease and active opportunistic
infection (230, 231). CD 16+ monocytes are believed to be at a more advanced stage of
differentiation compared to CD 16·cells (223, 226) and they are more susceptible to HIV-1
infection than the classical CD 14high+CD16-subset of cells, presumably as a result of their
increased CCR5 expression (228). They produce high levels of TNF-a (232) and it has
been suggested that the increasing prevalence of these cells may, in part, be responsible for
the progressive dysregulation of the cytokine network that occurs during disease
progression. CD141ow+CD16high+monocytes are greatly expanded in patients with AIDS-
related dementia (233) and it has been proposed that, during neuropathogenesis, increased
numbers of these cells migrate into the CNS to become CD141ow+CD16high+CDI63+
perivascular macrophages (234). Unlike microglia, these cells are continuously
repopulated by blood-derived monocytes. Perivascular cells are uniquely situated at the
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intersection between the nervous and immune systems and are believed to play an
important role in a number of inflammatory diseases including bacterial meningitis and
experimental allergic encephalomyelitis, as well as simian immunodeficiency virus (SIV)
and HN-l encephalitis (234-238). Other studies have shown that upon differentiation into
macrophages, and interaction with T cells, CDI6+ MDM-T cell conjugates become major
sites of HIV-l replication (239, 240).
As with monocytes, tissue macrophages are characterized by extensive
heterogeneity and a high level of plasticity. They respond to, and are profoundly affected
by, a wide range of immuno-modulatory cytokine, chemokine and microbial gene products
that are present in different tissue environments (241-246). These interactions lead to the
differential modulation of cytokines, chemokines and cell surface receptors, resulting in
the emergence of distinct subsets of macrophages that differ in their functional and
phenotypic properties. Alveolar macrophages, for example, express high levels of pattern
recognition receptors and scavenger receptors that are involved in clearing viruses and
other microorganisms, as well as environmental particles (247), whereas osteoclasts
express markers that are fundamental to the remodeling of bone tissue (215, 248, 249).
Macrophages located at sites of pathogen entry in the intestine have high phagocytic and
anti-bacterial activity, but produce only low levels of inflammatory cytokines, a
mechanism that prevents unnecessary over-stimulation due to constant exposure to
commensal and pathogenic microbes (250-252). Tissue-specific differences can have a
major effect on the capacity of macrophages to support productive HN -1 infection.
Macrophages are widely distributed in peripheral tissues, including mucosal
membranes. They play an important role in the establishment and dissemination of HN-l
infection, and they serve as viral reservoirs throughout the course of HIV -1/AIDS (246).
Alveolar, peritoneal and placental macrophages, as well as microglia are all susceptible to
HN -1, and depending on the local environment, the number of infected macrophages can
range from 1% to 50% (253-255). Although macrophages serve as reservoirs of "latent"
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infection, they can also support high levels of viral replication, especially during
opportunistic infection (226, 255) and late-stage disease when CD4+ T cells have been
severely depleted (226, 256). Macrophages are infected predominantly by CCR5-tropic
viruses, however, viral isolates using CXCR4, CCR3 and CCR2b as the co-receptor can
also infect and replicate in monocyte-derived macrophages (MDM) (257-260). Unlike
CD4+ T cells, macrophages are relatively resistant to the cytopathic effects of HIV-I, and
virus archived in long-lived macrophages such as microglia can survive for many years
(218, 260, 261). The persistence of intracellular HIV-I in sanctuary tissues such as the
central nervous system (CNS), where the penetration of protease inhibitors (PIs) is
restricted by the blood-brain, represents a major obstacle to the treatment-induced
elimination of infection (226, 262, 263). Both protease and RT inhibitors are less effective
in chronically infected macrophages compared to CD4+ T cells (226, 264, 265).
HIV-1 infection leads to the impairment of monocyte-macrophage function. This,
in turn, results in inefficient control of opportunistic pathogens and further enhancement of
immune activation and disease pathogenesis. Monocytes, alveolar macrophages and MOM
obtained from HIV-l-infected patients have all been shown to exhibit reduced phagocytic
. capacity (266-268). This reduction is not due to the down-regulation of phagocytic
receptors (complement, FcR), but instead appears to involve the inhibition of tyrosine
phosphorylation and an impairment of downstream signaling pathways (260, 266). HIV-l
also inhibits phagosome-lysosome fusion and intra-cellular killing of opportunistic
pathogens, and the degree of inhibition correlates with the stage of disease (260, 269).
Monocytes obtained from patients with AIDS also have defective migratory responses due
to a down-regulation of receptors for chemotactic ligands (ie. C5a and fMLP) (270, 271).
Chronic immune activation of monocytes and macrophages by HIV-I or other antigenic
stimuli, leads to altered secretion of pro- and anti-inflammatory cytokines and chemokines,
and ultimately to dysregulation of the host immune system.
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1.4 ROLE OF GASTROINTESTINAL TRACT IN HIV-l PATHOGENESIS
1.4.1 Overview of the Intestinal Immune System
The gastrointestinal mucosa is located at the interface between a sterile internal and
a microbially contaminated external environment. It serves the conflicting needs of nutrient
absorption and host defense, functions that require intimate contact with the external
environment (272, 273). As a result, the GIT has evolved a thin polarized epithelium and a
large surface area characterized by mucosal folds, villi and microvilli. In the small intestine
of healthy persons, antigen exposure comes primarily from the diet, whereas in the ileum
and colon the antigenic load is further enhanced by an abundant and complex array of
commensal microbes (274). The organization of the epithelial barrier with its tight
junctions helps reduce the risk of luminal antigens entering the mucosa (including
commensal and pathogenic microbes), but it does not completely prevent this process
(274-276). Some food proteins and non-pathogenic commensal bacteria enter the mucosa
through breaks in the tight junctions, possibly at the villus tip where epithelial cells are
shed, a process that is relatively limited in healthy individuals (277). The task of mounting
an effective immune response to invading pathogens while remaining relatively
unresponsive to commensal microbes and food antigens poses a daunting challenge to the
GIT.
As a result, the gut mucosa has evolved an elaborate system to protect its host from
infectious agents. This system consists of two anatomically separated but functionally
linked components of the common mucosal immune system (273). An afferent component,
which contains elements involved in the initiation of the immune response including
antigen presentation and lymphocyte proliferation, and an efferent component containing
elements directly involved in antibody production and CTL responses. Structurally, the
afferent system consists of distinct lymphoid follicles overlaid by an epithelial membrane
containing M cells. These cells transcytose particulate antigens to antigen-presenting
macrophages located at the basal surface of the epithelium (278, 279). Macrophages are
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the first phagocytic cells to interact with microorganisms that have entered the intestinal
mucosa. Intestinal macrophages have avid phagocytic and bactericidal activities that
protect the host from pathogenic organisms and they regulate the immune response to
commensal bacteria (discussed in more detail below) (251). Antigen-presenting DC survey
the microenvironment by extending processes between gut epithelial cells. They sample
both commensal and pathogenic microbes for subsequent transport and presentation to B
and T lymphocytes in the spleen and lymph nodes (280, 281). Cells of the efferent
compartment are diffusely scattered throughout the epithelium and lamina propria of the
intestine. In addition to CTL, IFN-y-producing lymphoctyes and IgGllgA-secreting plasma
cells, antibody-dependent cytotoxicity may also play an important role in the adaptive
immune response (273, 282-284). Together, this defense system consisting of the innate
immune system, the epithelial barrier and its associated mucous layer and the adaptive
immune system, can effectively prevent or restrict the entry and propagation of commensal
and pathogenic organisms, including HIV-1 (252).
Recently, in North America, there has been a dramatic increase in inflammatory
bowel disease in the absence of overt microbial infection (274). This finding suggests that
some, as yet unknown factor, is perturbing the balance between the normal microflora of
the gut and host immunity. It will be important to determine whether this change is due to
the use of antibiotics and a treatment-associated reduction in commensal flora. It has been
suggested that, under normal homeostatic conditions, the anti-inflammatory responses
induced by commensal flora protect the intestinal epithelium from pathogenic insults (285,
286). This relationship, however, appears to extremely delicate and anything that perturbs
either immune or epithelial homeostasis can lead to inflammation and life-long
inflammatory conditions such as Crohn's disease and ulcerative colitis. Patients afflicted
by these disease suffer from chronic diarrhea, weight loss and fatigue, in addition to other
potential complications such as skin ulcers, arthritis and bile-duct inflammation (287).
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1.4.2 Intestinal Macrophages as Unique Effector Cells
The mucosa of the GIT contains the largest reservoir of macrophages in the body
(288). These cells, which form part of the innate immune system, are the first line of
defense against microorganisms that have entered the mucosa. Macrophages in the
intestinal mucosa have developed a unique and highly distinctive set of phenotypic and
functional properties that are not found in other tissue macrophages, properties that
promote the phagocytosis and elimination of harmful pathogens while, at the same time,
protecting the gastrointestinal mucosa from chronic over-stimulation and inflammation
(Figure 1.8).
Accumulated evidence suggests that intestinal macrophages are continually
replenished by blood monocytes that are recruited in response to endogenous or
inflammatory chemokines. Following exposure to transforming growth factor-B (TGF-~)
and other stromal factors present in the lamina propria, these monocytes mature into
resident macrophages. Unlike lymphocytes, these tissue macrophages do not proliferate
and they lack chemotatic activity (217, 252). Resident intestinal macrophages express high
levels of HLA-DR and aminopepetidase N (C013), but exhibit a profound down-
regulation of innate response receptors, including receptors for bacterial lipopolysaccharide
(LPS) (COI4), for IgNJgG (C089, CDI6, C032 and C064), CR3 (COllb/C018) and
CR4 (COlIc/C018) (252). Growth factor receptors involved in the production of pro-
inflammatory cytokines including IL-2 (C025) and IL-3 (C0123) and the integrin LFA-l
(CDlIalC018) are also down-regulated in resident macrophages (252). As a result,
intestinal macrophages in non-inflamed tissues do not produce pro-inflammatory cytokines
such as IL-l, IL-6, IL-lO, IL-12, CCL5IRANTES, TGF-~ and TNF-a (251, 252, 289).
They also do not express CCR5 and CXCR4 (290, 291), the primary co-receptors for HIV-
1, or C080, CD86 and C040, co-stimulatory molecules required for the induction of T cell
activation (292). To facilitate pathogen identification, however, intestinal macrophages
express a number of pattern recognition receptors including the toll-like receptors (TLR)
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such as TLR5 and TLR9 which are capable of interacting with foreign carbohydrate and
lipid structures to promote the clearance of harmful pathogens in the absence of
inflammation (252, 289).
In contrast to the profound down-regulation of pro-inflammatory markers that is
observed in the non-inflamed intestine, monocytes recruited to an inflamed intestinal
mucosa retain their potential to develop into pro-inflammatory cells. For example, up to
30% of the intestinal macrophages in inflammatory bowel disease (ffiO) patients express
CD14 and have the potential to secrete pro-inflammatory cytokines (293, 294). They also
express the triggering receptor expressed on myeloid cells- (TREM-I), a finding that may
explain the respiratory burst activities frequently observed in ffiO patients (295, 296).
Intestinal macrophages in the inflamed mucosa also exhibit increased co-stimulatory
activities as measured by the up-regulation of C080, C086 and CD40 (297, 298).
1.4.3 HIV·l Enteropathy, Microbial Translocation and Immune Activation
HIV-I-associated enteropathy is a poorly-defined clinical condition in which
chronic diarrhea, malabsorption and wasting occurs in the absence of a detectable enteric
pathogen (273, 299). Whether this condition is due to subclinical enteric infections,
chronic inflammation or direct effects of HIV-1 on the epithelium of the GIT remain to be
established. Although there is little evidence that HIV-1 infects enterocytes, various
histological studies have reported that the intestinal mucosa of HIV-1-infected persons is
characterized by chronic inflammation, villous atrophy, crypt hyperplasia, nuclear
enlargement and apoptosis. It has also been reported that jejunal enterocytes have an over-
developed smooth endoplasmic reticulum and decreased levels of mitochondria (300-302).
In vitro studies, performed on duodenal biopsies have shown that HIV-1-infected patients
with diarrhea have decreased trans-epithelial resistance when compared to patients without
diarrhea (303). At the molecular level, the binding of gp120 to GPR151B0b expressed on
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the basal surface of epithelial cells has been shown to cause decreased acetylation of
tubulin, microtubular depolymerization and cytoskeletal rearrangements, changes that
result in increased intestinal permeability, increased levels of intracellular calcium and
diarrhea (304). Other studies have reported that HIV-1 infection is associated with
degenerative changes in the enteric nerves and in the vasculature of the lamina propria
(305, 306) and that the protease inhibitors, saquinavir, ritonavir and nelfinavir (but not
indinavir) cause damage the epithelial barrier (307). Irrespective of the mechanism(s),
HIV-1 enteropathy appears to be a subtle phenomenon.
Studies showing massive depletion of CD4+ T cells in the GALT during the first
few weeks of infection have suggested that this loss in helper T cell function together with
the damage caused to the epithelium, may alter the antimicrobial properties of the gut
allowing for the increased translocation of luminal microbes and microbial products (112,
121). This phenomenon, known as microbial translocation, can occur in the absence of
overt viremia and is a prominent feature of mD (308). Damage to the intestine during
invasive intestinal surgery and during immunosuppressive conditioning for bone marrow
transplantation can also increase the level of microbial translocation (308, 309). This leads
to both local and systemic immune activation and, in the case of transplant patients, an
intensification of graft-versus-host disease (GVHD) (309). Quantification of plasma LPS, a
major component of the cell wall of Gram-negative bacteria (310) is routinely used to
measure the extent of epithelial leakage and bacterial translocation (311, 312).
Based on preliminary data showing that microbial translocation may be a cause of
systemic immune activation in chronic HIV-l infection, a new model of HIV-l
pathogenesis is beginning to emerge. In this model, the level of immune competency that
exists after the acute phase of infection, especially as it relates to the control microbial
pathogens in the GIT, determines the rate of disease progression to AIDS (112). Ithas been
known for some time that markers of immune activation are better predictors of HIV-l
disease progression than CD4+ T cell counts and plasma viral load (313). However, the
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factors driving immune activation, including polyclonal B cell activation, increased
activation and turnover of T cells and increased levels of circulating pro-inflammatory
cytokines and chemokines remain unclear (314-317). Evidence supporting the view that
microbial translocation is an important cause of systemic activation is based on studies
showing that: I) LPS is significantly increased in the plasma of patients with chronic HIV-
I infection; 2) plasma LPS correlates with other measures of innate and adaptive immune
activation; 3) long-term non-progressors have undetectable to low-level LPS in association
with low levels of immune activation; 4) antiretroviral therapy leads to a partial reduction
in circulating LPS, and 5) non-pathogenic SIV infection of sooty mangabeys does not lead
to increased levels of LPS or immune activation, despite extensive CD4+ depletion in the
GIT (112, 121).
1.5 ANTIRETROVlRAL THERAPY (ART)
1.5.1 Historical Perspective and Current Drug Regimens
Following the identification of HIV-I as the causative agent of AIDS, many
scientists focused their efforts on developing a therapeutic strategy aimed at eliminating
the virus. The very first antiretroviral drug was zidovudine (ZDV), a nucleoside analog that
competitively inhibits the viral reverse transcriptase (RT) by inducing chain termination
and an interruption of HIV-I cDNA synthesis (318). Unfortunately, shortly after its
discovery and approval by the FDA, scientists discovered the limitations of monotherapy
(319, 320). It became increasingly clear that, because of the ability of HIV-l to rapidly
generate drug-resistant mutations, a combination of drugs would be required to slow the
emergence of resistance and induce a more profound and sustained suppression of viral
replication. With an increased understanding of the HIV-1 life cycle, additional viral
proteins, most notably the protease enzyme were identified as potential therapeutic targets.
This led to the development of the PIs, a highly potent class of therapeutic agents that bind
directly to the active site of the HIV-I protease enzyme, preventing virion maturation and
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the formation of infectious virus (321, 322). Soon thereafter, triple combination therapy
consisting of a PI and two nucleoside RT inhibitors (NRTIs), ultimately referred to as
highly active anti-retroviral therapy (HAART), was introduced as the standard of care for
HIV-1+ patients in the developed world (323). Subsequently, a third class of anti-HIV-1
agents, the non-nucleoside RT inhibitors (NNRTIs) became available. NNRTIs are a
structurally diverse group of drugs that bind to the HN-1 RT at a position distal from the
active site, causing conformational changes in the reactivity of the active site (321). In
common with PIs, NNRTIs have a synergistic effect when used in combination with two
different NRTIs (321).
Other treatment options that are in an advanced stage of evaluation include two
promising entry inhibitors, Enfuvirtide and Maraviroc. Enfuvirtide, or T20, is a fusion
inhibitor that has been approved for use in treatment-experienced patients (324-326). It is a
synthetic peptide that mimics amino acids 127-162 of HIV-1 gp41, a key domain involved
in viral fusion with the cell membrane. Maraviroc, on the other hand, binds with CCR5
preventing interaction with HN and CCR5-mediated signaling events (327). Maraviroc is
currently under investigation in expanded phase III clinical trials (327, 328).
1.5.2 Emerging Drug Targets and Future Directions
Concerns about toxicity and the emergence of drug resistance continue to drive the
search for simple effective low-cost drugs that can be used to boost the therapeutic efficacy
of current regimens. Such drugs are needed, not only to reduce the risk of toxicity and
resistance, but also to provide treatment options for patients who have failed their first- and
(or) second-line drug regimens. In addition to the entry inhibitors described above, drugs
that target the viral integrase are showing significant therapeutic promise, primarily
because of the unique enzymatic activity of the viral IN. Two potential approaches are
possible: one that uses small molecular inhibitors to directly target the active site of
integrase and a second approach that blocks formation of the Pre-Integration Complex
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(PIC) (329). Most integrase inhibitors currently under development block the transfer
activity of the enzyme. Unfortunately, like all anti-HIV-l compounds, resistance mutations
develop during extended exposure to integrase inhibitors (330).
HIV -1 assembly and budding also remains a significant unexploited target for
antiretroviral therapy. While anti-budding agents, so far, have not been practical due to
their significant cellular toxicity, inhibitors targeting TSGI0l-p6 interactions may prove
valuable (329). In addition, Vpu plays an important role in virus budding from human cells
and may be a potential target for antiretroviral therapy. Specifically, recent studies have
shown that Vpu restricts the antiviral activity of tetherin, an integral membrane protein that
binds to and retains fully formed virions on the surface of infected cells (331). Tetherin is
thought to represent a late stage antiviral barrier preventing the dissemination of HIV-l
thus targeting Vpu-tetherin interactions may represent a novel therapeutic target (331).
Finally, it has been suggested that innate antiviral mechanisms may provide an
important new class of therapeutic agents. These host targets are particularly attractive
since they do not mutate in response to drug selection pressure and therefore do not
develop resistance. APOBEC3G is a particularly attractive candidate. APOBEC3G is a
DNA editing enzyme that exerts its antiviral activity by introducing C-to-U changes in the
newly synthesized viral single stranded cDNA (332). However, in the setting of HIV-l, the
antiviral activity of APOBEC3G is negated by the presence of HIV-1 Vif, a protein that is
incorporated into HIV -1 virions and targets APOBEC3G for proteosomal degradation
(332). Small molecular inhibitors directed against the Vif-APOBEC3G interaction may
provide a novel therapeutic option.
1.5.3 Success of ART in the North America and Europe
Since the introduction of ART 28 years ago, substantial progress has been made in
both the treatment and prevention of HIV -11AIDS, especially in resource-rich regions of
the developed world where drugs are readily available. In the USA alone, it is estimated
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that more than 3 million years of life have been saved since 1989, as a direct result of
progress in AIDS care and treatment, including prophylactic treatment for the prevention
of opportunistic infections (DIs) and treatment with antiretroviral therapy (ART) (333). In
addition, prevention of mother-to-child transmission efforts averted an estimated 2,900
childhood infections, the equivalent to an additional 137,000 years of survival benefit (333,
334). Cost-effective analyses have suggested that, overall, prevention efforts in the USA
have averted between 204,000 and 1,585,000 infections at a cost that is less than that
required to treat an individual patient for HIV-I-related disease (335). Similar levels of
success have been observed in other resource-rich regions of the world, including Western
Europe and Australia. Despite these advances, significant challenges remain if HAART is
to be universally implemented (see Section 1.5.5). Many of the challenges, in the
developing world, relate the limited repertoire and high cost of drugs, the lack of clinical
and laboratory infrastructure, the shortage of health care workers and the high prevalence
of opportunistic co-infections, as well as universal concerns relating to drug toxicity and
the emergence and transmission of drug resistance.
1.5.4 Immune Reconstitution Inflammatory Syndrome (IRIS)
Combination antiretroviral therapy has led to significant declines in AIDS-
associated morbidity and mortality, reducing the frequency of opportunistic infections and
prolonging survival (336-338). These benefits appear to be the result of a partial recovery
in the host's immune system, as manifested by an increase in CD4+ T cells and a decrease
in plasma viral loads (339). In some patients, treatment-induced immunological change,
which includes a rapid restoration of pathogen-specific immunity, is associated with
clinical deterioration despite increased levels of CD4+ T cells and decreased HIV-I loads
(340-342). This condition, known as the "Immune Reconstitution Inflammatory
Syndrome" (IRIS) usually occurs within the first 3 months after the initiation of therapy
(343). IRIS is often self-limiting but can, in some patients, lead to significant morbidity
and death.
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Accumulated evidence suggests that IRIS represents an inflammatory response or a
"dysregulation" of the immune system to an antigenic stimulus. This stimulus can be a
viable infectious agent, a dead or dying infectious organism, or a tumor antigen such as
HHV-8, the causative agent of Kaposi's sarcoma (KS) (344-346). Two different types of
IRIS have been described - an "unmasking" form which is directed against a previously
untreated subclinical (replicating) pathogens and a "paradoxical deterioration" form
directed against residual antigens of dead or dying organisms that have been previously
diagnosed and are being treated (343). The most common forms of IRIS are due to
mycobacterial infections (tuberculosis, non-tuberculous mycobacteria, leprosy), fungi
(cryptococcus, pneumocystis, histoplasma, candida), herpes simplex virus (HSV), herpes
zoster virus (HZV), and cytomegalovirus (CMV), although protozoa (toxoplasma,
microsporidia, Lesihmania, cryptosporidia), helminth (schistosoma) and non-herpes
viruses (hepatitis B (HBV) and hepatitis C (HCV» can also induce IRIS (343).
IRIS appears to be more common in patients with low CD4+ counts «200
cells/mL) (340, 347) and in patients who exhibit an increased rate of CD4+ T cell recovery
during ART (348, 349). In most cases, CD4+ T cell recovery occurs within the first 1-2
weeks after starting treatment and continues for 2-3 months. The initial recovery is due
primarily to a rapid redistribution of activated CD4+CD45RO+ memory T cells from
lymphoid tissues (350, 351). These cells are primed to recognize previous antigenic stimuli
and thus, may contribute to the early manifestations of IRIS. This is followed by an
increase of naive T cells, a process that is responsible for the quantitative increase in CD4+
T cell counts (352). Thus, the clinical manifestations of IRIS may be due to a combination
of quantitative restoration of immunity and qualitative changes in T cell function and
phenotype. Alteration in the ThllTh2 cytokine balance may also help explain some of the
manifestations of IRIS (353). Increased levels of IL-6, CCR3 and CCR5 have been
detected on monocytes and granulocytes of patients who have a history of IRIS (354).
Factors limiting our understanding of IRIS relate to the small sample size of most studies,
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the retrospective nature of the studies and the fact that most analyses are based on
peripheral blood rather than tissue specimens collected from lymphoid organs, or from the
site of infectious disease (343).
1.5.5 Constraints to ART in Africa and Resource-Poor Settings
Treating and caring for millions of Africans living with HNIAIDS poses an
inescapable challenge to the continent and the world in general. According to UNAIDS, as
of December 2007, an estimated 3 million people in low- and middle-income countries
were receiving antiretroviral drugs (I). This represents 31% of those who need medication.
However, little is known about the long-term efficacy of HAART in African populations
infected with non-B SUbtypes. In a recent U.K. study, African patients had good initial
responses to HAART but the duration of the response was shorter than that observed for
Caucasians with a number of patients showing viral rebound after nine months (355).
Although the reasons for the more limited response in African patients are not known, they
are likely to be complex. One potential reason may be related to the lack of diagnostic and
laboratory monitoring (viral load, CD4+ T cell counts) and financial resources. As a result,
treatment is often initiated too late in the course of infection to prevent high mortality
rates. Patients started on late therapy have a high incidence of concurrent viral and
bacterial infections, such as tuberculosis (356). These infections cause chronic activation
and dysregulation of the host immune system making it difficult to control viral replication
and dissemination. Such patients may also be more likely to suffer from IRIS. Finally, as
in the developed world, toxicity and resistance is always a concern.
In addition to being simple, safe and affordable, effective anti-retroviral treatments
for Africa need to be pregnancy friendly and compatible with TB treatment (given the high
incidence of TBIHIV-I and TBIKSIHN-I and other multiple infections) (357). As stated
previously, the successful treatment of HIV-I/AIDS in Africa will depend on the
development of therapeutic strategies for treating DIs, either prior to, or concurrently with
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HAART. At the present time, regimens that combine two NRTIs, zidovudine (ZDV) or
stavudine (d4T) and lamivudine (3TC), with one NNRTI, either nevirapine (NVP) or
efavirenz (EFV), are recommended as first-line therapy in South Africa (358).
1.6 RATIONALE ANDAIMS OF THE CURRENT STUDY
1.6.1 Relevance to Existing Knowledge
Three decades into the global AIDS pandemic our understanding of HIY-l
pathogenesis continues to evolve. It has become increasingly apparent that generalized
immune activation is a key pathogenic determinant in the development of AIDS and that
immune activation is a better correlate of disease progression than either CD4 counts or
plasma viral load (112, 313). Many new insights have emerged from comparative studies
of natural vs. pathogenic SlY infection. Sooty mangabeys, the natural hosts of SlY, do not
progress to AIDS despite high viral loads and mucosal CD4+ T cell depletion (179). In
contrast, SlY infection of rhesus macaques has a disease course similar to HIY-I in
human. The fundamental difference driving pathogenesis appears to be sustained immune
activation following the resolution of acute infection (179). Based on this information, the
important questions then become: What are the mechanisms driving chronic immune
action in HIY-I-infected persons? Is this immune activation preventable? Can an improved
understanding of immune activation be used to design improved prevention and treatment
strategies?
Studies of immune activation, in the setting of HIY-I, have focused primarily on
components of the cellular immune response. However, recent data suggests that microbial
translocation and high levels of circulating LPS may be the cause of systemic immune
activation in HIV-l-infected patients and, by inference, that the innate immune system may
play an important role in driving HIY-I-associated pathogenesis, either directly or
indirectly (121). Monocytes and macrophages, the primary targets of LPS-induced
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activation, are key regulators of inflammation. They are responsive to a wide range of
microbial and environment stimuli and depending on the type of stimuli can undergo
functional polarization to either an "immuno-responsive/inflammatory" or a "tissue
remodeling" phenotype (359). Cells of monocyte-macrophage lineage are also susceptible
to HIV-I infection and can serve as long-lived viral reservoirs during ART (226, 260).
HIV -1 infection of monocytes and macrophages also leads to impaired phagocytosis,
chemotaxis and cytokine production (260).
1.6.2 Aimsof the Current Study
Given the importance of immune activation in driving progression to AIDS, the
overall aim of the current study was to obtain a comprehensive understanding of the
relationships between MPS activation/polarization and RIV -I pathogenesis. A main focus
of the study was to investigate the in vitro and ex vivo potential of these cells to serve as
targets of HIV -I infection and mediators of immune and inflammatory responses.
Specific aims, at the in vitro level, were to determine how cytokine-induced
polarization of monocyte-derived-macrophages (MOM) can alter the phenotype and
functional properties of MDM and affect their ability to support productive vs. latent
infection. An additional aim was to examine the affects of polarization on the ability of
MDM to transmit HIV-I to susceptible C04+ T cell targets. These studies were designed to
obtain new insights into the relationship between macrophage polarization and the capacity
of these cells to serve, not only as targets and reservoirs of infection, but also as vehicles of
viral dissemination and spread to T cells. This work also serves as a baseline for studies
aimed at elucidating the activation profiles of blood monocytes and tissue macrophages at
the clinical level.
Given that immune activation may play a particularly important role in driving
RIV -1 pathogenesis in Africa and other parts of the developing world, clinical studies were
conducted in treatment naive South African patients infected with SUbtype e, a viral
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variant that constitutes >50% of global infections. The overall aim of this work was to
obtain new insights for the immune-based enhancement of antiretroviral therapy in patients
with late stage disease. More specific aims included establishing an immune activation
profile for blood monocytes and identifying factors driving the activation of these cells (ie.
microbial translocation vs. RIV -l-induced activation). The final aim of the study, given the
importance of mucosal tissues in RIV -1 pathogenesis, was to investigate the affects of
HN -1 infection on intestinal macrophagess in the duodenum and colon. Since intestinal
macrophages drive chronic inflammation and immune dysfunction in mD, it seemed
reasonable to investigate whether these cells playa similar role during HN-l infection.
In summary, the main overall objective of the study was to examine the relative
contribution of MPS activation/polarization to the chronic immune activation and
dysfunction associated RIV-I disease. MP may be functionally important in driving this
phenomenon since they playa pivotal role at the interface between immune activation,
RN -1 pathogenesis and microbial translocation. An increased understanding of these
different parameters disease pathogenesis may lead to the design of novel treatment
strategies aimed at reducing systemic immune activation.
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1.7 FIGURE LEGENDS
FIGURE 1.1. Global view of HI V-I infection in 2007. Map showing the distribution and
frequency of HIV-1/AIDS in different regions of the globe relative to the total number of
HIV-1 infections worldwide as presented in the UNAIDS report on AIDS for 2008.
FIGURE 1.2. HIV-l subtypes and CRFs. Map showing the unequal distribution ofHIV-
1 subtypes and Circulating Recombinant Forms (CRFs) at the global level. These maps are
based on prevalence data contained in the UNAIDS reports on AIDS and on sequence data
available through the Los Alamos National Laboratory (LANL) database (from Taylor et
al. N Engl J Med 2008; 358: 1590).
FIGURE 1.3. Overview of the HIV-llife cycle. The infectious life cycle begins when
the HIV-l gp120 glycoprotein binds to the CD4 receptor on the surface of helper T cells,
macrophages or dendritic cells (Step 1.). This interaction induces conformational changes
in the core region of gp120, leading to unmasking of the chemokine co-receptor (CCR5 or
CXCR4) binding site. Further interaction with CCR5 (or CXCR4) leads to further
conformational changes, activation of gp41 and virus fusion with the cell membrane (Step
2.). The viral core is then extruded into the cytoplasm where it is reverse-transcribed into
cDNA before being transported to the nucleus and integrated into the human genome, a
process that is catalyzed by the HIV-1 integrase enzyme (Step 3.). Transcription of the
integrated proviral DNA leads to the production of multiply, singly and unspliced mRNAs
that are then transported back to the cytoplasm where they are translated and processed
into HIV-1 structural and accessory proteins (Step 4.). Env and immature precursors of the
capsid (Gag) and viral polymerase (Pol) are transported to the cell membrane and
assembled into HIV-l virions. Virus infectivity is acquired after Gag and Gag-Pol
cleavage, particle maturation and budding from the cell surface (Step 5.). Most currently
available drugs target the reverse transcription (nucleoside and non-nucleoside RT
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inhibitors) or the protease cleavage step required for the development of infectivity (from
Monini et al. Nat Rev Cancer 2004;4:861).
FIGURE 1.4. Schematic showing HIV-I-associated damage to the gastrointestinal
tract (GIT). (a) A healthy GIT consisting of an intact epithelial barrier with villi and
crypts, a lumen containing secreted IgA and defensins and a lamina propria containing an
abundance immune cells including macrophages, dendritic cells, B cells and T cells. (b) An
HIV-l-infected GIT showing damage to the epithelial barrier, enterocyte apoptosis, high-
level viral replication, massive C04+ T cells depletion and _increased membrane
permeability in association with increased microbial translocation (from Mowat et al. Nat
Rev ImmunoI2003;3:331).
FIGURE 1.5. Characteristics of T cell Exhaustion during chronic viral infections.
Virus-specific C08+ T cells responses are complex, ranging from cytokine (IFN-y, TNF-a
and IL-2) production to protection from apoptosis and antigen-induced T cell proliferation.
Many of these functions, including cytokine production and the proliferative potential of T
cells, are progressively exhausted during the course of chronic infection. Factors
contributing to this exhaustion are chronic antigen-driven immune activation and the
severe depletion of CD4+ helper T cell function. Increased expression of the Programmed
Death receptor, PD-I by virus-specific T cells, and its corresponding ligand, PO-LIon
antigen presenting cells are also major contributors to T cell exhaustion during the chronic
phase of viral infections, including HIV-1 (from Freeman et al. J Exp Med 2006;
203:2223)
FIGURE 1.6 Schematic showing the similarities and differences between pathogenic
(human, rhesus macaques) and non-pathogenic retroviral infections. Although rapid
and severe depletion of mucosal CD4+T cells during the acute phase of HIV-I (and SIV)
infection is an important determinant of pathogenesis, it is not sufficient to cause
AIDS/SAIDS. Continued immune activation and enhanced microbial translocation during
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the chronic phase of HIY -lISIV infection are now believed to the primary factors driving
disease progression and the ultimate collapse of the immune system (Paiardini et al. AIDS
Rev 2008;10:36-46).
FIGURE 1.7 Schematic demonstrating how HIY-1 exploits DC·SIGN to circumvent
antigen processing by dendritic cells and efficiently transfer virus to CD4+ T cells. (a).
HIV-l is captured by DC-SIGN+ DC, internalized into lysosome-like vesicles and
transported to distal lymphatic tissues protected from neutralizing antibodies, cytotoxic T
cell responses and other host defense mechanism. Upon arrival at lymphoid tissues, the
virus recycles back to the DC surface and is trans-transmitted to CD4+ T cells. (b) In the
presence of high levels of cell-free virus, DC-SIGN may enhance virus presentation to the
CD4+/co-receptor complex, promoting virus entry and productive infection of DC. The
newly synthesized virions are released into the circulation for subsequent infection of new
CD4+ target cells. (c) DC-SIGN may also function as antigen presenting receptor to
internalize and process viral antigens for 'presentation to T cells via MHC class I and II
molecules (van Kooyk et al. Nat Rev in ImmunoI2003;3:697).
FIGURE 1.8 Summary of the phenotypic and functional differences between
intestinal macrophages and blood monocytes. In the healthy mucosa, monocytes
recruited to the lamina propria acquire a distinct "anergic" phenotype as they become
mature into resident macrophages. Although these cells remain HLA-DR, CD13, CD36
and TGF-~ positive and retain their potent phagocytic and bactericidal properties, they do
not express innate response or co-stimulatory receptors, including receptors for
lipopolysaccharide (LPS), IgA, CR3, CR4, CD40, CD80, CD86, TREM-l or the HIV-l
co-receptors, CCR5 and CXCR4 (from Smith et al. Imrnunol Rev 2005;206:149).
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CHAPTER2
PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF CLASSICALLY (Ml)
AND ALTERNATIVELY (M2a) ACTIVATED HUMAN MONOCYTE-DERIVED
MACROPHAGES.
2.0 INTRODUCTION
Mononuclear phagocytes are characterized by extensive plasticity, wide-spread
tissue distribution and an ability to respond to a wide range of environmental stimuli, most
notably cytokines and microbial products 0-3). These endogenous and exogenous stimuli
interact with a broad range of cell membrane receptors resulting in altered intracellular
signaling and complex changes in gene activation and suppression. This, in tum, can lead
to changes in a number of important physiological processes including cellular adhesion
and migration, cytokine and chemokine production, antigen processing and host defense
mechanisms (4-7). The identification of biomarkers that can be used to discriminate
between these different modalities of mononuclear phagocyte activation would be highly
beneficial for understanding the relationship between activation and various
pathophysiological conditions.
By analogy to the THlffH2 nomenclature of CD4+ helper T cells, it has been
recently proposed that mononuclear phagocytes may also become polarized along either
classical pro-inflammatory (MI) or alternative anti-inflammatory (M2) activation
pathways (8-14). MI cells are classical pro-inflammatory macrophages that express high
levels of IL-l(3, IL-12, IL-23 and TNF-a, produce effector molecules such as reactive
oxygen and nitrogen intermediates, participate in the induction of polarized THI responses
and mediate resistance to tumors and intracellular pathogens. Monocyte-derived
macrophages (MDM) can be induced to differentiate into Ml cells with GM-CSF or IFN-
'Y, either alone, or in combination with bacterial LPS or TNF-a (11, 15, 16). In contrast, M2
macrophages are anti-inflammatory cells that secrete IL-IO, produce small amounts of IL-
12 and IL-23, express high levels of scavenger (CDI63) and mannose (CD206) receptors
84
(R) and participate in polarized TH2 responses (11. 15, 17-19). M2 macrophages are
generally considered to be more heterogeneous than Ml cells and, depending on their state
of activation, can participate in a number of diverse activities aiming at suppressing
inflammation, enhancing phagocytosis, promoting tissue repair and eliminating parasites
(3, 11, 15, 17-23). In order to reflect these different forms of activation, M2 cells have
been further subdivided into M2a, M2b and M2c subgroups (12). M2a (induced by
exposure of macrophages to IL-4 or IL-13) and M2b (induced by stimulation with immune
complexes, TLR or the IL-IR antagonist, ILlra) cells exert immuno-regulatory functions
and drive TH2 responses, while M2c macrophages (generated by stimulation with IL-lO)
play a predominant role in the suppression of immune responses and tissue remodeling
(12).
Transcriptome analyses conducted in mouse models, and more recently in human
cells, have identified a large number of genes that are differentially expressed in Ml versus
M2a macrophages. These studies have highlighted important interspecies differences in the
gene expression profiles associated with the Ml and M2a polarization (14). In this study, I
used a human monocyte-derived-macrophage (MDM) model to examine polarization-
induced changes in MOM function and phenotype at the protein level. Some cell surface R
were either up- or down-regulated in both Ml and M2a MOM relative to unpolarized
controls, while other R were differentially modulated by MI versus M2a polarization. One
surface R, dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin
(DC-SIGN) was strongly upregulated in M2a- and downregulated in MI-MOM. Several
cytokines and chemokines were differentially upregulated by Ml or M2a polarization. In
most cases, secretion of these cytokines and chemokines returned to baseline levels 3 to 7
days post-polarization. In contrast, two chemokines, CXCLlO (Ml) and CCL22 (M2a)
remained upregulated for at least 7 days after exposure to a single polarizing stimulus.
Further amplification of these signals was mediated by a transient down-regulation of
cytokines and chemokines typically secreted by macrophages of the opposite activation
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phenotype. Thus, Ml and M2a polarization programs appear to have a profound but
transient effect on macrophages, altering their capacity to respond to signaling events
involved in tissue homeostasis. Several of the markers described in this study may prove
useful in assigning a functional role to infiltrating macrophages in damaged tissue.
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2.1 MATERIALS AND METHODS
2.1.1 Reagents. Human recombinant cytokines and Lipid A (Escherichia coli F583)
were purchased from R&D Systems (Minneapolis, MN) and used at concentrations of 2
ng/ml, (TNF-a), 20 nglmL (IFN-y and IL-4) and 1 ug/ml, (Lipid A). All cytokines were
declared by the manufacturer to contain <0.1 ng/ug of contaminating LPS. Brefeldin A
(BFA) and BSA were purchased from Sigma-Aldrich (St. Louis, MO). Ab were purchased
from Immunotools (Friesoythe, Germany) unless otherwise specified. Ficoll-Hypaque was
purchased from Amersham Pharmacia Biotech (Piscataway, NJ). DMEM, PBS, FBS,
normal human serum (NHS), penicillin, streptomycin, and glutamine were obtained from
Cambrex (Verviers, Belgium).
2.1.2 Isolation of monocytes and differentiation of human monocyte-derived
macrophages (MDM). PBMC were isolated from the buffy coat of healthy blood donors by
Ficoll-Hypaque density gradient centrifugation. The cells were then washed, re-suspended
in complete culture medium (D-MEM) supplemented with 1% penlstrep, 1% glutamine,
10% heat-inactivated FBS and 5% heat-inactivated NHS and seeded into 75 cm2 flasks
(Falcon, Becton Dickinson Labware, Lincoln Park, NJ) at 8xIQ6 cells/mL. After 2 h of
incubation at 37° C in a humidified atmosphere containing 5% C02 non-adherent cells
were removed by gentle pipette aspiration; an equivalent volume of fresh complete
medium was added to each flask. After 24 h of culture, adherent cells were washed twice
with PBS, detached from the flask by scraping with a rubber policeman, and counted after
Trypan blue vital dye staining. The cells ~85% monocytes as determined by staining with
anti-CDl4 mAb and flow cytometric analysis) were seeded into 48-well plastic plates
(Falcon) at 2.5xl05 cells/well and cultivated for 7-8 additional days at 37°C in 5% CO2 to
promote their full differentiation in MDM (24). Seven-day-old MDM ~95% CDI4+) were
then stimulated with either IL-4 or TNF-a plus IFN-y for 18 h in order to obtain M2a or
Ml cells, respectively, as described (14). Following 18 h of cytokine stimulation, Ml-,
87
M2a-, and control (unstimulated) MOM were washed with cytokine-free medium and
further analyzed in parallel cultures.
2.1.3 Flow cytometric analysis of cell surface determinants. Adherent MOM were
washed with cold EDTAlPBS (2 mM) and detached from the plastic plates by incubation
with cold EDTAlPBS for 30 min at 4 °C and scraping with a rubber policeman. Non-
specific binding of Ab was eliminated by pre-incubation of the cells in medium containing
15% serum (10% FBS and 5% NHS) for 15 min at 4 °C. Cells were then labeled by
incubation with mAb for 30 min at 4°C. Anti-CDI8 (FITC), anti-CD4 (PE) and anti-HLA-
DR (PE) were purchased from Immunotools (Immunotools, Friesoythe, Germany); anti-
CXCR4 (PE) mAbs from Becton Dickinson (Frankline Lakes, New Jersey); anti-CDl6
(PE) from Beckman Coulter (Miami, Florida) and anti-CD 163 (PE) and anti-CD209 (PE)
mAb were obtained from and R&D Systems. Cells were washed with cold PBS and fixed
with 2% paraformaldehyde (PFA). CCRS expression was assessed using biotinylated
human CCL4 (Fluorokine, R&D Systems). Flow cytometric acquisition was performed by
means of CYAN ADP flow cytometer (DAKO Cytomation, Glostrup, Denmark) and the
results were analyzed with the FlowJo software version 8.4.3 (Tree Star Inc., Oregon). ).
Results are reported as percentage of positive cells and mean fluorescence intensity (MFI),
the later describing the level of expression on positive cells.
2.1.4 Cytokine and chemokine expression. Commercially available ELISA kits
(R&D Systems) were used to individually measure CCL3, CCL22 and CCL24
concentrations in MOM culture supernatants. Customized Bio-Plex plates (Bio-Rad,
Hercules, eA) were used to quantify secretion levels of IL-l, IL-lra, IL-6, IL-lO, IL-12,
CCL2, CCL4, eeLS and CXCLI0 according to the manufacturers' instructions.
Intracellular staining for CCL3 expression was determined after 18 h of polarizing
cytokine stimulation in medium containing BFA (1 J.lglml). Following cytokine
stimulation, Ml- and M2a-MDM were detached from the plastic surface by scraping and
fixed in 2% PFA. The cells were then permeabilized with Saponin buffer (0.1% Saponin,
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0.5% BSA in PBS) and stained with Allophycocyanin conjugated anti-CCL3 Ab for 30
min at 4°C. After staining, the cells were washed twice with cold PBS and analyzed with a
CYAN ADP apparatus (DAKD Cytomation).
2.1.5 Statistical analysis. Prism 5 from GraphPad Software (La Jolla, CA) was used
for statistical analyses. Results are reported as mean values ± SD. The values were first
normalized to those of unstimulated control cells and the analysis of variance followed by
one-way ANDVA and the Tukey post-test. To compensate for inter-donor variability, all
assays were performed on triplicate samples with MDM derived from 4 to 6 independent
donors, as further specified.
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2.2 RESULTS
2.2.1 Cytokine polarization shapes MDM morphology. After 7 days of
differentiation, prior to stimulation with either TNF-a plus IFN-y (Ml) or IL-4 (M2a),
MDM exhibited a mixed morphology consisting of approximately equal numbers of
spindle-shaped fibroblastoid and large flat-round/fried egg-shaped cells (50.5±6.2 and
49.56.1 %, n=5), respectively (Figures 2.1 A, left panel). Stimulation for 18 h with Ml
polarizing cytokines led to a significant increase in the number of fibroblastoid cells
(69±6.2%, n=5, p=O.027 vs. controls; Figure 2.1 B) and in the length of the cellular
projections extending from the cell poles (Figure 2.1 A, middle panel). Conversely, IL-4
stimulation of MOM was associated with a significant increase in the number of flat-round
cells (73±14.1%, n=5, p=0.016 vs. controls; Figure 2.1 B). When compared to control
MDM, M2a cells exhibited a more condensed morphology with short cellular projections
accumulating at the poles of the cells (Figure 2.1 A, right panel). Activation had no
adverse effect on cell survival as assessed by Trypan blue dye exclusion.
2.2.2 Differential expression of cell surface molecules by MI- and M2a-MDM.
Recent transcriptional profiling has led to the identification of more than 2,000 genes that
are regulated by MI or M2a polarization (14). Although highly informative, it is well
known that the levels of a given RNA transcript do not always correlate with the amount of
protein that is synthesized and, eventually, secreted (25). In this study, I investigated and
quantified changes in protein expression in response to M I vs. M2a polarization, focusing
on cell surface determinants that are known to playa key role in immune modulation and
RIV pathogenesis. Some molecules, such as the integrin f3 chain COlS, were highly
expressed in control MOM and were unaffected by either MI or M2a polarization both in
terms of the percentage of positive cells and their mean fluorescence intensity (MFI;
Figure 2.2 and Table 1). Other surface molecules showed a similar increase (or decrease)
in both MI- and M2a-MDM. RLA-OR, which was highly expressed in control MOM, was
further upregulated in terms of MFI in both MI- and M2a-MOM (Figure 2.2 and Table 1).
90
A significant decrease in the percentage of cells expressing CD4 and CXCR4 occurred in
Ml and, to a lesser extent, in M2a cells (Figure 2.2 and Table 1). In contrast, expression
of CCR5, remained unchanged and, in some donors, was upregulated on the surface of
M2a-MDM vs. Ml- and controls (Figure 2.2 and Table 1). These surface molecules serve
as the main entry R (CD4) and co-R (CXCR4, CCR5) for RIV-I, the causative agent of
AIDS (26-28). The biological implications of RIV-l R modulation will be further
discussed in Chapter 3.
Other surface R were differentially regulated by cytokine polarization. The FcyRIII
(CD16) and the hemoglobin scavenger (CD163) R were clearly expressed on control
MDM (Figure 2.2). Exposure to Ml cytokines significantly decreased the number of both
CD16+ and CD163+ cells in association with the disappearance of a brightly stained
population of cells bearing the CD163 molecule (Figure 2.2). Ml stimulation also resulted
in a down-regulation in the number of these R on a per cell basis, especially in the case of
CD16+ (Table 1). Polarization towards M2a-MDM, on the other hand, had no effect on
either the number of positive cells, or level of CD16 or CD163 expression relative to
control MDM (Figure 2.2 and Table 1).
2.2.3 DC-SIGN is selectively upregulated in M2a-MDM and downregulated inMl-
MDM. DC-SIGN, a molecule that plays a crucial role in capturing viral pathogens such as
RIV and hepatitis C virus (HCV) (29-32) on the surface of myeloid DC (33), was
expressed at low levels on the surface of control MDM (Figure 2.2). A near complete
disappearance of DC-SIGN was observed in MI-MDM. This is in sharp contrast to the
upregulation of this receptor on M2a cells, both in terms of percentage of positive cells and
MFI (Figure 2.2 and 2.3, and Table 1).
2.2.4 Differential patterns of chemokine and cytokine secretion by M1- and M2a-
MDM. The impact of Ml- and M2a-MDM polarization on the secretion of different
chemokines (CCL2, CCL3, CCL4, CCLS, CCL22, and CXCLlO), pro-inflammatory (IL-
l~, IL-6, 1L-12) and anti-inflammatory (IL-lra, IL-lO) cytokines was evaluated in cell
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culture supernatants collected at regular intervals post-stimulation. After 18 h of
differential stimulation, a significant upregulation of CXCLlO, CCL3 and CCrA was
observed in the supernatants of MI-MDM relative to M2a-MDM (215 vs. 2.5 fold, 25 vs.
2.2 fold, and 14 vs. 1.6 respectively; Table 2). CeLS, which was undetectable in both
control and M2a-MDM, was significantly upregulated in MI-MDM in 50% of donors
(Table 2). M2a-MDM, on the other hand, showed a 3-fold increase in CCL22 and a
relatively modest but significant 2-fold reduction in CCL2 production.
In order to determine whether activation induced polarization affected the entire
MDM population, or only a cell subset of these cells, the synthesis of the Ml-induced
chemokine, CCL3, was measured at the intracellular level using a fluorescence-labeled
anti-CCL3 Ab. Although no changes were detected in the MPI of ccts' MI-MDM versus
control MDM, a clear increase in the percent of CCL3+ cells was observed in Ml- relative
to control MDM (ie. from 1-3% to 12-21%, a mean increase of 7 ± 2.31-fold vs. Nil )(n =
5, p=0.023; Figure 2.4 A). Stimulation with Lipid A resulted in an even greater (20-fold)
increase in both the number and MFI of MDM expressing intracellular eCL3 (Figure 2.4)
suggesting that Ml polarization affects only a subset of the macrophages with the potential
to secrete eeL3. Compared to chemokine secretion, the impact of Ml and M2a
polarization on cytokine production was quantitatively less dramatic. A 2.3-fold increase in
IL-6 and a 5.2-fold increase in IL-IO secretion was observed after 18 h of polarization with
Ml and M2a cytokines, respectively, while no effects were observed on either IL-12, IL-
1~ or IL-lra secretion (Table 2).
2.2.5 Transient nature of Ml-MDM and M2a-MDM functional polarization. To
examine the duration of the stimulatory response, MDM were polarized for 18 h toward
either an Ml or M2a phenotype, and then incubated for an additional 7 days in fresh
cytokine-free complete medium. Removal of the stimulatory cytokines led to a near
complete reversal of Ml- and M2a- induced morphologies. These morphological changes
were associated with a parallel reversion in Ml and M2a surface R phenotypes (data in
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chapter 3 and 4). Most secretory molecules, including CCL3, IL-6 and IL-lO, returned to
baseline levels 3 to 7 days after removal of the polarizing cytokines (Figure 2.S). In
contrast, CXCLIO secretion remained significantly (p=O.004) upregulated for at least 7
days in MI-MDM compared to control cultures. Furthermore, secretion of CCL22, a
chemokine upregulated in M2a-MDM, was further upregulated after the removal of IL-4
(p=O.032). CCL22 expression remained above control levels until day 7, the last time point
studied (Figure 2.S).
2.2.6 Contra-regulatory effects of M1IM2a polarization on cytokine and chemokine
expression. In addition to the fading of most Ml- and M2a-MDM features, removal of the
polarizing cytokines was associated with an impaired secretion of cytokines and
chemokines associated with the opposite polarization pathway. In particular, secretion of
the Ml-associated factors CCL3, CXCLIO and IL-6 was significantly, although
transiently, decreased in M2a cultures following removal of IL-4. Conversely, secretion of
the M2a-associated molecules CCL22, IL-lO, and IL-Ira was decreased in MI-MDM
(Figure 2.6). Thus, although transient, the polarized secretion of MI and M2a cytokines
and chemokines is amplified by a secondary wave of down modulation involving
molecules of the opposite activation pattern.
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2.3 DISCUSSION
In this study, I investigated the phenotypic and functional properties of
differentially polarized human MDM obtained after 18h of stimulation with TNF-a plus
IFN-y (MI-MDM), or IL-4 (M2a-MDM), respectively. MI-MDM assumed a
predominantly fibroblastoid shape while M2a-MDM were mostly flat-round/fried egg-
shaped. Certain cell surface R, such as CD16 (FcyIIIR) and CD163 (hemoglobin scavenger
R), were differentially regulated in Ml- vs. M2a-MDM, whereas others were concordantly
up- (CCR5, HLA-DR) or down- (CD4, CXCR4) modulated in both Ml and M2a-MDM.
DC-SIGN was the only determinant showing a clear-cut, reciprocal pattern of
downregulation in Ml- and upregulation in M2a-MDM. Polarization-induced changes in
chemokine expression were more dramatic than those observed for cytokines. CCL3 and
CXCLIO were upregulated in MI-MDM. CCL22 was upregulated and CCL2 was
downregulated in M2a-MDM. Most phenotypic and functional changes were transient with
full reversion occurring 3-7 days after removal of the activating stimulus. The two
exceptions were CCL22 (M2a) and CXCLlO (MI) which remained upregulated for at least
7 days post-stimulation. Finally, a "mirror image" downregulation of Ml cytokines and
chemokines in M2a-MDM and of M2a cytokines and chemokines in MI-MDM was noted
with trough levels occurring 1-3 days after removal of the polarizing cytokines.
The finding that MI-MDM were mostly fibroblastoid-like, whereas M2a-MDM
were primarily flat-round, egg-shaped cells is consistent with previous studies (20).
However, it has also been reported that exposure of MDM to TGF-~, a type 2 cytokine
with anti-inflammatory properties, induces a fibroblastoid-like morphology similar to Ml
macrophages (20). While correlated to Ml and M2a polarization, this suggests there is no
absolute associated between morphology and inflammatory and ant-inflammatory profiles.
Of particular note, was the clear-cut upregulation of DC-SIGN on M2a-MDM. This
finding is in sharp contrast to its downregulation on MI-MDM and its low-level expression
on control macrophages. These results are compatible with transcriptome studies showing
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a 27-fold increase of DC-SIGN mRNA in M2a- relative to MI-MDM (14). DC-SIGN+ DC
have been shown to secrete TNF-a and IL-6 in response to LPS (37), stimulate the
proliferation of allogeneic T-cells and capture, store and effectively transmit HN-l to
CD4+T lymphocytes in trans (38). My observations suggest that DC-SIGN+M2a-MDM
may exhibit similar functions including the ability to transmit HIV-1 in trans (see Chapter
4). When expressed on alveolar macrophages and Kupffer cells, DC-SIGN may also
contribute to the establishment and dissemination of diseases such as Ebola, Marburg and
SARS or HCV respectively (30, 31, 39, 40).
CD16 (FcyRIII) and CD163 (hemoglobin scavenger) R were expressed at high
levels on control and M2a-MDM, but not on MI-MDM. Upregulation of CD16 on human
monocytes stimulated with GM-CSF, IL-4 and IL-lO, and its downregulation by TGF-~,
have been previously reported (41). In mice it has been reported that CD16 and other FcR,
such as CD32 and CD64, are increased on the surface of Ml, but not M2a, macrophages
further indicating that there are important differences between the murine and human
systems (12). Interestingly, CD16+ monocytes are increased in several inflammatory
diseases and in the central nervous system increased infiltration and differentiation of HIV-
l-infected CDI6+ monocytes into perivascular macrophages is associated with
development AIDS-related dementia.
Expression of HLA-DR, a prototypic marker of immunological activation, was
increased on both Ml and M2a cells with a greater increase occurring in MI-MDM. These
results are consistent with published data showing that IFN-y upregulates HLA-DR in most
macrophages, while IL-4 increases HLA-DR expression on a subset of macrophages only
(18, 42). MDM stimulated with IFN-y have also been shown to express higher steady state
levels of HLA-DR mRNA and surface Ag expression compared to cells stimulated with
IL-4 (42).
CCR5 and CXCR4, the main HIV-l entry co-receptors (26, 44), were also
modulated by polarization. Similar to HLA-DR, CCR5 was upregulated, in some donors,
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by M2a activation. Although CCR5 is well-recognized marker of T cell activation,
regulation of its expression on macrophages is not well defined. Some studies have
suggested that IFN-y upregulates CCR5 on adult blood monocytes (45), while others have
reported downregulatory effects (46). In contrast to CCR5, CXCR4 was downregulated on
both MI- and M2a-MDM. These results differ from studies conducted in T cells (47-49)
and from a recent transcriptional study showing that, in humans, M I polarization leads to
an upregulation of CXCR4 mRNA (14). However, our results are is in agreement with
publications showing that, at the protein level, both IFN-y and IL-4 decrease CXCR4
expression (46,50).
In agreement with transcriptome studies (14), differential regulation of chemokine
secretion was a dominant feature of MI and M2a polarization of human MDM. A major,
and consistent, upregulation of CCL3 (MIP-Ia) and CCL4 (MIP-I~) and an even greater
increase in CXCLlO (Interferon Inducible Protein-If), IP-IO) was observed in MI-MDM
vs. control and M2a-MDM. Secretion of these chemokines has been linked to the
recruitment of activated Thl cells, NK cells, and mononuclear phagocytes expressing
either CCRI and CCR5, or CXCR3, respectively (12). CCL22 (Macrophage Derived
Chemokine, MDC), a chemokine that was constitutively expressed before polarization,
was even further up-regulated in M2a- relative to MI- and unstimulated MDM. The failure
to super-induce CCL22 expression in MI-MDM is consistent with the known inhibitory
effect of IFN-y on CCL22 expression (5, 12). Another chemokine constitutively expressed
by MDM, CCL2 (MCP-I) was downregulated in M2a-MDM vs. control cells (Table 2).
This chemokine plays a central role in the recruitment of' monocytes to sites of tissue
inflammation. The impact of M IIM2a polarization on cytokine secretion was less
quantitatively important than that observed for chemokines. However, the patterns
observed confirmed the pro- and anti-inflammatory commitments of the MI and M2a
activation programs.
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A recurrent finding was the significant overlap in expression patterns between
control and M2a-induced markers. In this regard, it has been suggested that the M2
activation may represent a default phenotype that serves to maintain a balanced
microenvironment in the lung, gut and other tissues that are under constant microbial
stimulation (11, 14). Alternatively, circulating monocytes may be predisposed toward a
M2 phenotype as a result of exposure to relatively high levels of M-CSF in plasma (from
187-7,604 pg/ml) (51). This hypothesis, suggested by Martinez et a1. (14), was based on
transcriptional data showing that M1 polarization is associated with more dramatic
variations in steady-state mRNA relative to M2a polarization (90% vs. 8% variance from
the control, respectively).
Along with morphological heterogeneity, some cell surface markers, including
CD16, CD163, HLA-DR, CCR5 and DC-SIGN, showed a heterogeneous bimodal
distribution pattern when analyzed by flow cytometry. Heterogeneity within our MDM
population was further confirmed in experiments showing differences in the number of
MI-MDM expressing intracellular eeL3 after activation with IFN-y plus TNF-a. versus
Lipid A, a stimulus that acts via the CDl4ffLR4 complex, to up-regulate eeL3 expression
(52). (15% and >80%, respectively). These findings suggest that IFN-y plus TNF-a.
stimulates only a subset of MDM that are capable of producing eCL3. The reasons why
our MDM appear more heterogeneous than in another recent study are unclear (20), but
may be due to differences in culture conditions, the type of stimulus, and (or) the duration
of the activation period. Our polarization protocol was adopted and modified from
previous studies conducted with human cells (14). However, our monocytes were
differentiated in the presence of human serum rather than GM-CSF and/or M-CSF (24). It
has been suggested that these two cytokines can pre-bias MDM toward either M1 (GM-
eSF) or M2 (M-eSF) pathways, reducing the inherent heterogeneity of the MDM
population (3, 11, 14,53).
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My study also yielded new information on the kinetics of MIIM2a polarization and
its reversibility. Similar to other studies (14), most polarization-induced changes were
detected after only 18 h of polarization confirming the ability of macrophages to rapidly
respond to a range of different inflammatory and anti-inflammatory signals. In contrast to
most activation markers, which showed a rapid return to baseline within the first 3 days,
secretion of CXCLlO and CCL22 remained persistently elevated for at least 7 days after
removal of the polarizing signals, in Ml- and M2a-MDM, respectively. These findings
suggest that some functional aspects of MI and M2a polarization are relatively long-
lasting despite removal of the inductive signal. In this regard, I also detected a symmetrical
wave of counter modulatory effects leading to the downregulation of Ml-associated
cytokines and chemokines in M2a-MDM, and ofM2a cytokines/chemokines in MI-MDM.
These effects included the downregulation of IL-lO, IL-Ira and CCL22 secretion in MI-
MOM, and of IL-6, CXCLlO (IP-IO) and CCL3 (MIP-Ia) in M2a-MDM as well as
downmodulation of CD4 and CXCR4 in both polarizing conditions. These observations
are consistent with studies describing the inhibitory effects of IL-4 (an M2fTh2-inducing
cytokine) on the Ml-associated chemokines CCL5 (RANTES), CXCL9 and CXCLIO (IP-
10) (12).
In summary, I have identified a discrete panel of protein biomarkers that can be
used to investigate and accurately discriminate between pro-inflammatory MI (DC-
SIGNoeg,CXCLlO, CCL3, IL-6) and anti-inflammatory M2a (DC-SIGN+, CCL22, IL-lO)
macrophages in humans. These markers should prove useful for investigating the impact of
different tissue environments on macrophage phenotype and function, and for elucidating
the contribution of macrophages to a wide range of pathological conditions, including
cancer and infectious diseases.
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2.4 TABLES
Table 1. Cell surface phenotype changes (percent) in M 1- and M2a- vs. control MDM.
Marker N° Parameter Ml M2a Ml vs. M2a vs. ~l vs
Control Control M2a
positive cells O.87±O.39 1.14±O.O5
CD18 4 MFI 1.00±O.16 1.19±O.27
positive cells O.14±O.OS O.32±O.OS ** ** *
CD4 5 MFI O.92±O.O7 O.91±O.O5 * *
positive cells O.2S±O.23 O.50±O.O9 * **
CXCR4 5 MFI 1.13±O.29 1.14±O.21
positive cells 1.27±O.O6 1.87±O.72
CCRS 5 MFI O.98±O.Ol O.91±O.11
positive cells 1.07±O.O6 1.00±O.72 * *
HLA·DR 4
MFI 1.89±O.Ol 1.57±O.11 * *
positi ve cells O.O9±O.11 O.92±O.13 ** *
CD16 4 MFI O.34±O.41 O.94±O.15 *
positive cells O.57±O.1O O.9S±O.02 * *
CD163 4
MFI O.42±O.10 O.92±O.10 * **
DC· positive cells O.34±O.11 9.0S±2.93 * * *
SIGN 4 MFI O.74±O.25 2.11±1.11 * *
"Fold changes vs. control MDM. Expression of surface antigens was analyzed by cytofluonmetnc
assay. *p:5(>.D5,** p:50.001 as assessed by one way ANaVA and tukey post test. "N identifies the
number of independent monocyte donors.
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Table 2. Cytokine and chemokine secretion changes (percent) in Ml- and M2a- vs. Control MDM.
Chemokinel Range Mean° Ml M2a Ml vs. M2a vs. Ml
Cytokine N° (Control) ±SD (fold vs. (fold vs. Control Control vs.
(pg/ml) control) control) M2a
CCL2 4 2,519 - 8,506 5,OO6±2,783 1.4±0.6 0.5±0.3 * *
CCL3 6 26 - 274 82.5±96 25±8.3 2.2±1.1 * * *
CCL4 6 154-4,532 222±58 14±5.4 1.6±o.8 ** **
CCLS 6 "n.d "n.d 69±85.8 "n.d
CCL22 4 165-886 398±330 1±0.4 3.9±0.3 * *
CXCLIO 4 185 - 6,186 1,734±2526 215±157 2.5±3.3 * *
IL.l~ 4 0.17 - 0.28 O.21±o.04 1.1±O.5 1.1±O.3
Hs-Ira 6 115 - 3,031 1,572±1458 1.0±O.3 0.9±0.3
IL-6 4 0.38 - 18 6.9±7.6 2.3±1.1 1.0±0.3 * *
IL·I0 6 0.99- 18 6.2±6.9 1.7±O.7 5.2±3.5 * * *
Chemokines and cytokines were tested after 18 h of polarizing stimulation ofMDM. * p~.05 as
assessed by one way ANOV A and tukey post test. "n.d = not detectable
100
2.5 FIGURE LEGENDS
Figure 2.t Morphology of polarized and unpolarized MDM cultures. A.
Monocytes were differentiated for 7 days in complete medium containing human serum
and then cultivated for additional 18h in the same medium (Control), or in medium
containing Ml or M2a inducing cytokines (Original magnification: 40X). B. Mean
percentage of fibroblastoid vs. flat-round cells in Ml- and M2a-MDM established from the
PBMC of 5 independent healthy donors. *p ~O.05 (Ml vs. M2a vs. Control for both
morphological types). Percentages were determined by counting the number of
fibroblastoid and flat-round cells from 3 individual fields per each culture condition from
MDM of every donor.
Figure 2.2 Cell surface determinants of Ml- and M2a·MDM. The results shown
refer to the analysis of MDM derived from monocytes of a single donor representative of 5
donors tested. Unstimulated MDM and MDM activated for 18 h with Ml or M2a cytokines
were labeled with a panel of mAb and analyzed using Cyan ADP flow cytometer and
FlowJ0 software.
Figure 2.3 Differential expression of DC·SIGN on Ml- and M2a·MDM. MDM
were stained with a PE conjugated mAb directed against DC-SIGN. Results of the MDM
cultures established from 4 independent donors are expressed as the average fold
induction/reduction relative to their unpolarized control cells.
Figure 2.4 Up regulation of CCL3 expression in a subset of Mt·MDM. A.
Intracellular levels of CCL3 in control (Nil) MDM, and in MDM stimulated with Ml or
M2a polarizing cytokines or with Lipid A. Results from MDM cultures established from
monocytes of a single donor representative of five tested are shown. B. Percentage and
MFI of CCL3 expressing cells in control MDM (Nil) and in MDM subjected to different
polarizing conditions. MDM were established from monocytes of 5 independent healthy
donors. *p ~O.05 (Ml vs. M2 vs. Nil)
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Figure 2.5 Transient modulation of cytokine and chemokine secretion in Ml-
and M2a-MDM. Ml- and M2a-MOM were washed and cultivated for 7 days in complete
cytokine-free medium. In order to normalize inter-donor variability and differences in
secretion levels among different analytes, all results were expressed in terms of fold
induction/reduction relative to autologous control cultures. Levels of cytokines were
assessed using custom-made Bio-Plex plates (If-Ira, IL-6, IL-lO, CXCLlO) or
commercially available ELISA assays (CCL3, CCL22). The bar graphs show the average
result for 4-6 donors per cytokine, and are expressed as the fold induction relative to
control MOM (*p ~O.05, one way ANOVA).
Figure 2.6 Transient downregulation of opposing chemokineslcytokines
following Ml and M2a activation. After removal of the stimulatory cytokines a transient
down-regulation of M2a-related cytokines and chemokines was commonly observed in Ml
stimulated MOM, and of Ml-related cytokines/chemokines in M2a-MOM. Results are
expressed as the average of the mean fold induction of 4-6 donors per secreted
chemokine/cytokine. Statistical differences were assessed using one way ANOVA and
tukey post-test.
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2.6FIGURES
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CHAPTER3
Ml ANDM2a POLARIZATION OF HUMAN MONOCYTE·DERIVED MACROPHAGES
INHmITS HIV·l REPLICATION BY DISTINCT MECHANISMS
3.0 INTRODUCTION
Cells of the macrophage lineage playa pivotal role in a broad range of innate and
adaptive immune responses. In addition, they are an important early target cell for human
immunodeficiency virus type 1 (HN-l) and contribute to the dissemination and cell-to-cell
spread of the virus (1-4). Unlike CD4+ T cells, macrophages are less refractory to the
cytotoxic effects of RN -1 and because of their longevity and ubiquitous distribution in
tissues and organs serve as viral reservoirs throughout the course of RN-l disease (3-5).
The early establishment of viral reservoirs during primary infection (6-8) has stimulated
interest in characterizing the mechanisms underlying the persistence and replication of
RN-l in both CD4+ T cells and monocyte/macrophages (9, 10).
Macrophages respond to a variety of different cytokines and microbial gene
products and their susceptibility to RN -1 is profoundly influenced by these stimuli (11-
16). Interferon-c/-B (IFN-a/-~)potently inhibit HN-l replication in macrophages while
other cytokines, including interleukin-l (IL-l) and IL-6 stimulate viral replication (17-19).
Depending on the stage of macrophage differentiation and the timing of cytokine exposure,
some cytokines can either promote or inhibit RIV -1 infection. IL-4 and IL-13, for example,
enhance viral replication in monocytes, but inhibit replication in differentiated monocyte-
derived macrophages (MDM) (20, 21). On the other hand, exposure of MDM to tumor
necrosis factor-a (TNF-a) before infection is inhibitory, while stimulation of latently
infected macrophages or monocytic cell lines leads to the upregulation of virus
transcription and expression via activation of the cellular transcription factor NF-kB (16,
22,23).
A relatively recent concept in immunology, developed primarily in mouse models,
has been the observation that cytokine stimulation can trigger the polarization of
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macrophages into opposing pro- and anti-inflammatory programs. By analogy with CD4+
T helper (TH) cell differentiation, these polarization pathways have been designated M 1
and M2 (24-26). M2 macrophages are generally considered to be more heterogeneous than
MI cells. To reflect these differences M2 cells have been further subdivided into M2a,
M2b and M2c subgroups (24). M2a (induced by exposure to IL-4 or IL-13) and M2b
(induced by stimulation with immune complexes, TLR or the IL-IR antagonist, ILIra)
macrophages exert immunoregulatory functions and drive TH2 responses, while M2c cells
(generated by stimulation with IL-lO) play a predominant role in the suppression of
immune responses and tissue remodeling (24).
Recent molecular profiling of human MDM has identified >2,000 transcripts that
are differentially modulated during MI vs. M2a polarization giving rise to macrophages
with highly specialized phenotypic and functional properties (27). Although it is well
documented that cytokines playa critical role in the regulation of HIV-1 replication (28),
the effects of MI and M2 polarization on viral replication have not been thoroughly
investigated. In this study, I investigated the effects of MI (TNF-a plus IFN-y) and M2a
(IL-4) polarization on the ability of human MDM to support productive HIV-I infection.
The study focuses primarily on MI and M2a cells since these phenotypes mediate THI and
TH2 responses and it has been proposed that a switch from a THI to a TH2 immune
response may playa role in the pathogenesis of HIV-lIAIDS (29, 30). I found that both
polarization pathways led to a strong inhibition of virus production in association with
specific alterations in the expression of cell surface receptors, chemokines and cytokines
involved in HIV-I entry, replication and dissemination. However, the magnitude and
duration of the inhibitory response and the mechanisms underlying these responses were
clearly different in MI- versus M2-MDM. This study describes the transient and reversible
nature of these differential responses both in terms of cytokine/chemokine secretion and
the cells' capacity to support productive infection.
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3.1 MATERIALS ANDMETHODS
3.1.1 Reagents. Human recombinant cytokines were purchased from R&D Systems
(Minneapolis, MN) and used at concentrations of 2 ng/mL (TNF-a.) and 20 ng/mL (IFN-'Y
and IL-4), respectively. All cytokines were declared by the manufacturer to contain <0.1
ng of LPS per pg of protein. Ficoll-Hypaque was purchased from Amersham Pharmacia
Biotech (Piscataway, NJ). D-MEM, PBS, FBS, normal human serum (NHS), penicillin,
streptomycin and glutamine were obtained from Cambrex (Verviers, Belgium).
3.1.2 Isolation of human monocytes and their differentiation into monocyte-
derived- macrophages (MDM). Peripheral blood mononuclear cells (PBMC) were isolated
from the buffy coats of healthy HN -seronegative blood donors by Ficoll-Hypaque density
gradient centrifugation. The cells were then washed, resuspended in D-MEM containing
pen/strep (1%), glutamine (I %), heat-inactivated fetal bovine serum (FBS, 10%) and heat-
inactivated normal human serum (NHS, 5%) (complete medium) and seeded into 75 cm2
flasks (Falcon, Becton Dickinson Labware, Lincoln Park, NJ) at of 8xl06 cells/mL. Non-
adherent cells, including T lymphocytes, were removed by gentle pipette aspiration after 2
h of incubation at 37° C in a humidified atmosphere containing 5% CO2, and an equivalent
volume of fresh complete medium was added to each flask. After 24 h of culture, adherent
cells were washed twice with PBS, detached from the flask by scraping with a rubber
policeman, and counted after Trypan blue vital dye staining. These cells ~85% monocytes
as determined by flow cytometric analysis after staining with anti-CD14 mAb) were
seeded into 48-well plastic plates (Falcon) at the concentration of 2.5xlOs cells/well and
were cultivated for 7-8 additional days at 37°C in 5% CO2 to promote their full
differentiation into MDM (12). These cells ~95% CDI4+) were then stimulated for 18 h
with either TNF-a. plus IFN-y or IL-4 in order to obtain Ml- or M2a-MDM, respectively,
as described (27). MI-, M2a- and unstimulatedlunpolarlzed (control) MDM maintained in
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culture for 18 h in the absence of specific cytokines or polarizing stimuli were washed with
cytokine-free medium and further analyzed in parallel cultures.
In order to investigate the persistence of MOM polarization, M1-, M2a- and control
MOM were thoroughly washed and cultivated for 7 additional days in the absence of
further stimulation and monitored for cell surface antigen expression and
cytokine/chemokine secretion after 0, 3 and 7 days post-polarization.
3.1.3 Flow cytometric analysis of cell surface determinants. Adherent MOM were
washed with cold EDTAlPBS (2 mM) and detached from the plastic plates by incubation
with cold EDTAlPBS (2 mM) for 30 min at 4 °C and scraping with a rubber policeman.
Non-specific binding of Ab was eliminated by pre-incubating the cells in medium
containing 10% FBS and 5% NHS for 15 min at 4°C. The cells were then incubated with
anti-C04 (PE) (Immunotools, Friesoythe, Germany) monoclonal Abs (mAbs) for 30 min at
4°C, washed with cold PBS and fixed with 2% paraformaldehyde (PFA). CCR5 expression
was assessed using biotinylated human CCL4 (Fluorokine, R&D Systems). Flow
cytometry was performed using a CYAN ADP instrument (DAKO Cytomation, Glostrup,
Denmark) and the results were analyzed with the FlowJo software version 8.4.3 (Tree Star
Inc., Ashland, OR). Results are reported as percentage of positive cells and mean
fluorescence intensity (MFI), the later being used to describe the level of expression on a
population of positive cells.
3.1.4 Beta-Chemokine secretion and expression. Chemokines were quantified in
culture supernatants of MOM 18 h after their polarization (day 0) as well as on days 3 and
7 post-polarization. The levels of CCL3 released into the supernatants of MOM cultures
were quantified by commercial ELISA kits (R&D Systems), whereas the concentrations of
CCL4 and CCLS were determined in customized Bio-Plex plates (Bio-Rad, Hercules, CA).
These assays were performed according to the manufacturer's instructions.
3.1.5 HIV-J infection and replication. Control, Ml-, and M2a-MDM were infected
with the macrophage-tropic, CCR5-dependent (R5) laboratory-adapted strain HIV-18aLat
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the multiplicity of infection (m.o.i) of 0.1. In certain experiments, MDM were also infected
with RN-18aL (m.o.i.=O.l) 3 and 7 days after polarization. To assess virus production and
spread, multiple aliquots of the culture supernatant were collected every 3-4 days over a 5-
week period and stored at _200C. At the end of each culture period, these supernatants
were thawed and analyzed for virus replication by measuring the levels of reverse
transcriptase (RT) activity released into the supernatant, as described (12). The detection of
virion-associated RT activity in culture supernatants is a surrogate marker for de novo
virus production.
3.1.6 Quantification of HN-J DNA by real-time peR. Unpolarized control, Ml-
and M2a-MDM were infected with DNAse/RNAse-free RN-l8aL (m.o.i.=O.l) and were
then cultivated in complete medium for 48 h, a period estimated to be required for
completion of a single round of RN replication in macrophages (31). The infected MDM
(106 cells/mL) were then washed, resuspended in lysis buffer containing polyoxyethylene
10 lauryl ether (0.1%) and proteinase K (0.1 mglmL) from Sigma and digested at 65°C for
2 h; proteinase K was then heat-inactivated at 95°C for 15 minutes (32). An amount of
lysate corresponding to 2.5xl04 cells was amplified by real-time quantitative PCR
reactions using primers and a probe that recognize the RN -1 gag gene (33, 34): forward
primer 5'-ACATCAAGCAGCCATGCAAAT-3'; reverse primer 5'-
ATCTGGCCTGGTGCAATAGG-3'; probe 5'-(FAM) CATCAATGAGGAAGCTGCA
GGAATGGGATAGA (TAMRA)-3'. This primer/probe combination detects all forms of
viral DNA synthesized after second-strand transfer mediated by RT. The number of RN-l
DNA copies were normalized to those of human GAPDH by an external standard curve
showing a linear distribution (r=O.99) between 10 and 106 copies". The primers and probe
for GAPDH were: forward primer 5'-ACCACAGTCCATGCATCACT-3'; reverse primer
5'-GGCCATCACGCCA CAGITT-3'; probe 5'-(FAM)
CCCAGAAGACTGTGGATGGCCCC (TAMRA)-3'. Thermal cycling conditions for real-
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time PCR with SYBR Green quantification were 50 "C for 2 min and 95 °C for 15 min
followed by 40 cycles at 95 "C for 15 sec and 65 °C for 1 min (34).
3.1.7 Western blot analysis of cell-associated HIV-J proteins. Cells were scraped
from the wells with a rubber policeman and lysed with 100 ul of buffer C per million cells
(20 mM Hepes, 0.4 M NaCI, 0.1 mM EDTA, 0.1 mM EGTA, 1.5 mM MgCh. 0.5%
glycerol). Cellular proteins were denatured in an equal volume of 2x sample buffer (0.125
M Tris-HC!, pH 6,8; 4% SDS; 10% 2-2-ME; 20% glycerol) for 5 min at 100°C, separated
on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane (Hybond ECL;
Amersham) by electroblotting. Membranes were blocked in 5% nonfat milk, 20 mM Tris,
pH 7.6, 137 mM NaCl, and 0.2% Tween 20 for 30 minutes at room temperature and
further incubated for 1 hour with the serum (1: 1000 dilution) from an HIV-I-infected
individual containing high titers of anti-HIV-I Abs. Ab binding was visualized by using
HRP-conjugated anti-human Abs (Amersham Pharmacia Biotech, Piscataway, NJ). The
signal was detected using ECL reagents (Amersham) according to manufacturer's
instructions.
3.1.8 Statistical analysis. Prism 5 from GraphPad Software (La Jolla, CA) was used
for statistical analyses. Results are reported as mean values ± SD. To minimize inter-donor
variability, values were normalized relative to unstimulated control cells. One-way
ANOVA and the Tukey post-test were used for multivariate analysis. To further
compensate for inter-donor variability, all assays were performed on triplicate samples
with MDM derived from 4 to 6 independent donors, as further specified.
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3.2 RESULTS
3.2.1 Both Ml and M2a polarization of human MDM results in the inhibition of
RN-l replication. To assess the relative capacities of Ml- and M2a-MDM to support
productive infection, MOM were established from 15 independent HIV-I seronegative
donors and were either left unpolarized (controls) or were polarized with MI (TNF-a plus
IFN-y) or M2 (IL-4) inducing cytokines for 18 h, as previously described (Chapter 2), prior
to infection with R5 RIV-IBaL. Virus replication in control MDM increased progressively
reaching peak levels 14-18 days post-infection followed by a drop to low levels of
persistent replication (Figure 3.1 A). In contrast, HN-l replication was strongly inhibited
in polarized MOM with Ml cells showing a significantly stronger inhibition in comparison
to M2a-MDM (the mean inhibition of peak RT activity levels in Ml- and M2a-MDM vs.
control cultures was 92% and 62%, respectively). Although M2a polarization decreased
replication in all cell cultures, it did not affect the kinetics of HIV spreading as measured
by peak RT activity (Figure 3.1 A). The levels of viral suppression in MI-MOM ranged
from 51-75% in 20% of independent cultures to 76%-100% in the remaining 80% of
cultures (Figure 3.1 B). In comparison, the levels of suppression in M2a macrophages
ranged from <25% in 7% to 26-50%, 51-75% and >76% in 7%, 33% and 53% of
independent MOM cultures, respectively (Figure 3.1 B).
3.2.2 Ml and M2a polarization differentially modulates the expression of receptors
and chemokines involved in RIV-l entry. In order to investigate the effects of MI and M2a
polarization on MDM susceptibility to RN -1 infection, I monitored changes in the
expression of CD4 and CCR5 the primary receptor and the major co-receptors for RN-l
entry into monocytes and macrophages, respectively (35, 36). MI, and to a lesser extent
M2a polarization resulted in a significant reduction in the percentage of MOM expressing
C04, a finding that may account, at least in part, for their decreased capacity to support
productive infection (Table 1). In contrast, expression of CCR5, the major co-receptor for
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macrophage-tropic strains of HN -1, remained unchanged and, in some donors, was
upregulated on the surface ofM2a-MDM vs. Ml- and controls (Table 1).
Next, I investigated the effects of Ml and M2a polarization on the secretion of the
CCR5-binding chemokines CCL3, CCrA and CCL5. These chemokines are well-
characterized potent inhibitors of R5 HN-l entry in CD4+ T lymphocytes as well as in
MDM (16, 37). Secretion of CCL3 and CCrA was detected in all donors and was
significantly upregulated in Ml- vs. M2-MDM (25-fold in Ml vs. approximately 2-fold in
M2-MDM for CCL3; 14-fold in Ml vs. <2-fold in M2 for CCrA) (Figure 3.2 A). CCL5,
which was undetectable in both control and M2-MDM, was significantly upregulated in
MI-MDM (range: 61-186 pglmL) from 3 of 6 donors (Figure 3.2 A). The increased
production in CCL3, CCrA and CCL5 (in some donors) suggests that these chemokines
may contribute to the polarization-induced inhibition of HN-l replication in MI-MDM by
preventing or curtailing virus entry.
3.2.3 MJ, but not M2a, polarization restricts HW-J entry into MDM. To further
examine the mechanisms underlying the inhibition of HIV -1 replication in M 1- vs M2a-
MDM I quantified the amount of viral DNA that accumulated during the first 48 h of
infection, a time considered sufficient for a single round of virus replication in these cells
(31). Ml polarization consistently led to a marked decrease in the accumulation of HN-l
DNA (range: 54-97%) by 48 h after infection. In contrast, no statistically significant
differences were observed in the amount of HIV-l DNA that accumulated in M2a- and
control MDM at this time point (Figure 3.2 B), indicating a clear-cut difference in the
HN-inhibitory mechanisms induced by Ml vs. M2a polarization.
3.2.4 M2a polarization restricts HW-J production at the level of viral assembly
and/or budding. To further delineate the mechanisms underlying the inhibition of HN-l
infection in Ml- versus M2a-MDM, I measured the accumulation of viral proteins during
the first 7 days of infection using western blot methodology. As expected, Ml polarization
was associated with a marked decrease in the accumulation of HN -1 proteins relative to
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control cells (Figure 3.3 B). This data is consistent with the low levels of viral DNA in
these cells. In contrast, M2 polarization had no effect on the synthesis or accumulation of
viral proteins despite the marked reduction in the production and release of HN -1 virions
into the culture supernatant (Figure 3.3 A). The finding that HN-l protein levels in M2a-
MDM were similar to those detected in control MOM (Figure 3.3 B) provides further
confirmation that the restriction of HN -1 infection M2a occurs at a late step in the viral
life cycle (ie. post-transcription and post-translation).
3.2.5 Polarization-induced inhibition of virus replication is transient and of shorter
duration in Ml- vs. M2a-MDM. Next, I examined the duration of the anti-HN-l responses
following a single 18 h exposure to Ml and M2a-inducing cytokines. For these studies,
control and polarized MOM were thoroughly washed and infected with HN-IBaL either
immediately (day 0) or on days 3 and 7 post-polarization. Exposure to HIV-l immediately
after polarization led to a rapid decrease in HN-l replication in both MI- and M2a-MDM
relative to control cells. However, the kinetics and duration of the inhibitory response
differed in Ml and M2-MDM with the nadir of inhibition in M2a-MDM occurring on day
10 (Figure 3.4, upper left panel). A more prolonged suppression of virus replication
lasting for up to 25 days was observed in MI-MDM (Figure 3.4, upper left panel). When
infection was delayed until day 3 post-polarization, M2a-MDM still maintained their
ability to inhibit HN-I replication, whereas MI-MDM had already lost their inhibitory
phenotype in that they supported HIV replication at the same levels of control cells
(Figure 3.4, upper right panel). When MI- and M2a-MOM were infected 7 days after
polarization, replication levels were similar to those observed in control cells (Figure 3.4,
lower panel). Thus, the inhibitory effects of MDM polarization, particularly in the case of
MI-MDM, are transient and do not render macrophages permanently refractive to HN-l
infection and replication.
In parallel to these virological findings, removal of the polarizing stimuli led to a
near complete reversal of Ml and M2a cytokine/chemokine profiles (Chapter 2) and cell
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surface phenotypes by day 7. Significantly, three days after polarization, cell surface CD4
expression had returned to control levels in MI-MDM, whereas the return of CD4
expression on the surface of M2a-MDM to control levels occurred more slowly (Table 2).
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3.3 DISCUSSION
In this chapter, I demonstrate that MDM polarization into either Ml or M2a
macrophages leads to a restriction in their capacity to support productive HIV -1 infection.
Furthermore, Idemonstrated that such restrictions occur at different levels of the viral life
cycle (Le. entry/early, pre-integration events for MI- and post-transcription and translation
for M2a-MDM). Macrophage polarization into an Ml phenotype was associated with a
more profound suppression of HIV-1 replication and a more dramatic modulation of CD4
and f3-chemokines compared to M2a-MDM. The downregulation of CD4 and increased
secretion of CCL3, CCL4 and CCL5 correlated with a sharp decrease in HIV-l DNA
synthesis at 48 h, a decrease in the synthesis and accumulation of HIV -1 proteins at day 7
and a loss of inhibition in Ml cells infected 3 days after polarization. In contrast, M2a
polarization was associated with a less profound but more sustained inhibition of virus
replication with no detectable impairment of virus entry/reverse transcription or protein
accumulation. Finally, I demonstrate that the transient and reversible nature of Ml- and
M2a-MDM polarization (for most determinants, see Chapter 2) is associated with the loss
HIV-1 inhibition.
Collectively, my results indicate that impairment of early events in the HIV life
cycle (from viral entry to reverse transcription) is the main, if not sole, mechanism
responsible for inhibition of HIV-l replication in MI-MDM. This interpretation is
consistent with previous reports showing that both IFN-y and TNF-a can downregulate
CD4, thereby preventing or limiting HIV-l entry. In this regard, previous studies have
shown that IPN-y decreased CD4 expression in monocytes, while TNF-a, either alone or in
combination with IL-13 downregulated CD4, as well as CCR5 and CXCR4, from the
surface of MOM (16). My study confirms and extends these observations to MI-MDM
generated by the short-term co-stimulation of MDM with TNF-a plus IPN-y. Interestingly,
however, I found no decrease in CCR5 levels in spite of the high-level secretion of CCL3,
CCL4 and CCL5, the natural ligands of CCR5. These some what counter intuitive results
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are likely explained by the transient nature of the polarization phenotype induced by short
term stimulation.
While the down regulation of CD4 and up-regulation of beta-chemokines explains
the inhibitory phenotype of Ml MDM, the severity of inhibition makes it tempting to
speculate that additional factors may contribute to the phenotype. Consistent with
early/preintegration inhibition of Ml MDM, APOBEC3G expression increases in MDM
stimulated with IFN-a, but also, although to a lesser extent, with IFN-y (38). A cellular
protein, APOBEC3G is incorporated into HIV-1 virions and exerts its antiviral activity
after the virus has entered a new target cell by introducing C-to-U changes in the newly
synthesized single stranded cDNA (39). This, in tum, leads to G-to-A hypennutations in
the sense strand of retroviral DNA, a process that can lead to lethal mutagenesis in a single
replication cycle. Although not shown here, preliminary data clearly show that
APOBEC3G is up-regulated in our Ml MDM model system. ,
Another salient feature ofMl polarization ofMDM, as discussed in Chapter 2, was
the strong and sustained upregulation of CXCLIO (at least up to 7 days post-polarization),
a chemokine that plays an important role in promoting HIV-l encephalitis (40, 41).
Previous studies have shown that CXCLIO stimulates HIV replication by downregulating
the secretion of CCR5-binding chemokines, thereby enhancing viral entry (42-44).
CXCLlO associated enhancement of HIV -1 infection was not observed in our system,
likely as a result of the early potent inhibitory effects of TNF-a and IFN-y on CD4
expression, the upregulation of CCR5-binding chemokines and the resultant decrease in
HIV-I DNA accumulation. However, the prolonged secretion of CXCLI0 following Ml
polarization may have contributed to the downregulation of beta-chemokine secretion in
these cells (see Chapter 2).
CD4 was also downregulated in M2a-MDM, but to a lesser extent than in Ml-
MDM (Table 1). As previously reported for monocytes preincubated with IL-4 for 5 days
(45), however, the decrease in CD4 on M2a-MDM did not lead to a reduction in viral entry
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or in the accumulation of HIV-1 DNA at 48h and cannot explain the inhibitory phenotype
of M2a MOM. Interestingly, in monocytes exposed to IL-4 before infection, virus
production is highly dependent on an inhibition of cell proliferation during in vitro
differentiation into macrophages (45). In my studies, the IL-4-dependent increase in CCR5
expression observed in some donors, (Table 1) may have compensated for the decreased
levels of CD4 expression on M2a cells. This interpretation is consistent with the
observation that macrophages expressing high levels of CCR5 and low levels of CD4 are
fully susceptible to infection by R5 HIV-I, such as HN-iBaL (46). A feature that could
potentially account for the post-entry restriction of HN expression in our M2a-MDM is
the accumulation of transcriptional inhibitory p50 homodimers in the cell nucleus (47-49).
While we investigated this hypothesis, we did not find evidence of such a phenomenon, at
least not under the experimental conditions used in our study (data not shown).
The finding that the synthesis and accumulation of HIV -1 proteins was unaffected
by M2a polarization suggests that the block in HIV-l replication in M2a-MOM occurs at a
post-transcription/post-translation step of the viral life cycle, most likely at the level or
virion assembly or budding. This is in contrast to a study published by Schuitemaker et al.
who reported that the IL-4-induced inhibition of HN -1 replication in MDM occurs at the
level of reverse transcription (45). This apparent discrepancy is most likely due to
differences between the two MDM models. Unlike our I8-hour polarization protocol, they
differentiated monocytes for 5 days in the presence of IL-4 prior to infection (45). Other
studies have shown that exposure of MOM to IL-I0 prior to infection inhibits HIV-l
replication at the level of protein processing suggesting that M2a and M2c may inhibit
HN at similar levels (50).
Another distinctive feature of M2a-MOM from Chapter 2 that may have relevance
on HIV replication, was the persistent upregulation of CCL22 secretion. This was not
observed in either control or MI-MDM. In this regard, CCL22 was originally described as
a suppressive factor released by activated CD8+ T cells as part of their repertoire of non-
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lytic soluble inhibitory factors of HIV (51). Although this observation was not confirmed
by all laboratories (52, 53), we have reported that CCL22 inhibits HIV-l in MOM but not
in activated PBMC by acting at a post-entry step of the viral life cycle (12). This data is
consistent with the inhibition of HIV -1 replication observed with our M2a-MOM.
CCL2, a pro-inflammatory chemokine that was constitutively secreted by M 1 and
control MOM, was downregulated in M2a-MOM (see Chapter 2). In this regard, CCL2 is
involved in the early recruitment of monocytes to inflammatory lesions (14) and has been
shown to enhance the replication of X4 HIV -1 strains in activated PBMC (54) whereas
neutralization of this chemokine has been shown to inhibit the late phase of virion release
in primary MOM (55). Thus, the reduction in CCL2 secretion together with increased
CCL22 production may have contributed to the prolonged post-transcription/translation
inhibition of HIV-l replication observed in M2a-, but not in MI-, MDM.
Both MI- and M2a phenotypes were reversible 3 to 7 days after removal of the
inductive stimuli, although with some exceptions. Of interest, I observed symmetrical
contra-modulatory effects temporally associated with the loss of M 1 and M2a polarization.
This phenomenon may amplify and prolong the consequences of individual polarization
programs. In this regard, a strong correlation was observed between the return to a non-
polarized state and the loss of inhibition of viral replication, with MI cells exhibiting an
earlier recovery in both the expression of surface membrane CD4 and the capacity to
support HIV replication compared to M2a-MOM. With the exception of CXCLI0 (MI)
and CCL22 (M2a), both MI- and M2a-MOM showed a complete reversion to control
levels 7 days after the removal of polarizing cytokines. The transient nature of MI and
M2a phenotypes, at least for most determinants, suggests that the observed restrictions in
virus replication are linked to the complex and multi-factorial polarized phenotypes.
In conclusion, my findings suggest that cytokine-mediated polarization of mature
macrophages, as investigated in human MDM, may be an important regulator of
macrophage susceptibility to HIV-I infection and/or replication in polarized MI and M2a
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cells. The transient and reversible nature of the dynamic changes in cell phenotype and
activation status may represent a mechanism through which these cells, that are typically
resistant to the cytopathic effect of RIV -1(3-5), cycle between a state of resistance or latent
infection and productive viral expression and spreading.
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3.4 TABLES
Table 1. Fold changes of mv receptor and co-receptor expression in M 1- and M2a- vs. Control MDM.
Receptor N° Parameter Average Ml M2a Ml M2a Ml
Expression (fold over (fold over vs. vs. vs.
(control) vs. Cont) vs. Cont) Cont Cont M2a
Positive 41%±3.3 O.14±O.O8 O.32±O.O8
CD4 5 cells ** ** *
MFI 12±2.3 O.92±O.O7 O.91±O.O5
* *
Positive 21%±1.8 1.27±O.O6 1.87±O.72
CCR5 5 cells
MFI 44±3.1 O.98±O.Ol O.91±O.11
Mean fold change in the number of positive cells and MFI in Ml- and M2a-MDM vs. control
MDM. MFI and expression of surface receptors/co-receptors was analyzed by cytofluorimetry.
*p<O.05,**p<O.OOl as assessed by one way ANOVA and Tukey post-tests. N"denotes the number
of MDM donors studied.
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Table 2. Kinetics of CD4 expression following MDM polarization.
Days after N° Polarization % CD4+ Ml vs. M2a vs. Ml vs.
polarization MDM Control Control M2a
Control 41±3.3
0 5 Ml 6±1.9 ** ** *
M2a 13±2.6
Control 35±6.7
3 5 Ml 31±9.2 * *
M2a 13±5.5
Control 33±4.8
7 5 Ml 31±6.9
M2a 26±2.9
Mean CD4 expression on control, Ml- and M2a-MOM. *p:SO.05,**p~.OOl as assessed by one
way ANOVA and Tukey post-test. N° denotes the number of individual MOM donors tested.
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3.5 FIGURE LEGENDS
Figure 3.t Stronger inhibition of R5 HIV-t replication in Ml- vs. M2a-MDM.
A. The effects of MDM polarization on HIV-1 replication kinetics were monitored by
determination of the RT activity content in culture supernatants over a 35-day infection
period. The results represent the average replication (±SO) of infected MDM cultures
established from 15 independent donors. B. Pie chart showing the percent levels of
suppression of HIV-1 in the 15 infected MDM cultures studied. Values ranged from near-
complete/complete (76%-100%) inhibition in 80% of independent MI-MOM cultures to
51%-75% in the remaining 20% of cultures. Lower levels of inhibition of virus replication
were observed in M2a-MOM.
Figure 3.2 Differential secretion of CCR5-binding chemokines in Ml- and
M2a-MDM is associated altered accumulation of HIV-t DNA. A. Levels of CCL3,
CClA and CCLS secretion in control, Ml- and M2a-MOM determined after 18 h of
cultivation in the presence of polarizing cytokines, expressed as pglmL. These results
represent the mean (±SD) levels of cytokines secreted by MOM cultures established from
6 independent donors. B. Control, Ml- and M2a-MOM were infected with HIV-IBaL and
harvested after 48 h. Levels of HIV-1 gag DNA ranged from 52 to 4,463 copies per
1,000,000 cells in infected MOM, while uninfected MDM routinely expressed <1 copy
viral RNA per 1,000,000 cells. These results represent the mean (±SO) of 8 individual
infections of independent MDM cell cultures. Statistical differences were assessed using
the multivariate one-way ANOVA and Tukey's post-test.
Figure 3.3 Mt but not M2a polarization is associated with decreased viral
protein accumulation. A. Control, Ml and M2a were infected with HIVBAL(m.o.i, 0.1)
and RT activity was assessed in culture supernatant 7 days post-infection. The same cells
were also used in Western blot analysis. B. Accumulation of viral proteins was also
determined in control, M1- and M2a-MDM 7 days post-infection using the serum from an
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RIV-infected individual with high anti-RIV antibody titers. Results are representative of 3
independent experiments.
Figure 3.4 Time-dependent kinetics of inhibition of HIV-t replication in Ml-
and M2a-MDM. Ml-, M2a- or control MDM were infected either immediately after
polarization (day 0) or on days 3 arid 7 after polarization, as indicated by the arrows. The
results are shown as mean fold change in RT activity relative to unpolarized control MDM.
These results were obtained from a single MDM culture representative of 5 cultures
established from independent donors. The inhibitory effects were completely lost when
MI-MDM were infected 3 days after polarization, unlike what was observed for M2a-
MDM. The apparent increase in the replicative capacity of Ml- and M2a-MDM observed
at late time points in cells infected on days 0 or 7 is explained by the low levels of virus
replication detected in control MDM cultures.
132
3.6 FIGURES
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CHAPTER4
RESTRICTED PRODUCTION OF HIY-l IN DC-SIGN+ M2a MDM IS ASSOCIATED
WITH EFFICIENT TRANSMISSION OF HIY-l TO PBMC
4.0 INTRODUCTION
Cells of the macrophage lineage are one of the first target cells infected by HN-l
and they playa critical role in the cell-to-cell spread and dissemination of the virus,
particularly in the central nervous system (CNS) (1-3). Macrophages are relatively resistant
to the cytopathic effects of HIV-l and because of their longevity, abundance and
ubiquitous distribution in peripheral tissues serve as long-lived reservoirs of viral infection
(4-6). However, the ability of macrophages to support productive HIV-l infection is
profoundly influenced by cytokines and chemokines in the microenvironment (7-11). In
Chapters 2 and 3, I demonstrated that macrophages can be polarized into Ml (pro-
inflammatory) or M2a (anti-inflammatory) populations that differ in their phenotypic,
functional and regulatory properties, and in their ability to support virus production (12-
14). Another important finding arising from this work, with particular importance for HIV
pathogenesis, was the finding that DC-SIGN was differentially regulated on MI (down-
regulation) versus M2a- (upregulation) MOM. Since DC-SIGN mediates the capture and
transmission of HIV-l from dendritic cells (DC) to CD4 T cells in vitro (15,16), it has
been proposed that this molecule may play an important role in the dissemination and
transport of HIV-1 from sites of mucosal transmission to T cell areas of lymphoid tissues.
Numerous studies have reported that the DC-mediated transmission of HIV-I
involves the capture of extracellular virions by DC-SIGN and the subsequent transfer of
this virus to permissive T cells, with or without internalization (15-18). In contrast, the
mechanisms underlying the transmission of HN -1 from macrophages to T cells have not
been thoroughly investigated. Similar to DC, MDM-mediated transmission appears to take
place across a transient virological synapse (VS) formed at the MDM-T cell interface (19).
Assembly of the VS is driven by the co-polarization of HIV-I Gag and Env in the MOM
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with CD4+ on T cells and is most likely stabilized by cell-cell adhesion interactions (19).
Other studies have shown that in HN -l-infected macrophages accumulate virions in
multivesicular bodies (MVB) of the exocytic pathway and in complex invaginated plasma
membrane domains (19-21). Virions sequestered in these compartments remain infectious
for at least six week and during VS formation rapidly move to the site of cell-cell contact
for presentation to susceptible T cells (22).
In this Chapter, I investigated the effects ofMl and M2a polarization on the HIV-l
transmission properties of MDM. As discussed in Chapter 2, DC-SIGN was strongly and
differentially upregulated on the surface of M2a MDM and remained above control levels
up to 7 days post-stimulation. Despite a significant downregulation of CD4 receptors on
M2a MDM (Chapter 2 and 3), CD4Iow+/DC-SIGNhigh+M2a and CD4high+'DC_SIGNlow+
control MDM bound similar levels of virus. However, only M2a-MDM were capable of
efficiently transmitting HN -1 to susceptible target cells. In addition to binding, DC-SIGN
also compensated for the loss of CD4 receptors on M2a-MDM by enhancing viral entry
and reverse transcription. Finally I found that the sustained upregulation of DC-SIGN on
M2a cells was associated with a decreased capacity to support productive HIV -1 infection,
possibly through DC-SIGN- mediated signaling events. Collectively, these data suggest
that DC-SIGN expression on M2a macrophages play an important role in the regulation of
cis- vs. trans-infection. By enhancing HIV-l entry and inhibiting viral replication, DC-
SIGN may also contribute to the development of latent infection in macrophages of the
M2a phenotype.
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4.1 MATERIALS ANDMETHODS
4.1.1 Reagents. Human recombinant cytokines were purchased from R&D Systems
(Minneapolis, MN) and used at concentrations of either 2.0 (TNF-a.) or 20.0 (IFN-y, IL-4)
nglmL. All cytokines were declared by the manufacturer to contain <0.1 ng of
contaminating LPS per ug of protein. Ficoll-Hypaque was purchased from Amersham
Pharmacia Biotech (Piscataway, NJ). D-MEM, PBS, Fetal Bovine Serum (FBS), Normal
Human Serum (NHS), penicillin, streptomycin and glutamine were obtained from
Cambre x (Verviers, Belgium). Anti-CD4 (Leu3a) and anti-DC-SIGN (clone 612)
antibodies were purchased from Becton Dickenson (Frankline Lakes, New Jersey) and
R&D Systems respectively. The RETROtek P24 Antigen ELISA assay was obtained from
ZeptoMetrix (Buffalo, New York).
4.1.2 Isolation of human monocytes and differentiation into monocyte-derived-
macrophages (MDM). Peripheral blood mononuclear cells (PBMC) were isolated from the
buffy coats of healthy HIV-I-seronegative blood donors by Ficoll-Hypaque density
gradient centrifugation. The cells were washed, resuspended in D-MEM containing 1%
pen/strep, I% glutamine, 10% heat-inactivated FBS and 5% heat-inactivated NHS
(complete medium) and seeded into 75 cm2 flasks (Falcon, Becton Dickinson Labware,
Lincoln Park, NJ) at a concentration of 8xl06 cells/mL. After 2 h of incubation at 370 C in
a humidified atmosphere containing 5% CO2, the non-adherent cells including T
lymphocytes were removed by gentle pipette aspiration. An equivalent volume of fresh
complete medium was then added to each flask. Adherent cells were cultured for an
additional 24 h, washed twice with PBS and detached from the flask by scraping with a
rubber policeman. Following re-suspension, the cells were tested for viability by Trypan-
blue exclusion and counted by haemocytometer. The purity of these monocyte isolations,
as determined by anti-CDI4-PE staining and flow cytometry, exceeded 85%. The cells
were then seeded into 48-well plastic plates (Falcon) at the concentration of 2.5x lOS
cells/well and cultivated for 7-8 additional days at 37 °C in 5% CO2 to promote their full
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differentiation into MDM(7). MDM ~95% CDI4+) were stimulated for 18h with either
IL-4 (M2a) or TNF-a plus IFN-y (Ml) cytokines (23). Following 18 h of cytokine
stimulation, Ml-, M2a- and unstimulated (control) MDM were washed with cytokine-free
medium and analyzed in parallel. To investigate the sustainability of the polarizing
response, Ml-, M2a- and control MDM were thoroughly washed and cultivated for 7
additional days in absence of polarizing cytokines. Changes in the expression of DC-SIGN
were measured at days 0,3 and 7 post-polarization.
4.1.3 Flow cytometric analysis of DC-SIGN and CCL3 expression. Adherent MDM
were washed with cold EDTNPBS (2 mM) and detached from the plastic plates by
incubation with cold EDTNPBS (2 mM) for 30 min at 4 °C and scraping with a rubber
policeman. Non-specific binding of Ab was blocked by pre-incubating the cells in medium
containing 15% serum (10% FBS and 5% NHS) for 15 min at 4°C. Cells were incubated
with anti-DC-SIGN (PE) from R&D Systems for 30 minutes at 4°C, washed with cold PBS
and fixed with 2% paraformaldehyde (PFA). Acquisition of flow cytometric data was
performed using a CYAN ADP cytometer (DAKO Cytomation, Glostrup, Denmark) and
the results were analyzed with the FlowJo software version 8.4.3 (Tree Star Inc., Ashland,
OR).
Intracellular staining for CCL3 expression was determined after 18 h of polarizing
cytokine stimulation in medium containing BFA (1 ug/ml). Following cytokine
stimulation, M1- and M2a-MDM were detached from the plastic surface by scraping and
fixed in 2% PFA. The cells were labeled with anti-DC-SIGN Ab (as described above),
permeabilized with Saponin buffer (0.1% Saponin, 0.5% BSA in PBS) and stained with
Allophycocyanin conjugated anti-CCL3 Ab for 30 min at 4°C. After staining. the cells
were washed twice with cold PBS and analyzed with a CYAN ADP apparatus (DAKO
Cytomation).
4.1.4 Microscopic evaluation of DC-SIGN expression on MDM. Control. Ml and
M2a .MDM were washed twice with cold DMEM containing 10 % FCS and 5% NHS and
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stained with 25 Ill/well of PE-conjugated anti-DC-SIGN mAb (R&D Systems) for 30 min
at 4°C. Cells were then washed 4 times with cold PBS and fixed with 4% PFA in PBS.
Nuclei were stained by adding 1 ug/ml of Hoechst 33258, pentahydrate (bis-benzimide,
m.w. of 623.96, Molecular Probes) for 15 min at RT. After two more washes in PBS, cells
were covered with 200 III of PBS and analyzed by IN Cell analyzer 1000 (Amersham).
Each condition was assayed in triplicate (for a total of 800-1200 cells per condition, image
magnification 20x). DC-SIGN+ cells were recognized when fluorescence intensity was
greater than 50% that of background.
4.1.5 RN-1 binding assay. Control, MI- and M2a-MDM were pulsed with the
macrophage-tropic, CCR5-dependent (R5) reference strain HIV-18aL at a multiplicity of
infection (m.o.i.) of 1.0 for 2 hours at 4°C. The cells were then washed thoroughly (to
remove unbound virus), lysed with 50 JlI of lysis buffer and processed for HIV-l Gag
quantification using the RETROtek P24 antigen ELISA assay as specified in the
manufacturer's instructions. For antibody blocking experiments, polarized and control
MDM were pre-incubated with 20 ug/ml of anti-CD4 or anti-DC-SIGN Ab, either alone or
in combination, for a period of 30 min at room temperature.
4.1.6 Quantification of RN-} DNA by real-time peR. Control, MI- and M2a-
MOM were infected with DNAse/RNAse-free HIV-18aL at m.o.i. of 0.1. In antibody-
blocking experiments, the MDM were pretreated 20uglml anti-DC-SIGN mAb (R&D
Systems) for 30 minutes at room temperature prior to infection. Following infection, the
MOM were cultivated in complete medium for 48 h, the estimated time required to
complete a single viral replication cycle in macrophages (24). The infected MDM (106
cells/mL) were then washed, resuspended in lysis buffer containing 0.1% polyoxyethylene
10 lauryl ether (Sigma) and 0.1 mglmL proteinase K and digested at 65°C for 2h; the
proteinase K was then heat-inactivated at 95°C for 15 minutes (25). For each PCR
reaction, an amount of lysate corresponding to 2.5 x 104 cells was amplified in real-time
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quantitative PCR reactions using primers and a probe that recognize the HIV-1 gag gene
(26, 27): forward primer 5'-ACATCAAGCAGCCATGCAAAT-3'; reverse primer 5'-
ATCTGGCCTGGT GCAATAGG-3'; probe 5'-(FAM)
CATCAA TGAGGAAGCTGCAGGAA TGGGATA GA (TAMRA)-3'. This primer/probe
combination detects all viral DNA that is synthesized after second-strand transfer including
both pre- and post-integration DNA. HN-l copy numbers were normalized against human
GAPDH as determined using an external standard curve with a linear distribution (r =
0.99) between 10 and 106 copies. The primers and probe for GAPDH were: forward primer
5' -ACCACAGTCCATGC ATCACT-3'; reverse primer 5'-
GGCCATCACGCCACAGITT-3' ; probe 5'-(FAM) CC
CAGAAGACTGTGGATGGCCCC (TAMRA)-3'. Thermal cycling conditions for real-
time PCR with SYBR Green quantification were: 50°C for 2 min and 95 °c for 15 min
followed by 40 cycles at 95°C for 15 sec and 65 "C for 1min (27).
4.1.7 HIV-J infection and replication. Separate control, MI- and M2-MDM
cultures were incubated for 20 minutes at room temperature in the presence (or absence) of
anti-CD4 or anti-DC-SIGN blocking antibodies, prior to infection with HN-IBaL at an
m.o.i. of 0.1. To assess virus production and spread, replicate aliquots of the culture
supernatant were collected every 3 days over a 12-day period and stored at -20° C. At the
end of each culture period, the supernatants were thawed and analyzed for viral replication
as determined by measuring the amount of HN -1 reverse transcriptase (RT) activity
released into the supernatant, as previously described (7)
4.1.8 HIV-J transmission assay. Polarized and control MDM pre-treated with and
without anti-DC-SIGN mAb (20 ug/ml; 20 min at room temperature) were incubated with
HNmB (X4, m.o.i. 0.1) for 2 hours at 37°C. These control, MI- and M2-MDM were then
washed extensively to remove unbound virus and co-cultured (1:1 ratio) with monocyte-
depleted IL-2-treated PBMC for either 6 hours or 12 days. The separated PBMC (removed
after 6 hours) were then washed, re-plated in fresh media and maintained in culture for an
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additional12 days. Supernatants from PBMC and MDM-PBMC cultures were collected at
regular intervals (every 3 days) over a 12-day period and stored at -200 until analyzed.
Ongoing viral replication was determined by assessing RT activity in culture supernatants
as previously described (Chapter 3).
Statistical analysis. Prism 5 from GraphPad Software (La Jolla, CA) was used for
statistical analyses. Results are reported as mean values ± SD. Multivariate analyses were
conducted using one-way ANOVA and the Tukey post-test. To compensate for inter-donor
variability, all assays were performed on triplicate samples with MDM derived from 4 to 8
independent donors, as further specified.
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4.2 RESULTS
4.2.1 DC-SIGN is upregulated on M2a-, but not MJ-MDM. Of particular interest in
clarifying the potential role of macrophages in the cell-mediated spread of HIV-1, was the
finding that DC-SIGN was the only receptor to show a divergent pattern of expression on
control, MI- and M2a-MOM. This receptor, which was expressed at relatively low levels
on control MOM, was strongly upregulated on the surface of M2a-MDM both in terms of
the percentage of positive cells (9-fold increase) and MFI (2-fold increase) (Figure 4.1 A
and Chapter 2). This is in clear contrast to the near-complete down-regulation of DC-
SIGN on the Ml cells of most donors (Figure 4.1 A and Chapter 2). Microscopic
examination of MDM stained with PE-Iabeled anti-DC-SIGN mAb confirmed the results
obtained by flow cytometry. On average, 50.7% of M2a, 10.2% of control and only 4.6%
of MI-MOM tested positive for DC-SIGN (Figure 4.1 B).
To establish whether a single 18 hour exposure to IL-4 could induce a sustained
upregulation DC-SIGN, MOM were thoroughly washed, cultured for an additional 3 to 7
days in medium alone and tested for DC-SIGN. The expression levels of DC-SIGN on
M2a-MDM remained consistently above control values for 7 days, the last time point
studied. This prolonged expression contrasts with the more transient nature of polarization-
induced changes in membrane receptor expression (Chapter 2 and 3). As previously
reported, most cytokines and membrane receptors, including CD4, return to control levels
3-7 days after removal of the polarizing stimulus, either Ml or M2a. Interestingly, the
number of DC-SIGN receptors per cell, as determined by MFI, continued to increase and
peaked 3 days after removal of IL-4 (Figure 4.1 C). A similar kinetic was observed for the
M2a chemokine CCL22 (Chapter 2) and suggests that M2a polarization may occur in
multiple waves. Consistent with its M2a specificity, OC-SIGN+ cells in control and M2a
cultures tested negative for intracellular CCL3, an Ml-associated chemokine (Chapter 3)
that is strongly and differentially upregulated by TNF plus IFN-y (Figure 4.1 D).
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4.2.2 Anti-DC-SIGN mAb blocks HIV-J binding to M2a-MDM. It has been reported
that compared to CD4, DC-SIGN may have a higher binding affinity for HIV-1 (29).
Although the HIV -1 attached to DC-SIGN on dendritic cells can be internalized, available
evidence suggests that the majority of DC-bound virus remains on the cell surface and is
efficiently transmitted to T cells without internalization. To investigate the effects of DC-
SIGN expression on the binding of HN-l to M2a-MDM, we incubated MDM with HN-
IBAL(rn.o.i 1) at 4°C (a condition which prevents virus entry) and measured the amount of
HIV-1 p24 antigen that was attached to the cell surface after 2 hours. As expected, all three
MDM populations showed an ability to bind R5 HIV-lsadFigure 4.2 A) with M2a and
control MDM exhibiting a greater binding affinity than MI-MDM (34.9 and 35.7 vs. 29.6
pg p24/ml respectively). Blockage of DC-SIGN with an anti-DC-SIGN mAb led to a 52.5
% (range 29% to 74%) reduction in the amount of HIV-l bound to the surface of M2a-
MDM compared to M2a that were not pre-treated with anti-DC-SIGN mAb (Figure 4.2).
In contrast, pre-incubation with anti-DC-SIGN antibody had no significant effect on virus
attachment to either control or MI-MDM, cells that express relatively low or negligible
amounts of cell surface DC-SIGN (Figure 4.2 B). Blockage of CD4 with anti-CD4 mAb
(Leu3a) led to a mean 47% (range 36% to 67%) decrease in virus attachment to control
MDM but not to Ml- or M2a-MDM. The failure of anti-CD4 mAb to cause significant
inhibition of HIV-l binding to Ml- and M2a-MDM is consistent with the severe
polarization-induced down-regulation of CD4 on these cells (Figure 4.2 B).
4.2.3 Co-expression of DC-SIGN on Control and M2a MDM modulates HIV-J
entry. Previous studies have shown that co-expression of DC-SIGN and CD4 on the
surface of monocyte-derived DC and transfected cell lines (ie. CD4+IDC-SIGN+ Raji
cells) can increase the efficiency of CD4-mediated entry, especially when CD4 levels are
limiting (25, 26). To investigate whether the IL-4 induced expression of DC-SIGN on
M2a-MDM could compensate for the polarization-induced downregulation of CD4, we
infected control, Ml- and M2a-MDM with HN-laaL and measured the amount of
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intracellular HIV-1 DNA that accumulated during the first 48 hours of infection. This is
the time required for HIV -1 to complete a single cycle of reverse transcription, nuclear
import and viral integration in macrophages (Chapter 3). Previous studies have shown the
initial increase in HIV -1 DNA is an accurate marker of virus entry and reverse
transcription. Viral DNA levels in M2a-MDM, as measured by real-time PCR, were
comparable to those observed in unpolarized control cells indicating that there was no
impairment of HIV-1 entry or early replication in M2a-MDM despite the significant
downregulation ofCD4 (Figure 4.3 A). Pre-treatment with anti-DC-SIGN mAb resulted in
a 24% decrease in HIV-l DNA levels in M2a-MDM (Figure 4.3 B). This finding is
consistent with studies conducted on DC-SIGW monocyte-derived DC showing that when
CD4 levels are limiting, DC-SIGN facilitates the CD4-mediated entry of HIV-1 into DC
(25, 26). As expected based on their low-level expression of DC-SIGN, blocking of DC-
SIGN with mAb had little, or no, effect on HIV-1 DNA levels in M1-MDM. Interestingly,
the blockage of DC-SIGN on control MDM led to an average 41% increase, rather than a
decrease, in HIV-l DNA (Figure 4.3 B). Thus, in unpolarized control MOM, expressing
high levels of CD4, low levels of DC-SIGN appears to compete with C04 for HIV-l
binding decreasing the amount of virus that is internalized.
4.2.4 DC-SIGN inhibits virus production in a spreading M2a-MDM culture system.
Because of the sustained expression of DC-SIGN on M2a-MDM (for up to 7 days) and the
importance of this receptor in mediating immune responses, we investigated whether the
modulation of DC-SIGN expression contributed to the inhibition of viral replication that is
characteristic of M2a activation and polarization (Chapter 3). In these experiments, control,
M1- and M2a-MDM were incubated with anti-DC-SIGN or anti-CD4 blocking antibodies
prior to infection with HIV-18aL (m.o.i. 0.1). Virus production was assessed at regular
intervals over a 12-day incubation period by measuring the amount of HIV-1 reverse
transcriptase released into the culture supernatant. HIV-1 RT levels were significantly
reduced in both M1- and M2a-MDM relative to control MDM as discussed in Chapter 3
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(Figure 4.4). In all three MOM populations, blocking of CD4 with anti-CD4 mAb
completely inhibited RT activity over the entire 12-day infection period, underscoring the
essential nature of CD4 for both virus entry and the establishment of productive infection.
Interestingly, blocking DC-SIGN prior to infection led to an increase in RT activity in the
supernatants of M2a-MDM (Figure 4.4, lower panel). Thus, although DC-SIGN enhances
the CD4- mediated entry and reverse transcription of HIV -1 in the first round of infection,
it appears to have a paradoxical inhibitory effect on viral replication as measured in a
spreading culture system. In contrast, exposure to anti-DC-SIGN antibody had no
significant effect on virus production in Ml and control cells that express only low or
negligible levels of DC-SIGN (Figure 4.4, top and middle panels).
4.2.5 High-level expression of DC-SIGN on M2a-MDM mediates efficient
transmission of HW-l to T-cells. DC-SIGN expressed on the surface of immature DC,
activated B-Iymphocytes and transfected B-eell lines (DC-SIGN+/CD4+-Raji cells) has
been shown to strongly bind and transmit HIV-l to T-cells. In this study, we tested
whether DC-SIGN+ M2a-MOM also possessed this capacity. For these studies, control and
polarized MI- and M2a-MOM were incubated with X4 (T-tropic) HIV-l (HIV-lrrm) for 2
hours, thoroughly washed to remove unbound virus and then incubated with IL-2 activated
monocyte-depleted PBMC. As expected (30, 31), the X4-tropic strain used in these
experiments did not replicate in control, Ml or M2a MDM. In one set of co-cultures,
PBMC were separated from the adherent HIV-l-pulsed MOM (X4-MDM) after 6 h of co-
culture and incubated for an additional12 days in complete medium containing IL-2. HIV-
1 transmission to "separated" PBMC target cells was quantified by measuring viral RT
activity released into the culture supernatant. M2a-MDM exhibited an enhanced ability to
transmit X4 virus to susceptible separated PBMC relative to control and MI-MDM
(Figure 4.5A). Blockage of DC-SIGN receptors on MOM before pulsing with X4 virus
resulted in an 84.1% to 93.7% reduction in HIV-l transfer from M2a-MDM to T cells
indicating that all, or nearly all, of the transmission was mediated by DC-SIGN (Figure
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4.5 B, left column). In another set of experiments, X4-MDM were maintained in co-
culture throughout the entire 12-day incubation period. Unexpectedly, in these long-term
co-cultures only low levels of HN -1 transmission were observed for M2a-, as well as M l-
and control MDM (Figure 4.5A). Blocking DC-SIGN resulted in decreased transmission
from M2a, but not from Ml or control MDM, indicating that the small amount of viral
transfer that did occur during prolonged exposure to X4-M2a-MDM was also mediated by
DC-SIGN (Figure 4.5 B, right column). Collectively, these data provide evidence for a
strong association between M2a-induced expression of DC-SIGN and enhanced trans-
transmission ofHN-l, especially in short-term (6 h) co-cultures.
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4.3 DISCUSSION
We have previously reported that cytokine-induced polarization of MOM into Ml
(pro-inflammatory) and M2a (anti-inflammatory) macrophages leads to an inhibition of
productive HIV-l infection, but that the degree of viral restriction and the phenotypic
changes associated with these responses are clearly different (Chapter 3). In this chapter
we describe an additional mechanism related to DC-SIGN expression that may be of direct
relevance to the HIV -1 pathogenesis in M2a environments. As discussed in Chapter 2, DC-
SIGN, a molecule that binds and transmits HIV-l, was the only surface membrane receptor
that showed a clear-cut divergent (or inverse) pattern of expression on Ml- (down-
regulation), M2a- (upregulation) and control MOM. As described in this Chapter, the
expression of DC-SIGN on M2a-MDM changed both the infection and transmission
properties of these cells.
The strong association between M2a polarization and the upregulation of DC-SIGN
suggests that this C-type lectin may play an important role in the M2ffh2 axis of
immunity. This concept is strengthened by studies showing that IL-13, another type 2
cytokine, also upregulates DC-SIGN on MDM and that the treatment of breast milk
macrophages with IL-4 leads to the induction of DC-SIGN (32, 33). In vivo, DC-SIGN has
been detected on specialized macrophages of the lung and the placenta. Both of these
tissues are TH2environments with high levels of anti-inflammatory cytokines (32, 34-36).
Elevated levels of DC-SIGN have also been detected on DC in allergic nasal polyps, a
well-characterized TH2-mediated disorder (32). In the gastrointestinal tract, the expression
of DC-SIGN on DC has been linked to an increase in the IL-1O:IL-12 ratio and a switch to
a more TH2-type environment (37).
In this Chapter, I show that the level of DC-SIGN expression may playa key role,
not only in virus binding and entry, but also in the replication and transmission of HIV-l to
T cells and that these functions are closely associated with CD4 expression. I found that in
M2a-MDM expressing low levels of CD4, DC-SIGN co-expression significantly enhanced
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the binding, internalization and reverse transcription of HIV-1. These results confirm and
extend previous studies in DC and transfected Raji cells showing that, when CD4 levels
are low, DC-SIGN co-expression can increase the efficiency of CD4 mediated viral entry.
Collectively, these data indicate that, in the presence of high levels of DC-SIGN, only low
levels of CD4 expression are required for the efficient viral entry and reverse transcription.
Blocking DC-SIGN on the surface of M2a-MDM led to significant decreases in both HIV-
1 binding and viral DNA accumulation 48 hours post-infection. The observation that
47.5% of the binding to M2a-MDM was CD4IDC-SIGN-independent suggests that, as
previously proposed (38, 39), additional C-type lectin receptors, such as the mannose
receptor (MR) may contribute to HIV-I binding to MDM.
In contrast, a different scenario was observed in control MDM expressing moderate
levels of CD4 and low levels of DC-SIGN. As would be expected, the binding of HIV -1 to
the surface of these cells was significantly reduced (47%) by anti-CD4, but not by anti-
DC-SIGN, blocking antibodies. As proposed for M2a-MDM, the remaining 53% of the
binding to control MDM may be due to HIV-1 capture by MR and other C-type lectins. An
unexpected finding in control cultures was that the blocking of DC-SIGN on these cells led
to a 41% increase, rather than a decrease, in virus entry and HIV -1 DNA synthesis.
Although the mechanisms are not known, this finding suggests that in control MDM, low
levels of DC-SIGN may be competing with CD4 for the binding and capture of HIV-I
virions. The blocking of HIV -1 infection by anti-CD4 antibodies, in all three MDM
populations (control, MI and M2a) indicates, that even under conditions of high DC-SIGN
expression, the CD4 receptor is still essential for virus entry and HIV -1 DNA synthesis.
As reported in Chapter 3, and re-confirmed in this Chapter, virus production was
strongly inhibited by both MI and M2a polarization. In MI-MDM, the suppression of
productive infection was expected, given the dramatic polarization-induced down-
regulation of both CD4 and DC-SIGN on the surface of these cells. However, in M2a-
MDM, suppression of virus production occurred despite a DC-SIGN-mediated
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enhancement of viral binding, internalization and HN -1 DNA synthesis. As previously
discussed, these findings suggest that in MI-MDM, the block in HN-l infection occurs at
the level of viral entry while in M2a-MDM virus production is restricted at a late step in
the viral life cycle. Of particular interest in this study, was the finding that pre-treatment of
M2a-MDM with anti-DC-SIGN could partially overcome the late-stage block in M2a
infection. The mechanisms underlying this reversal of inhibition are not known but may be
due to a DC-SIGN-mediated signaling event (potentially Raf-I upregulation of IL-lO) that
was either initiated or inhibited by the interaction with anti-DC-SIGN mAb.
The strong, clear-cut association between the expression of DC-SIGN and the
ability ofM2a-MDM to bind and rapidly transfer HN-l to PBMC (ie. within 6 h) suggests
that, as observed for dendritic cells, DC-SIGN may play an important but restricted role in
the trans-transmission of HN -1 from M2a macrophages to CD4+ T cells. Consistent with
this observation, I found that pre-incubation of M2a-MDM with anti-DC-SIGN antibodies
led to a near-complete (84%-94%) block in HIV-l transmission. The reason why short-
term exposure to X4-pulsed MOM led to efficient viral transmission, while long-term (12
day) exposure abolished transmission are not known but may be related to the complexity
of the MDM-PBMC co-culture system, including a potential upregulation of inhibitory
cytokines and chemokines by polarized MDM. An understanding of the factors limiting
virus production in these co-cultures may lead to insights for the control of cell-to-cell
transmission.
In summary, the restricted expression of DC-SIGN on M2a-MOM correlates well
with in vivo studies showing that DC-SIGN is expressed on a limited subset of tissue
macrophages found in TH2 environments. The dichotomous effect of DC-SIGN on HN-l
entry (enhancement) and virion production (inhibition) in M2a-MDM suggests that DC-
SIGN may play a role in the establishment of viral reservoirs in cells of the M2a
phenotype. Of particular interest in this regard, is the finding that different levels of DC-
SIGN and CD4+ co-expression maya pivotal role in the regulation of cis- versus trans-
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infection. Finally, DC-SIGN+ macrophages may facilitate in vivo transmission of HN-l at
mucosal membranes, especially in tissues with a high concentration of macrophages and a
predominantly M2ff H2 environment.
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4.4 FIGURE LEGENDS
Figure 4.1 Impact of Ml and M2a polarization on the expression of DC-SIGN.
A. Changes in DC-SIGN expression on the plasma membrane of M2a-MDM after 18 hour
polarization. Cells were labeled with anti-DC-SIGN mAb and analyzed by flow cytometry.
Results from a single donor are representative of 6 donors tested. B. Upregulation of DC-
SIGN on M2a-MDM as determined by microscopic evaluation. Results shown are for a
single representative donor of 2 donors analyzed. 800-1200 cells were counted per donor
in triplicate for each MOM condition. C. The kinetics of DC-SIGN expression at an
individual cell level were assessed on control and polarized MOM after 18 hours, and at
day 3 and 7 post-stimulation. Results are reported as the mean values from 4 individual
donors. D. Evaluation of DC-SIGN as a marker of M2a polarization. Control, M 1- and M2
MDM were labeled with anti-DC-SIGN, fixed, permeabilized and labeled intracellularly
with CCL3 Ab. Results are reported as the average percentage of positive cells (DC-
SIGN+ CCL3-, DC-SIGN-CCL3+ or DC-SIGN+CCL3+) from 4 individual donors.
Figure 4.2 Binding of HIV-haL to Ml- and M2a-MDM correlates with the
differential expression of CD4 and DC-SIGN. A. HIV-I binding to control
(CD4high+DC_SIGNlow+),MI- (CD41ow+DC_SIGNlow+)and M2a- (CD41ow+DC_SIGNhigb+)
MOM. Virus attachment was determined by measuring the amount of p24 antigen bound
to the cell surface. B. Anti-DC-SIGN mAb inhibits virus binding to M2a-MDM, but not to
control or MI-MDM, whereas pre-incubation with anti-CD4 mAb, significantly inhibits
HIV-l to control MDM expressing high levels of CD4. Values were normalized relative to
non-antibody treated MDM and results are reported as the mean fold-change in p24
antigen in 3 independent replicates performed on MDM derived from 8 different donors.
Figure 4.3 Dichotomous effects of DC-SIGN on HIV-l entry and replication in
M2a- vs control and Mt-MDM. A. Blockade of DC-SIGN with anti-DC-SIGN mAb
decreased the accumulation of HIV-I DNA in M2a-MDM, but not in MI-MDM.
Conversely, blocking of DC-SIGN enhanced HIV-l DNA levels in control MDM. MOM
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were pre-incubated with anti-DC-SIGN mAb for 2 h at 4°C. Cultures were infected with
HIV-lBaL and harvested after 48 h. At the end of this time, the cells were lysed and the
amount of viral DNA in each lysate was quantified using a real-time PCR assay that
measures total HIV-1 gag DNA. Results shown are representative of 116 donors, all of
whom had similar DNA profiles. B. Data shown as the fold change (increase or decrease)
in HIV-1 DNA accumulation in the presence and absence (nil) of pre-treatment with anti-
DC-SIGN antibody. Results shown represent the average of 2 separate experiments
performed on a total of 6 independent MDM donors.
Figure 4.4 Blocking of DC-SIGN enhances virus production in M2a- but not
in Ml- or control MDM. Untreated MDM and MDM pre-treated with either anti-CD4 or
anti-DC-SIGN mAb were infected with HIV-lsaL at an m.o.i, of 0.1. Virus production in
control (upper panel), MI- (middle panel) and M2a- (lower panel) MOM was monitored
over a 12-day culture period by measuring the amount of RT activity released into the
culture medium. As shown, anti-CD4 antibodies completely inhibited productive infection
in all 3 MDM populations. Results represent the mean of 3 independent replicate assays ±
standard deviations. Similar results were obtained for MOM derived from 4 different
donors.
Figure 4.5 DC-SIGN-mediated transmission of HIV·t from M2a·MDM to
permissive PBMC is rapid and efficient. A. Effects of short- vs. long-term exposure to
MDM pulsed with X4-tropic virus. Control and differentially polarized MI- and M2a-
MOM were incubated with HIV-lrnB for 2 h at 37°C and then washed to remove unbound
virus. The HIV-l-pulsed MOM were then co-cultured with IL-2-activated PBMC for 6 h,
at which time the MDM were removed from PBMC culture (short-time exposure).
Alternatively, the HIV-l-pulsed MDM were retained in the PBMC co-culture throughout
the 12-day period (long-term exposure), a condition which suppressed virus production
and/or spreading, and obscured the transmission differences between the 3 MDM
populations. HIV-l transmission was determined by measuring RT activities in the PBMC
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supernatants. Results are expressed as the percent transmission relative to control MDM
(100%) ± standard deviations of 3 independent wells from 4 individual donors. B. Pre-
incubation with anti-De-SIGN mAb interferes with the ability of M2a-MDM to bind and
transmit RIV -1 to PBMe. Study design was the same as discussed above, except that De-
SIGN receptors on MDM were blocked with mAB before exposure to X4 RIV -1. Results
are expressed as the average from 4 individual donors.
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CHAPTERS
MONOCYTE ACTIVATION IN TREATMENT NAIVE SOUTH AFRICAN AIDS
PATIENTS IS INDEPENDENTLY DRIVEN BY HIV-1 AND MICROBIAL"
TRANSLOCATION
S.O INTRODUCTION
HIV-I transmission and pathogenesis are intimately related to the activation state
of the host immune system (1-3). Although immune activation is essential to mount an
effective response, it also provides an environment that drives HIV-I replication and
disease progression (4). Increased levels of immune activation correlate with CD4+ T cell
depletion (5-8) and chronic CD8+ T cell activation (9). In patients with advanced HIV-I
infection, activation is a stronger predictor of disease progression than plasma viremia (1).
In addition to enhancing HIV-l replication (9-12), chronic immune activation leads to
exhaustion and dysfunction of the host immune system (13-17). Thus, understanding the
factors that drive chronic immune activation may provide new insights into the
development of more effective therapeutic strategies.
Recently, it has been suggested that the massive CD4+ T cell depletion that occurs
in the gastrointestinal tract (OIT) during acute HIV -I infection leads to mucosal immune
dysfunction in association with increased microbial translocation, systemic immune
activation and progression to AIDS (18-20). In support of this hypothesis, sooty
mangabeys naturally-infected with simian immunodeficiency virus (SIV) do not show any
evidence of sustained microbial translocation and do not develop an AIDS-like illness
despite having high viral loads and mucosal CD4+ T cell depletion (21). In contrast,
pathogenic SIV infection in rhesus macaques leads to sustained microbial translocation,
high-level chronic immune activation and progressive disease, mimicking the typical
course of HIV -I infection in humans (22). Macaque infection is also associated with
alterations in innate immunity including the activation and proliferation of natural killer
(NK) cells, high levels of dendritic cell (DC) activation and an exacerbated lPN-a
response (23).
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In addition to CD4+ T lymphocytes, cells of the mononuclear phagocyte lineage
also play an important role in the activation- induced pathogenesis of HIV -1 infection (24).
Mononuclear phagocytes are the primary targets of LPS-induced activation and are key
regulators of inflammatory and anti-inflammatory responses. They respond to a wide range
of environmental stimuli and depending on the stimulus can be polarized into functionally
distinct "immune regulatory/inflammatory" (Ml) or "tissue remodeling" (M2) phenotypes
(25). In addition, a subset of inflammatory monocytes expressing high levels of CDI6 (the
Fc receptor y III, FcRyIII) is markedly upregulated in HIV -1 infected patients, especially in
patients with advanced disease (26, 27). In vitro, CDI4+CDI6+ monocytes are more
susceptible to HIV-l infection than CD16-negative cells and they are an important source
of the pro-inflammatory cytokine tumor necrosis factor-a (TNF-a) (28). CD14+CD16+
monocyte-derived-macrophages (MDM) are more efficient at activating resting T cells and
in vitro conjugates formed between CD14+CDI6+ MDM and T cells are major sites of
virus production (29, 30). In vivo, CD14+CDI6+ monocytes have been postulated to playa
key role in HIV-I infection of the central nervous system (CNS) by transporting virus into
the brain and, upon differentiation into perivascular macrophages, by releasing neurotoxins
that damage the underlying tissue (31-34). Although the activation of mononuclear
phagocytes appears to play an important role in HIV-l pathogenesis, the mechanisms
driving the activation of these cells are not fully understood.
In the present study, 1 investigated the relationships between markers of monocyte
activation, HIV-l viremia and LPS (an indicator of microbial translocation) in a cohort of
HIV-I+ ART-naive African patients with no evidence of active opportunistic or enteric co-
infections. Higher levels of monocyte activation were detected in HIV -1+ relative to
uninfected South Africans, and in South Africans compared to North Americans and
Europeans. Two distinct activation phenotypes were identified: one statistically linked to
microbial translocation, the other to HIV-1 replication. Plasma levels of LPS were
positively correlated with circulating sCD14 and TNF-a, suggesting that up-regulation of
171
these markers was causatively linked to microbial translocation. In contrast, the
upregulation of CCL2 and increased frequency of CDI4+CD16+ monocytes were
positively correlated with HIV-1 viremia, suggesting that HIV-1 rather bacterial products
are the primary determinant driving the expansion and potential recruitment of
CDI4+CD16+ monocytes to sites of tissue inflammation. Elevated levels of CCL2 and
CD14+CD16+ monocytes have been previously linked to the development of HIV-l-
associated dementia (HAD) (35, 36). These findings may have important implications for
preventing the deleterious effects of immune activation and enhancing the efficacy of
antiretroviral therapy.
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5.1 MATERIALS AND METHODS
5.1.1 Study cohorts. HIV-I-infected South African patients with peripheral blood
CD4 counts of <250 cells/ul were recruited at the Comprehensive Care, Management and
Treatment (CCMT) Clinic of the Tshwane District Hospital in Pretoria, South Africa.
Baseline CD4+ T cell counts, plasma HN-I RNA, full blood counts, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) testing was conducted as
part of their routine clinical assessment. Patients were considered for the study if they were
~I8 years of age, were ART-naive, tested negative for TB in sputum smears stained for
acid fast bacilli (AFB), had no evidence of an active bacterial or opportunistic infections
(DIs) and had not taken antibiotics for 6 months prior to sampling. Bacterial,
cytomegalovirus (CMV) and parasitic infections (including Cryptosporidium) of the small
intestine were excluded based on two negative stool cultures (MeS) and histological
examination of biopsy samples. A total of 19 African patients (11 females, 8 males) with
stage III or IV disease (WHO classification) (37) were recruited into the study. As
summarized in Table 1, these patients had a mean age of 35 years (SD ± 9.3, range 24-58),
a mean CD4+ T cell count of 108 cells/u! (SO ± 97, range 6-378) and a mean plasma viral
load of 4.5 10glOHN-I RNA copies/ml (SO ± 1.1; range 1.7-6.1). Since previous studies
have suggested that DIs may be largely responsible for the expansion of CDI4+COI6+
monocytes (38, 39), we also recruited and performed monocyte subset analyses on a subset
of patients with active OIs (n = 26). This latter group of patients was also ART-naive and
presented with a wide variety of bacterial, viral and fungal co-infections. Ten healthy HIV-
l-negative volunteers were recruited from an outpatient clinic. The protocol was approved
by the Ethics Committee of the University of Pretoria, South Africa and each participant
gave written informed consent.
5.1.2 Plasma viremia. Plasma was isolated from EOTA blood tubes by spinning at
1600 rpm for 10 minutes. After separation, plasma was stored in 0.5 ml aliquots at -80°C
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until needed for RNA isolation. RNA was extracted using a guanidinium-silica method
(Magnetic Extraction Reagent kit from BioMerieux Inc) with no modifications to the
protocol. HN-l RNA levels in plasma were quantified using the Nuclisens Easy Q HN-l
v.1.2 kit, also with no modifications to the protocol. As 1.0 ml of plasma was used for all
viral load determinations, the lower limit of detection was 40-50 copies/ml; the upper limit
was >500 000 copies/ml,
5.1.3 Determination of CD4+ T cell counts and monocyte subsets. CD4+ T-cell
counts and percentages were evaluated using a cocktail of anti-human murine CD45 (clone
1.33) and CD4 (clone 13B8.2) monoclonal antibodies (mAb) (Beckman Coulter, Fullerton,
California, USA). CDI4+CDI6+ monocyte percentages were determined using murine
mAbs directed against human CD14 (clone RM052) and CD16 (clone 308) molecules
(Beckman Coulter). These mAb, used as specified by the manufacturer, were added to 100
J.llof whole blood collected in an EDTA tube. The samples were vortexed, incubated in the
dark for 10 minutes at room temperature and then placed in TQ-Prep (Beckman Coulter) in
order to lyse the red blood cells and fix the leukocytes. Absolute counts and percentages
were determined using a single platform protocol and 100 J.ll of Flow Count Beads
(Beckman Coulter) on an FC500 flow cytometer (Beckman Coulter). Monocytes were
analyzed based on forward and side scatter properties and. on the expression of CDI4+ and
CD 16+markers.
5.1.4 Quantification of soluble activation markers. Plasma LPS levels were
quantified by the Limulus Amebocyte Lysate (LAL) assay QCL-l000 (Lonza, Valais
Switzerland). Samples were diluted 1:3 with LAL Reagent Water, inactivated for 30
minutes at 65°C and tested in a 96 well microplate. Plasma levels of soluble CD14
(sCDI4) were measured using an ELISA assay (R&D Systems, Minneapolis. MS).
Cytokine and chemokine levels in plasma [interferon-j (IFN-y), TNF-a, IL-4. IL-6. IL-12.
IL-I0, CCL2. CCL3. CCLA and CCL5 CXCLlO] were quantified using customized Bio-
Plex plates (Bio-Rad, Hercules. CA). For cytokine/chemokine analyses. plasma samples
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were diluted 1:5 with Human Serum Diluent (Bio-Rad) prior to quantification. All assays
were performed according to manufacturer's instructions.
5.1.5 Statistical analysis. Prism 5 from GraphPad Software (La Jolla, CA) was used
for statistical analyses. Results are reported as mean values ± SD or median values with
ranges. Analysis of variance was determined using the Mann-Whitney U test. Spearman
correlations (r and p values) were calculated to determine the relationships between HIV
viremia, plasma levels of LPS and activation markers.
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5.2 RESULTS
5.2.1 African AIDS patients without 01 show increased plasma levels of type J/type
2 cytokines and normal (eeL3, eeIA) or reduced (eeL5) expression of eeR5-binding
chemokines. In order to investigate the extent and pattern of immune activation in our
cohort of African patients with advanced HN -1 disease and no Ols, we measured the
plasma concentrations of eXeLlO. eeRS-binding chemokines (eeL3. eelA, eeL5),
type 1 (IPN-y. IL-12) and type 2 (IL-4, IL-lO) cytokines. These values were then compared
to those measured in uninfected Africans. Plasma levels of all type 1 and type 2 cytokines
were consistently higher (2.5 to 4.6-fold) in AIDS patients compared to the uninfected
controls (p=0.006 to 0.012) suggesting that HIV -1 causes a generalized up-regulation of
cytokines (Table 2). Although less dramatic, eXeLlO, a chemokine that plays an
important role in the enhancement of HIV-l encephalitis (40, 41) was also up-regulated
(1.8-fold; p=0.02) in HIV-l+ relative to the uninfected controls. No significant changes
were detected in the expression of the eeR5-binding chemokines, CCL3 and eClA.
between HN-l+ and uninfected individuals (Table 2). In contrast. plasma levels of CCL5
were downregulated in HN-l+ individuals relative to uninfected controls (p=0.0096)
(Table 2). No significant associations were detected between plasma levels of
chemokines/cytokines and either eD4+ T cell counts or HIV-l viremia.
5.2.2 Markers of immunological activation are higher in Africans vs. non-Africans.
When compared to published data from cohorts in North America and Europe, African
AIDS patients had elevated (2 to 5-fold increases) levels of both type 1 (IFN-y. IL-12) and
type 2 (IL-4. IL-lO) cytokines, in addition to increased expression of eCL3. celA, eeL5
and cxci.io (Table 2). Several analytes (IL-4. ILlO, ccta, eCL5 and CXCLIO) were
also expressed at higher levels in healthy HIV -1- Africans relative to uninfected American
and European controls, suggesting that even in the absence of HIV-I, Africans have an
increased "background" level of activation (Table 2) (42, 43).
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5.2.3 AIDS in Africans is characterized by a generalized upregulation of cytokines
and an increase in the IL-IO:IL-/2 ratio. To establish whether HIV-I infection in Africa
was associated with a polarization of cytokine profiles, we measured differences in the IL-
4/1FN-y (related primarily to T cells) and IL-IDIIL-12 (produced primarily by mononuclear
phagocytes) ratios of HIV-l+ vs. healthy controls. Interestingly, we observed that HIV-l
infection did not alter the T-cell associated ratio (1FN-y:IL-4) (Figure 5.1). However, there
was a D.8-fold increase (p=D.D34) in the IL-ID:IL-12 ratio in HIV-l+ compared uninfected
controls. Thus, advanced HIV-I disease was associated with a significant increase in the
expression of IL-lO, an anti-inflammatory and immunosuppressive cytokine produced
primarily by mononuclear phagocytes (Figure 5.1) (44).
5.2.4 Increasedfrequency of circulating CD14+CD16+monocytes in the absence of
active OIs and enteric parasites. Previous studies have shown that the expansion of
CD14+CDI6+ monocytes is most pronounced during late-stage disease, especially in
patients with OIs and AIDS-associated dementia (27). In this study, a statistically
significant increase in the frequency of circulating CD14+CD16+ monocytes was detected
in ART-naIve AIDS patients without OIs compared to controls (mean 26% versus 13%;
p=O.D02)(Table 3 and Figure 5.2). As observed for cytokines and chemokines, the values
for both infected and uninfected Africans were higher than those published for non-African
populations (26% vs 16% for infected and 13% vs 6.5% for uninfected controls) (Table 3).
Interestingly, no significant difference was detected in the mean frequency of
CD 14+CD16+ monocytes among African AIDS patients with or without active
opportunistic disease (n=26), (26% versus 27.4%, p=O.752) (Figure 5.2). However, we did
observe that CD14+CD16+ monocyte levels were more variable among patients with overt
opportunistic disease compared to those without co-infections. This may be a consequence
of the broad spectrum of bacterial (n= 1D), viral (n=9) and fungal (n=7) co-infections in this
group of patients (Figure 5.2).
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5.2.5 AIDS is associated with high levels of monocyte activation in African
patients. We next measured the plasma levels of several key markers of monocyte
activation. Both HIV -I positive and seronegative individuals had detectable plasma levels
of sCDI4, TNF-a, IL-6 and CCL2. All four markers were significantly upregulated (>2-
fold; p=0.0003 to 0.03) in the HIV-I + vs. uninfected controls with IL-6 and CCL2 showing
the most striking mean increases (2.7- and 3.9-fold, respectively) (Table 3 and Figure
5.3). TNF-a, IL-6 and CCL2 levels were higher in African compared to European and
North American populations, for both infected and uninfected controls (Table 3). High
levels of CCL2, but not of sCDI4, TNF-a or IL-6, were statistically associated with an
increased frequency of CDI4+CD16+ monocytes (Figure 5.4). This finding is consistent
with studies showing that CDI4+CDI6+ monocytes are an important source of CCL2 (29).
No correlations were found between these markers and the patients' CD4+ T cell count
suggesting that there is no direct relationship between monocyte activation and the loss of
CD4+ T cells, at least not in our cohort of patients with advanced HIV-l infection.
5.2.6 Monocytes are differentially activated by HW-I and microbial translocation.
In order to establish whether HIV-I viremia and/or bacterial products were correlated with
high levels of monocyte activation, Iinvestigated the relationships between plasma LPS (a
reliable marker of microbial translocation) (19, 35). HIV-I viremia and markers of
monocyte activation. High levels of plasma viremia were moderately correlated with an
increased frequency of CD14+CD16+ monocytes (r=0.56; p=G.Gl ) and, to a lesser extent,
with circulating levels of CCL2 (r=0.49; p=0.03). In contrast, no positive or negative
correlations were detected between HIV -I viremia and the other activation markers (ie.
sCD4, TNF-a or IL-6) (Figure 5.5).
As expected,(19, 35) circulating levels of LPS were higher in HIV+ patients vs.
HIV- controls (1.059 vs. 0.465 respectively, p=0.007, Figure 5.6A). Unlike viremia,
circulating levels of LPS were positively correlated with both sCD14 (r=O.53; p=0.02) and
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TNF-a (r=0.62, p=0.005), but not with IL-6, CCL2 or circulating levels of CDI4+CDI6+
monocytes (Figure 5.6B). No correlations were detected between LPS and the expression
of any of the other cytokines investigated in our study. Collectively, these correlations
suggest that HIV-1 is the primary determinant fueling the expansion and recruitment of
CDI4+CD16+ monocytes, while microbial translocation may be main factor driving the up-
regulation ofTNF-a and the release of sCD14 from mononuclear phagocytes.
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5.3 DISCUSSION
In this chapter, I investigated the relationships between markers of monocyte
activation, plasma LPS, HIV-1 viremia and levels of cytokines/chemokines in a
homogenous cohort of African AIDS patients without OIs. High levels of monocyte
activation (as measured by plasma concentrations of TNF-a, IL-6 and CCL2, and an
increase in the number of CD14+CD16+ monocytes) were detected in both HIV-l+
individuals and uninfected African controls. Although a generalized increase in cytokines
was detected in both cohorts, the increase was significantly greater in HIV -1+vs uninfected
controls. There was no clear-cut bias towards a type 1 or type 2 immune response.
However, we did note a disproportionate increase IL-IO relative to IL-12, especially in
HIV-1+ individuals. Increased circulating levels of CXCLI 0 and decreased levels of CCL5
(but not of other CCR5-binding chemokines) were typically observed in HIV -1+patients.
No correlations were detected between these markers and CD4+ T cell counts or viremia.
Interestingly, monocyte activation appeared to involve the induction of two distinct
pathways - an HIV -l-associated pathway involving the upregulation of CCL2 and
CDI4+CDI6+ monocytes and an LPS-associated pathway linked to the upregulation of
sCD 14 and TNF-a.
These results extend previous studies showing that the frequency of activated
(HLA-DR+) CD4+ T cells and the ratio of memory (CD45RO+) to naive (CD45RA+)
CD4+ T cells is increased in HIV-1+ and healthy Africans compared to non-African
populations (45). They also confirm and extend studies showing elevated levels of
eosinophilia, immunoglobulin, IL-6, TNF-a, soluble TNF receptors and CCR5 expression
in African populations (43, 46-49). African activation profiles have, for a long time, been
attributed to a high prevalence of parasitic and non-parasitic infections (including helminth
infections, malaria and tuberculosis) and it has been suggested that these infections may
contribute to the explosive nature of the AIDS epidemic in Africa (43, 45, 47, 50). It has
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also been proposed that, because of the high rates of helminth infections, Africans might
have a more prominent type-2 immune response (43). In our study, increased
"background" levels of type I (IFN-y, IL-12) and type 2 (IL-4, IL-IO) cytokines were
detected in the absence of active tuberculosis or enteric parasites, in healthy as well as
HIV-I+ Africans. There was no significant difference in the THI:TH2 cytokine ratio (IFN-
y:IL-4) in infected vs. uninfected Africans, a profile that is suggestive of a generalized
rather than a polarized activation profile. A similar lack of polarization has been reported
for HIV-l+ individuals living in the UK and North America (51,52). In our study, a higher
IL-I0:IL-12 ratio was detected in HIV-I+ vs. healthy Africans. Since both cytokines are
produced primarily by mononuclear phagocytes (53), this suggests that that there may be a
shift in the innate arm of the immune system towards a' more immunosuppressive
environment that is driven by IL-IO production. Whether the heightened state of immune
activation in Africa is due to past exposure to a broad range of THI and TH2 inducing
pathogens, subclinical co-infections that are difficult to detect and diagnose, or to other
host and environmental factors remains to be determined.
In addition to an up-regulation of soluble activation markers (TNF-a, IL-6, CCL2),
a marked increase in the frequency of CDI4+DI6+ monocytes was observed in HIV-l+
compared to uninfected Africans, and in African populations vs. their non-African
counterparts (54). These findings are consistent with previous studies describing elevated
levels of CDI4+CDI6+ monocytes in ART-naive patients with advanced subtype B
infection (26, 27) and in HIV-l+ Malawian women with malaria (38). In the Malawian
study, CDI4+CDI6+ monocytes were also found to express higher levels of CCR5 than
their CD16- counterparts and were significantly more likely to harbor HIV-l (38). The
factors driving the expansion of CDI4+CD16+ monocytes and the clinical relevance of this
expansion are not well defined.
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Perhaps, the most compelling evidence that monocytes play a role in clinical
disease is derived from studies showing that CD14+CD16+ monocytes infiltrate into the
CNS where they differentiate into perivascular macrophages and promote tissue injury (32,
55,56). A recent study, conducted in ART-experienced patients, reported that high levels
of circulating LPS were positively correlated with both monocyte activation (as defined by
high levels of CD69 and HLA-DR expression) and HN-l-associated dementia (HAD)
(35). Based on these findings, it was suggested that LPS may contribute to the pathology of
HAD by promoting increased activation and trafficking of CD14+CDI6+ monocytes into
the brain, altering the permeability of the blood-brain barrier (57, 58). Interestingly, similar
to my study, only a select subset of monocyte activation markers were positively correlated
with LPS, namely sCD14, CD69 and HLA-DR. No positive correlations were detected
between LPS and CCL2, or between LPS and the frequency of CD14+CDI6+ monocytes,
suggesting that factors other than LPS were driving this activation profile (35).
My data showing that HIV-I viremia is positively correlated with both
CD14+CD16+ monocytes and plasma levels of CCL2, together with results obtained in the
pre-HAART era, suggests that HN-I rather than LPS may be the primary factor driving
the expansion of CD 14+CDI6+monocytes and the upregulation of CCL2, at least in ART-
naive patients. This view is supported by a recent study of differential gene expression in
monocytes from patients with high vs. low viremia (59). In this study, patients with high
levels of plasma viremia had an increased frequency of monocytes with an "invasive
chronic inflammatory" phenotype characterized by elevated levels of CD 16, CCL2, CCR5
and CD 169 mRNA (59). Patients with HAD also had increased levels of CD69 mRNA, an
activation marker associated with apoptosis and cell death (27, 60). In this regard, previous
studies conducted in our laboratory (61, 62) have detected increased levels of CCL2 in the
cerebral spinal fluid of European AIDS patients with either HN -1- or CMV -encephalitis.
In addition, it has also been shown that HN -I replication and exposure to viral proteins,
namely Tat and gpl20Env, could drive the upregulation of CCL2 in MDM (63, 64).
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Furthermore, CCL2 has been shown to upregulate virus replication in PBMC isolated from
HIV-l infected patients (65) and a polymorphism in the CCL2 promoter has been linked to
increased production of this chemokine, higher levels of HIV-1 viremia and HAD (36).
In addition to CCL2 and CD 16, we detected increased levels of circulating
CXCLlO in African AIDS patients without Ols. Like CCL2, CXCLIO has been implicated
in the development of HIV-l-associated neuropathy (36, 66) whereas, in vitro, this
chemokine has been shown to promote viral replication (67). While both chemokines are
produced by CD14+CD16+ monocytes, CXCLIO is typically secreted in response to IPN-y,
promotes cell recruitment, adhesion to endothelial cells and induces neuronal apoptosis
(68, 69). Consistent with previous studies (70, 71), levels of CCR5-binding chemokines
were either unchanged (CCL3 and CCIA) or decreased (CCL5) in HIV-l+ vs uninfected
Africans. This observation, together with an independent report describing the up-
regulation of CCR5 in HIV-l +Africans (47) suggests that the high prevalence of R5-using
HIV-l strains in Africa may be driven by two reciprocal mechanisms: an upregulation of
CCR5 and a down-regulation of the CCR5 ligand, CCL5IRANTES.
Although my results support a link between microbial translocation and LPS-
induced monocyte activation, this relationship appears to be restricted to the differential
upregulation of a distinct subset of immune modulators that include TNF-Cl and sCD14.
Additionally, my results support the existence of a clear link between HIV-l viremia, the
expansion of CD14+CD16+ monocytes and the production of CCL2, a chemokine that
plays a key role in the recruitment and trafficking of monocytes. Additional studies are
needed to determine the relative contribution of these distinct but interrelated activation
profiles to the pathogenesis of HIV-1/AIDS and their potential differential response to the
introduction of ART.
183
5.4 TABLES
TABLE 1. Demographic and clinical characteristics.
Gender Male n=S
Female N=l1
Age (years) Mean::l: S.D. 35::1: 9.3
Median (range) 33 (24-5S)
Log plasma HIV RNA Mean::l: S.D. 4.5 ::I:1.14
(coples/rnl) Median (range) 4.6 (1.7-6.1)
CD4 T-cell count (cells/IJI) Mean::l: S.D. 10S::I: 97
Median (range) S9 (6-37S)
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5.5 FIGURE LEGENDS
Figure 5.1. Disproportionate increase in IL-10 relative to IL-12 in HIV-1-infected vs.
un infected African controls. Levels of IL-4, IFN-y, IL-IO and IL-12 were quantified in
the plasma of treatment-naive AIDS patients (n =19) and healthy uninfected controls
subjects. The ratios of IL-4:IFN-y and IL-IO:IL-12 were calculated to determine whether
HIV-I infection was associated with a shift in the balance between type I (IFN-y. IL-12)
and 2 (IL-4, IL-IO) cytokines.
Figure 5.2. Increased frequency of circulating CD14+CD16+ monocytes in African
AIDS patients with and without OIs. The frequency of CDI4+CDI6+ monocytes within
the total monocyte population was analyzed in treatment-naive patients with no evidence
of active opportunistic infections (01) including tuberculosis and enteric parasites (n = 19);
in patients with a range of different bacterial (n = 10). viral (n = 9) and fungal (n = 7) Ols
and in uninfected controls (n = 10). Total and CDI4+CDI6+ monocytes were distinguished
from granulocytes and NK cells by their forward and side scatter characteristics and their
expression CDI4 (PE-Cy5) and CD16 (FITC).
Figure 5.3. Increased levels of monocyte activation in HIV-1+ compared to healthy
un infected Africans. Levels of sCDI4, TNF-a., IL-6 and CCL2 were quantified in the
plasma of untreated AIDS patients with no evidence of opportunistic or enteric co-
infections (n = 19) and in uninfected African controls (n = 10).
Figure 5.4. Up-regulation of CCL2 is associated with an increased frequency of
circulating CD14+CD16+ monocytes. Spearman correlations (r and p-values) were
calculated to determine the relationships between the frequency of circulating CDI4+(PE-
CY5)CD16+(ATC) monocytes and other markers of monocyte activation in ART-naIve
AIDS patients without Ols (n = 19).
Figure 5.5. Increased CD14+CD16+ monocyte frequency and the up-regulation of
CCL2 in African AIDS patients are associated with high HIV -1 viral loads. The
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frequency of CD 14+(PE-CY5)CD16+(FITC) monocytes and plasma levels of HIV-1 RNA,
sCD14, TNF-a, IL-6 and CCL2 were quantified in treatment-naive African AIDS patients
(n = 19). Spearman correlations (r and p-values) were calculated to determine the
relationship between HIV-1 RNA levels and markers of monocyte activation.
Figure 5.6. Up-regulation of sCD14 and TNF-a in African AIDS patients are
associated with high levels of plasma LPS. (A) LPS was quantified in the plasma of HIV
negative controls (n = 10) and treatment-naive African AIDS patients (n = 19). P values
were calculated by the Mann-Whitney U test. (B) Levels of circulating CDI4+(PE-
CY5)CDI6+(FITC) monocytes, sCD14, TNF-a, IL-6 CCL2 and LPS were quantified in
the plasma of treatment-naive African AIDS patients (n = 19). Spearman correlations (r
and p-values) were calculated to determine the relationship between LPS levels and
markers of monocyte activation.
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CHAPTER6
PIVOTAL ROLE OF INTESTINAL MACROPHAGES IN CONTROLLING HIV·1
REPLICATION AND FUELING MICROBIAL TRANSLOCATION
6.0 INTRODUCTION
The gastrointestinal tract (GIT) is major site of HIV-l pathogenesis (1-3). In contrast
to the slow depletion of CD4+ T cells in the peripheral circulation, up to 90% of the
CD4+CCR5+ memory T cells in the gastrointestinal-associated lymphoid tissue (GALT) are
lost during the first few weeks of HIV-l infection (4, 5). Although the exact mechanisms are
not known, it has been suggested that this early damage to the GALT may set the stage for
increased microbial translocation, chronic activation and progressive immune dysfunction
leading ultimately, to the development of AIDS (3,5-7). However, studies of non-pathogenic
SIV infection in animal models have shown that severe CD4+ T cell depletion in the GIT,
and at other mucosal sites, is not sufficient to cause high levels of sustained microbial
translocation, chronic immune activation or AIDS (8-10). Moreover, in individuals with
inflammatory bowel disease (mD), microbial translocation commonly occurs in the absence
of CD4+ T cell depletion (11). Collectively, these data suggest that microbial translocation
and progression to AIDS is likely to be a complex phenomenon involving multiple
interrelated pathogenic events and immune cell populations.
Although the intestine contains the largest population of macrophages in the body,
these cells have received little attention in the setting of HIV-1/AIDS, presumably because of
their resistance to HIV-1 infection and their profound "inflammatory anergy" in healthy
mucosa (12, 13). Resident macrophages in' non-inflamed intestine do not express innate
response receptors including CD14 and thus, do not produce inflammatory cytokines in
response to microbial stimulation (13-15). In addition, healthy intestinal macrophages do not
express co-stimulatory molecules involved in T cell activation (14-16). They do, however,
retain an avid ability to phagocytose and kill invading pathogens (14, 15). These unique
properties allow for the effective elimination of dangerous pathogens while, at the same time,
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protecting the GIT from excessive immune activation due to constant exposure to high levels
of commensal bacteria (16).
In this study. we investigated the effects of HIV-1 infection and microbial
translocation on the activation of intestinal macrophages and the potential of these cells to
contribute to HIV-I pathogenesis. I detected a marked increase in macrophages expressing
innate response (C014, C016) and co-stimulatory (C080. CD86) receptors in both the small
and large intestine of HIV -l-infected patients with advanced disease and no evidence of
enteric co-infections. In the colon, but not the duodenum. the frequency of COI4+
macrophages was negatively correlated with tissue HIV-! RNA levels and positively
correlated with plasma LPS. I conclude that, similar to lBO, HIV-1 infection is associated
with a significant increase in the frequency of activated "inflammatory-like" macrophages
and that, in the colon, these cells may playa pivotal role in both the control of HIV-I
replication and the paradoxical enhancement of bacterial translocation and immune
activation.
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6.1 MATERIAL AND METHODS
6.1.1 Study participants. HN-I-infected South African patients with peripheral
blood CD4 + T cell counts of <250 cells/ul and chronic diarrhea were identified at the
Comprehensive Care, Management and Treatment (CCMT) Clinic of the Tshwane District
Hospital in Pretoria, South Africa. Baseline CD4 counts, HN -1 plasma viral loads, full
blood counts, alanine aminotransferase (ALT) and aspartate amino-transferase (AST)
testing as well as stool microscopy and culture were conducted as part of their routine
clinical assessment. Patients were considered for the study if they were older than 18 years
of age, were ART-naIve, had a weight loss of more than 10% of their body weight or had
chronic diarrhea and tested negative for TB in sputum smears stained for acid fast bacilli
(AFB). Bacterial and parasitic infections of the intestine were excluded by histological
examination of haematoxylin and eosin (H &E) stained tissue sections supplemented with
periodic acid-Schiff and Ziehl-Neelsen staining. Cytomegalovirus (CMV) was excluded by
immunohistochemistry (DakCytomation, Glostrup, Denmark; clones CCH2 and DOG9).
Patients that had no evidence of active bacterial or opportunistic infections (DIs) and had
not taken. antibiotics for 6 months prior to sampling were considered eligible for
recruitment into the study. A total of 18 African patients (10 female, 8 male) with stage III
and N disease (WHO classification) were recruited into the study. As summarized in
Table I, these patients had a mean age of 34.9 years (SD ± 10.5), a mean baseline C04+ T
cell count of 106 cells/ul (SD ± 96) and a mean baseline viral load of 4.93 10gIOHIV-I
RNA copies/ml of plasma (SD ± 1.0) (Table 1). Following clinical assessment, patients
were enrolled into a standard NRTIINNRTI-based treatment program consisting of
lamividine (3TC) and stavudine (d4T) in combination with either nevirapine (NVP)(n=7)
or effavirenz (EFV)(n=l1). Four healthy Hlv-l-negative volunteers were recruited from
an outpatient clinic. The protocol was approved by the Ethics Committee of the University
of Pretoria and each participant gave written informed consent.
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6.1.2 Sampling protocol. Blood was collected in EDTA tubes at baseline and at 3
and 6 months after the commencement of ART. After obtaining informed consent, biopsies
of the duodenum and left colon were obtained at baseline as part of a double balloon
enteroscopy using a Fujinon enteroscope and a Radial Jaw 3 biopsy forceps (Boston
Scientific). All endoscopic abnormalities were recorded. To examine the effect of ART on
mucosal cell populations, post-treatment follow-up biopsies from the duodenum were
collected at month 3, and from both duodenum and left colon at month 6. For all
procedures, 8-10 biopsies/site were collected for flow cytometry and immediately placed
in ice-cold RPMI containing 10% heat inactivated fetal calf serum (FCS). Biopsies
collected for the assessment of HN -1 RNA were snap frozen in liquid nitrogen and stored
at -80°C until extraction. Tissue samples for histology were placed in a 10% neutral
buffered formalin solution, processed and embedded in paraffin wax within 24 hours of
sampling.
6.1.3 Isolation of mucosal mononuclear cells. Duodenal and colonic biopsies
were washed once in RPMI medium containing 10% FCS and transferred to a 15 ml
centrifuge tube containing RPMI + 10% FCS and 0.5 mg/ml collagenase type IV (from
Clostridium histolyticum, Sigma Aldrich, St. Louis, MO). Samples were incubated at 37°C
for 30 minutes in a shaking water bath for optimal dissociation. After incubation in
collagenase, cell suspensions were passed through a 70 micron filter (Becton Dickenson
Labware, Lincoln Park, NJ) and stored on ice. Remaining tissue fragments were re-
digested as described above. The combined single cell suspension was washed to remove
any residual collagenase before processing for flow cytometry.
6.1.4 Monoclonal Antibodies. The monoclonal antibodies (mAb) used in this study
were obtained from a number of sources. Anti-CD45 PE (clone J.33), anti-CD3 PE-Cy5
(clone UCHT1), anti-CD4 mc (clone 13B8.2) and anti-CDl6 mc (clone 3G8) were
purchased from Beckman Coulter (Beckman Coulter, Fullerton, California); anti-CD33
APC (clone 6C512), anti-CD80 FITC (clone 37711) and anti-DC-SIGN PE (clone 120507)
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were obtained from R&D Systems; anti-CDl4 PE-Cy7 (clone 61D3) and anti-CD86 PE
(clone IT2.2) was purchased from eBioscience (San Diego, California).
6.1.5 Quantification of mucosal mononuclear cell subsets using flow cytometry.
Single cell suspensions of biopsies from the duodenum and colon were prepared as
described above and subjected to flow cytometry. Briefly, 50-100 ~ aliquots of a mucosal
mononuclear cell suspension were transferred to individual flow tube (Beckman coulter)
and labeled with a specific combination of monoclonal antibodies for 30 minutes at 4°C.
Red blood cells were lysed and mononuclear cells were fixed using a TQ-prep instrument
and Immunoprep reagents (Beckman Coulter). Macrophage populations were identified
based on their forward and side scatter characteristics, as well as their expression of CD33.
All CD33 positive cells were CD45 and CD68 positive. Lymphocytes were also gated
based on their forward scatter and side scatter properties since back-gating with CD3, CD4
and CD45 mAbs revealed a uniform population of CD4+ lymphocytes in all patients.
Samples were analyzed on an FC500 flow cytometer (Beckman Coulter) and a minimum
of 50,000 events were acquired per sample.
6.1.6 Histochemical analysis of macrophage distribution. Macrophage staining was
performed as previously described (17). Briefly, sections of paraffin embedded tissue were
pretreated in a microwave oven with two cycles of 5 minutes at 780W in O.OIM citrate
buffer and incubated for 2 hours with anti-CD68 antibody (PGM 1, 1:500; Dako,
Copenhagen, Denmark). Reactions were visualized with a nonbiotin peroxidase detection
system (30 minute incubation) using 3,3' diaminobenzidine free base as chromogen
(brown staining).
6.1.7 Measurement of tissue viral loads. Tissue biopsies (4-12 mg) were manually
minced with a razor blade, placed in lysis buffer (BioMerieux) and agitated overnight at
RT. The next day RNA was extracted using a guanidinium-silica method (ie. the Magnetic
Extraction Reagent Kit from BioMerieux Inc) with no modifications to the protocol. HIV-
l RNA levels were measured using the Nuclisens Easy Q HIV-! v.1.2 kit, also with no
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modifications to the protocol. Results are reported as number of HIV-1 RNA copies per
milligram of tissue, or per ml of plasma.
6.1.8 Quantification of plasma LPS. Plasma was isolated from EDTA blood tubes
by spinning at 1600 rpm for 10 minutes. After separation, plasma was stored in 0.5 ml
aliquots at -80°C until needed for testing. Plasma LPS levels were quantified using the
Limulus Amebocyte Lysate (LAL) assay QCL-lOOO (Lonza, Valais Switzerland). Samples
were diluted 1:3 with LAL Reagent Water, inactivated for 30 minutes at 65°C and tested in
a 96 well microplate according to manufacture's instructions.
6.1.9 Statistical analysis. Prism 5 from GraphPad Software (La Jolla, CA) was used
for statistical analyses. Paired observations were compared using Wilcoxon matched pair
tests and the Mann-Whitney U test was used to compare means between groups. Linear
correlations were assessed using Spearman's rank correlation coefficient. Two-tailed P
values less than 0.05 was considered significant.
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6.2 RESULTS
6.2.1 CD4+ T cell depletion is less severe in the colon and correlates with higher
levels of tissue HlV-l RNA and slower immune restoration. The depletion of CD4+ T cells
in the duodenum of ART-naIve patients with advanced HIV-l disease was more severe
than that observed in the colon (mean of 3.3±2.6% vs. 1O.6±5.7%. respectively; p <0.0001)
(Figure 6.1A). Following the initiation of ART, there was a modest but statistically
significant increase (from 3.3±2.6 % to 5.0±2.7%; p=O.OOO2)in CD4+ T cells in the
duodenum, reaching peak levels at month 3. This early increase in CD4+ T cells in the
duodenum, but not in the colon, is consistent with studies showing a more rapid immune
recovery in patients with low vs. high peripheral blood CD4+ T cell counts (IS-20). Our
data suggest that a similar phenomenon may occur in severely immunodepleted tissues.
Although viral RNA was detected in all patients, pre-treatment levels of HIV -1 RNA were
higher in the colon than in the duodenum (4.57 vs. 4.06 logm copies/mg tissue; p=O.Ol), a
finding that is consistent with the higher proportion of CD4+ target cells in this tissue. The
initiation of ART led to a marked reduction in HIV-l RNA at both sites (Figure 6.1B).
Although there was no correlation between CD4+ T cells and viral RNA levels at baseline,
in either the duodenum or the colon (Figure 6.1C), the peak increase in CD4+ T cells in
the duodenum at month 3 corresponded to the nadir in HIV-1 RNA in this tissue (Figures
6.1A and 6.1B).
6.2.2 Differential depletion, restoration and distribution of macrophages in the
colon vs duodenum of patients with advanced HlV-l disease. To our knowledge there is
currently no information on potential differences in the frequency, phenotype and function
of macrophages in different anatomical sites of the GIT during HIV -1 infection. Although
the patterns were similar, the depletion of intestinal macrophages was less severe than
CD4+ T cells with both sites retaining relatively large numbers of cells (Figure 6.2B). As
noted for CD4+ T cells, the loss of CD33+ macrophages was more pronounced in the
duodenum than in the colon (mean of 18.0 ± 6.4% vs 26.6 ± 9.8%, respectively; p=O.OlS)
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(Figure 6.2A). Also as observed for CD4+ T cells, the initiation of ART was associated
with a significant increase in duodenal, but not colonic macrophages. Macrophage
reconstitution occurred rapidly reaching peak levels at month 3 followed by a plateau 6
months after the introduction of ART. Despite this increase, macrophage levels at month 6
(in both the duodenum and colon) were still below those observed in uninfected controls
(Figure 6.2A).
Immunohistochemical staining with CD68 indicated that, in the majority of biopsy
samples, macrophages were concentrated immediately beneath the epithelium covering the
luminal surface of the lamina propria. This pattern is commonly encountered in all regions
of the GIT including the colon and duodenum (14, 15) and is characteristic of a healthy
intestinal mucosa (Figure 6.2B). Interestingly, 20% of colon specimens from AIDS
patients showed an altered distribution in which the macrophages were diffusely scattered
throughout the lamina propria. After the administration of ART, these macrophages
assumed a normal sub-epithelial pattern suggesting that the altered distribution was
reversible and HN-l-related (Figure 6.2C).
6.2.3 AIDS is associated with an increased frequency of intestinal macrophages
expressing innate response and co-stimulatory molecules. In sharp contrast to the GIT of
healthy individuals (14-16), macrophages in the duodenum and colon of AIDS patients
expressed elevated levels of receptors for LPS (CDI4) and Fey RIll (CDI6), as well as
increased levels of co-stimulatory molecules (CD80, CD86) involved in the activation of T
cells (Table 2). These findings are very similar to those reported in the inflamed mucosa of
patients with mD, with approximately one third of intestinal macrophages displaying an
altered phenotype (14). Interestingly, the levels of these activation markers were
consistently higher in the colon than the duodenum (Table 2, Le. CD14 30.9±11.6 vs
20.2±9.8% respectively, p=0.0029) suggesting that the colonic microenvironment may
further contribute to, and drive, this activated phenotype.
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In the duodenum, ART was associated with a transient increase (26.9 ± 9.5%) in
the frequency of CD14+ macrophages at month 3 followed by a return toward baseline
levels (l9.6±5.8%) 6 months after the initiation of therapy (Figure 6.3A). As previously
reported for CD4+ T cells, this increase may be due to a transient redistribution of
monocytes during early therapy. Although the colon was not sampled at the 3-month time
point, a significant decrease in CD14+ macrophages was observed 6 months after the
introduction of ART (ie. from 30.9% at baseline to 19.1% at month 6; p=0.018) (Figure
6.3A). Although the colon had higher pre-treatment levels of CDI4+ macrophages, both
tissues had similar post-treatment (month 6) levels of these cells. However, it is important
to note that the frequency of these cells, in both the duodenum and colon, was still
substantially higher. than that observed for healthy uninfected individuals.
HIV-I infection had no effect on the expression of DC-SIGN on resident intestinal
macrophages (a cell population that lacked expression of CDI4, CD16, CDSO and CDS6)
in either the duodenum or colon, or in biopsies sampled before and after the initiation of
ART (Figure 3B). This finding suggests that the increase in macrophages expressing innate
response and co-stimulatory molecules is most likely due to an influx of newly recruited
inflammatory monocytes rather than alterations in the phenotype of resident macrophages.
Further analysis of the relationships among inflammatory markers revealed strong
positive correlations between CD14 and CDl6 (approaching significance, r=O.47, p=O.08),
CD80 and CD86 expression (Figure 6.3C) suggesting that these receptors are tightly co-
regulated. Based on these associations and IBD studies showing that CD14 expression
strongly correlates with pro-inflammatory cytokine production (23, 24), CD14 was
selected as a representative activation marker for further investigations.
6.2.4 Frequency of CD14+macrophages in the duodenum correlates with CD4+ T
cell levels. To investigate whether the increased recruitment of inflammatory macrophages
to the duodenum occurred in response to HIV-l, and whether this recruitment was
associated with increased microbial translocation, we examined the relationships between
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circulating plasma LPS and tissue levels of CD14+ macrophages, CD4+ T cells and HIV-l
RNA. The frequency of CD14+ macrophages in the duodenum was weakly correlated with
tissue CD4+ T cell levels (P=O.082) (Figure 6.4) suggesting that recruitment of activated
monocytes may be dependent on T cell help. In contrast, no correlations were detected
between CD14+ macrophages in the duodenum and either tissue viral loads or plasma LPS
also suggesting that in the absence of adequate CD4+ T cell help. inflammatory
macrophages in the duodenum had little impact on either viral replication or microbial
translocation.
6.2.5 Increased frequency of CD}4+ macrophages in the colon is positively
correlated with bacterial translocation and negatively correlated with tissue HIV-} RNA.
In contrast. in the colon, a tissue with a more preserved immune environment. no
correlation was detected between the frequency of CD14+ macrophages and CD4+ T cells.
Instead, we found a strong positive association between CD14+ macrophages and levels of
plasma LPS (P=O.002) and a weaker. but statistically significant (P=O.035) negative
correlation between CD14+ macrophages and tissue HIV-I RNA levels (Figure 6.5). Thus.
in the colon with a more intact immune system and higher levels of CD4+ T cell help.
HIV-l-related recruitment of inflammatory macrophages appears to be sufficient to induce
a response that is partially effective in controlling viral replication. However. in this
setting. the increased frequency of inflammatory macrophages may also produce increased
levels of inflammatory cytokines, damaging the epithelium and facilitating microbial
translocation and LPS-induced activation.
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6.3 DISCUSSION
AIDS in Africa was initially referred to as "slims disease" because of the large
number of HW -I-infected individuals presenting with severe complications of the orr
including diarrhea, inflammation, digestive dysfunction and lymphocyte depletion (25).
Recently, advances in understanding mucosal pathogenesis have provided critical new
insights into the potential causes of HW-I enteropathy and CD4+ T cell depletion and have
rekindled interest in the OIT as a major site of pathogenesis (1, 3). These studies have also
shown that, although there is a rapid and profound loss of T-helper cell function in the OIT
during acute infection, the largest reservoir of T cells in the body (26-28), progression to
AIDS is dependent on additional factors related to persistent viral replication, microbial
translocation and chronic immune activation (5, 29). However, it is still unclear whether
immune activation is a cause or consequence of bacterial translocation and the mechanisms
linking these various pathogenic factors to HW -1 pathogenesis in the OIT have not been
fully elucidated.
Here, I report that HW-I infection is also associated with changes in the frequency,
distribution and phenotype of intestinal macrophages and that these changes are associated
with regional differences in the extent of CD4+ T cell depletion. In the small intestine, a
region of intestine that is characterized by discrete lymphoid aggregations known as Peyer's
patches (16, 28), a near-complete depletion of CD4+ T cells was observed in all patients.
Despite this profound loss of CD4+ T cells, moderately high levels of viral replication were
still detectable in this tissue. In contrast, in the colon, a site that contains a diffuse
distribution oflymphoid aggregates (16, 28), CD4+ T cell depletion was less severe and more
variable suggesting that, in our patient cohort, this tissue had a more intact immune system
and a higher level of residual CD4+ helper T cell function. Consistent with the high
prevalence of CD4+ T target cells, the colon also had higher levels of HIV-I RNA. The
reasons for these clear-cut regional differences are not known, but may be related to the
unique structural and organizational properties of the two tissues. The intestine is the largest
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and most complex component of immune system and its functionally distinct regions may
affect the functional activities of its immune cells (16).
As recently reported for CDl3+ myelomonocytic cells in the terminal ileum (30), we
found that CD33+ macrophages were significantly depleted in both the duodenum and colon
of HIV-l-infected patients. As observed for CD4+ T cells, macrophage depletion was less
severe in the colon vs. the duodenum and, in 20% of patients, was associated with an altered
distribution. Instead of being concentrated immediately beneath the epithelium(14, 15), the
majority of colonic macrophages in these patients were diffusely distributed throughout the
lamina propria. Whether this altered pattern is due to a re-distribution of resident sub-
epithelial macrophages or an increased influx of newly-recruited monocytes remains to be
determined but, as discussed below, it is most likely due to a newly acquired population of
activated macrophages. Interestingly, six months after the initiation of antiretroviral therapy.
these intestinal macrophages displayed a typical sub-epithelial distribution suggesting that
the changes were HIV-l-related.
Following the initiation of ART there was a small but statistically significant increase
in both CD4+ T cells and CD33+ macrophages in the duodenum, but not in the colon.
Interestingly, the pattern of duodenal reconstitution was similar for both cell types and
involved a peak increase at 3 months followed by a small decrease at month 6. This pattern is
compatible with that observed in peripheral blood in which an initial redistribution of CD4+
T cells is followed by a more sustained period of "true" immune reconstitution (18-20). The
early restoration of these cell populations in the duodenum, where CD4+ T cell depletion
was more severe, is consistent with studies showing that patients with low peripheral blood
CD4+ T cell counts show a more rapid and dramatic increase in circulating CD4+ T cell
levels following the introduction of HAART (18-20). Although the mechanism is not known,
it has been suggested that this phenomenon may reflect a more intense homeostatic pressure
at the lower limits of CD4+ T cell renewal (18-20). Despite the lack of a baseline correlation
between tissue viral loads and the frequency of either CD4+ T cells or CD33+ macrophages,
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immune restoration in the duodenum was inversely related to the pattern of HIV-I RNA
clearance in this tissue suggesting that HIV-I is likely to be a primary determinant driving
the depletion of both cell types, either directly or indirectly.
Perhaps the most important finding, however, was that HIV-I infection is associated
with marked increase in the frequency of intestinal macrophages expressing co-stimulatory
(CD80, CD86) and innate response receptors for LPS (CDI4) and immunoglobulin G
(CDI6). The increase in these receptors, which was detected in the absence of enteric co-
infections, was consistently 2- to 3-fold greater in the colon compared the duodenum.
Interestingly, these "inflammatory-like" changes are highly reminiscent of the events
occurring during inflammatory bowel disease (IBD) (31-33). In IBD, this dysregulated
immune response is independent of CD4+ T cell depletion and is directed against harmless
luminal microflora rather than a virus such as HIV-I (34). Furthermore, IBD pathogenesis is
related to defects in antigen presenting cell (APC) function and APC-T cell interactions that
result in aberrant T cell responses and ultimately, chronic inflammation (34). Although these
interactions are likely to be more complex in the presence of HIV-I, the observed
upregulation of co-stimulatory molecules on intestinal macrophages may also drive
inflammation and aberrant T cell responses in the GIT of HIV-I-infected individuals.
Moreover, the upregulation of CDI4+ receptors on these cells may result in increased
responsiveness to bacterial products (23). In the context of increased permeability of the
epithelial barrier (a process that begins in acute infection) and increased microbial
translocation (3, 5, 6), enhanced expression of CDI4 suggests a mechanism whereby
microbe-mediated activation of intestinal macrophages may fuel chronic inflammation.
In contrast to the up-regulation of innate response and co-stimulatory molecules,
there were no significant changes in the frequency of duodenal or colonic macrophages
expressing DC-SIGN. Thus, these "resident" DC-SIGW macrophages (which do not express
CD14, CDI6, CD80 or CD86) (21, 22) do not appear to be affected by either HIV-I or ART.
This finding is consistent with in vitro studies showing that resident intestinal macrophages
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do not exhibit the same plasticity as other tissue macrophages and cannot be induced to
express innate or co-stimulatory molecules (13). Collectively, these data suggest that HIV-I-
associated alterations in the phenotype of intestinal macrophages are the result of an
increased recruitment of "inflammatory" monocytes rather than a switch from a resident to
an activated phenotype. This view has important implications for treatment strategies. By
limiting the ongoing recruitment of inflammatory monocytes it may be possible to prevent
microbial translocation and reduce inflammation.
To investigate the potential implications of macrophage activation on HIV-I
pathogenesis, I examined the tissue-specific relationships between macrophage activation,
tissue viral loads, CD4 T cell depletion and microbial translocation as measured by
circulating levels of plasma LPS. In the duodenum, a site of severe immune deficiency, I
observed a weak positive correlation between the frequency of CD4+ T cells and CDI4+
macrophages suggesting that the recruitment of inflammatory monocytes may be dependent
on T cell help. No correlation was observed between CD14+ macrophages and tissue viral
loads in the duodenum also suggesting that a minimal level of CD4+ T cell help may be
required to mediate a protective response. In contrast, a negative correlation was observed
between the frequency of CDI4+ macrophages and tissue viral loads in the colon suggesting
that, in the presence of sufficient CD4+ T cell help, activated "inflammatory-like"
macrophages were able to contribute to the control of HIV-I infection and replication.
In contrast, I observed a strong positive correlation between the frequency of CD14+
macrophages in the colon and plasma LPS suggesting that activated intestinal macrophages
may also playa key role in driving microbial translocation and systemic immune activation.
Although microbial translocation may occur in other regions of the GIT, it seems logical that
the majority of bacterial products would be derived from colon, a site that contains extremely
high levels of commensal bacteria (35, 36). Interestingly, in IBD, both microbial
translocation and intestinal barrier permeability are tightly linked to macrophage activation.
In particular, increased secretion of IL-12 by activated macrophages has been linked to
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elevated levels of IFN-y production in T cells, a process that leads to increased epithelial
permeability and further enhancement of macrophage activation and microbial
translocation(15). Similar to mD, macrophage activation seems to be a key factor driving
microbial translocation in HN-l infected individuals.
Based on these findings, I hypothesize that intestinal macrophages may serve as the
missing link for unraveling the complex interactions between HN -1 pathogenesis. host
immunity and microbial translocation. While macrophage activation may be required to
mount an effective immune response against HIV-l in the acute phase of infection, chronic
immune activation may lead to aberrant T cell responses, amplification of localized
inflammation and increased microbial translocation. Thus, the key to controlling the chronic
manifestations of HN-l disease in the gastrointestinal may involve interrupting the
continuous recruitment of inflammatory monocytes to sites of tissue pathogenesis.
Importantly, in the central nervous system, increased recruitment and differentiation of
CDI4+CDI6+ monocytes (a subset of inflammatory monocytes that is upregulated in HIV-l
infection) into perivascular macrophages has been strongly linked to the development of
AIDS-associated dementia (37-39). Available data, together with results of the current study,
suggest that an improved understanding of monocyte/macrophage activation may lead to new
insights for the prevention and treatment of HN -l-associated pathogenicity.
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6.4 TABLES
Table 1: Clinical Characteristics of AIDS patients
BASELINE
Gender Male n.8
Female n .10
Age (years) Mean ± S.D. 34.9 ± 10.5
CD4 count (celis/ill) Mean ± S.D. 106 ± 96
Viral Load (log copies/ml) Mean ± S.D. 4.93 ± 1.00
HAART 3TC/D4T/NVP n.6
3TC/D4T/EFZ n -11
TREATMENT
CD4 count (celis/ill) Month 3 206 ± 124
Month 6 218 ± 111
Viral Load (log copies/ml) Month 3 2.49 ± 1.15
Month 6 <LDL
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6.5 FIGURE LEGENDS
FIGURE 6.1. Differences in the extent of HIV-l RNA clearance and CD4+ T cell
restoration in the duodenum vs colon of African AIDS patients. A. CD4+ T cell
depletion was more severe in the duodenum and showed significant reconstitution after
ART. Results are reported as the mean frequency of CD4+ T cells (± S.D, n=18.) in the
lymphocyte gate at baseline, and at month 3 and 6 post-ART. Statistical significance
(p>O.05) between time points is indicated by an asterisk. B. ART was associated with a
significant reduction in tissue HIV-1 RNA as early as 3 months after the initiation of
treatment. Viral RNA levels were measured using Nuc1isens Easy Q HIV-l v.1.2 kit and
results are reported as the number of HIV RNA copies per mg of tissue. Data is presented
as the mean viral load of the study cohort (n=18, *p<O.05). C. Degree of CD4+ T cell
depletion does not correlate with tissue HIV-l RNA levels. CD4+ T cell depletion in the
colon and duodenum were compared using the Spearman correlation test.
FIGURE 6.2. HIV-l infection was associated with macrophage depletion in the
duodenum and colon, and with an altered distribution of colonic macrophages. A.
Depletion of macrophages was more severe in the duodenum and showed significant
reconstitution after ART. The frequency of macrophages was evaluated based on CD33
expression. Results are reported as the mean frequency of CD33+ cells after excluding
debris and lymphocytes (n=18, *p<O.05). The dotted line illustrates the average frequency
of CD33+ cells in HIV-l negative controls. B. In a subset of patients, HIV-l infection in
the colon was associated with an alteration in the distribution of macrophages from a
normal sub-epithelial (HIV-l" and HIV-I+ phenotype) to a diffusely scattered pattern
(HIV+ phenotype 2). CD6S+ macrophages (brown cells) were visualized with a non-biotin
peroxidase detection system and 3,3' diaminobenzidine free chromogen (40X original
magnification). C. Alterations in macrophage distribution were resolved by ART. Results
shown are representative of 2 of 10HIV-I+ AIDS patients tested at baseline and at month
6 after the initiation of ART.
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FIGURE 6.3. HIV·l infection was associated with increased expression of CD14 on
intestinal macrophages. A. ART decreased the HIV-l-induced up-regulation of CD14
macrophages in the colon. The frequencies of inflammatory macrophages were calculated
by determining the percentage of CD33+ cells that were CD14+. Results are expressed as
the means of all study patients (n=18, *p<0.05). B. DC-SIGN, a marker expressed on
resident macrophages, was not altered by either HIV-l infection or ART. The data
obtained by flow cytometry is expressed as mean value (± S.D.). The frequency of DC-
SIGW macrophages represents the percentage of CD33+ cells that are also DC-SIGW. C.
CD14 expression on macrophages was positively correlated with other inflammatory
molecules. The relationship between CD14 expression and co-stimulatory molecules was
assessed using Spearman correlation test. Results were considered significant if p<O.OS.
Correlations were considered strong if r > 0.6.
FIGURE 6.4. Frequency of CD14+ macrophages in the duodenum was weakly
correlated with CD4+ T cell levels. Relationships between CD14+ expression on duodenal
macrophages and CD4+ T cell depletion, tissue viral loads and circulating levels of LPS
were assessed using Spearman correlation. Results were considered significant if p<O.OS.
Correlations were considered strong if r > 0.6.
FIGURE 6.5. In the colon, the frequency of CD14+ macrophages was negatively
correlated with tissue levels of HIV·l RNA and positively correlated with plasma
LPS. Relationships between CDI4+ expression on colonic macrophages and CD4+ T cell
depletion, tissue viral loads and circulating levels of LPS were assessed using the
Spearman correlation test. Results were considered significant if p<0.05. Correlations were
considered strong if r > 0.6.
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CHAPTER 7
CONCLUSIONS ANDPERSPECTIVES FOR IMMUNE BASED THERAPIES
7.0 DISCUSSION
RN-l is the most studied pathogen in recorded human history. Although this
intense focus on RIV-lIAIDS has led to major advances in the diagnosis and treatment of
retroviral infections (ie. the first antiretroviral drugs were developed against RN-I), there
is still no vaccine or therapeutic "cure" for AIDS. Nevertheless, the introduction of
HAART has dramatically improved the duration and quality of life for individuals infected
with RN-I. In the US alone, it is estimated that more than 3 million years of life have
been saved since the introduction of HAART in 1996 (1). Unfortunately, the cost of these
drugs is prohibitive and beyond the reach of many developing countries. Furthermore,
prolonged administration of HAART often leads to toxicity, the emergence of drug
resistance and ultimately therapeutic failure (2). The relative inability of HAART to
completely suppress HIV-1 for prolonged periods of time has been attributed to host,
pharmacological and viral factors including the establishment of viral reservoirs (3-5). As
discussed below, strategies aimed at suppressing immune activation have the potential to
enhance the efficacy of HAART and eliminate HN -1 in viral reservoirs.
It is becoming increasingly apparent that HIV-1 transmission and pathogenesis are
intimately related to the activation state of the host immune system (6-8). Although
activation is essential to mount an effective response, it also provides an environment that
drives RN replication and disease progression (9). Increased levels of immune activation
correlate with CD4+ T cell depletion (10-13) and, in patients with AIDS, activation is a
stronger predictor of progression than plasma viral load (6). In addition to enhancing HN-
1 replication (14-17), chronic immune activation leads eventually to exhaustion and
dysfunction of the host immune system (18-21). Recent comparative studies of SIV
provided further evidence of the importance of immune activation in mediating SN
pathogenesis (22,23). These studies have shown that AIDS is not an inevitable
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consequence of infection and that the main feature distinguishing pathogenic SlY infection
in macaques (and HN-l in human) from natural (non-pathogenic) infection in sooty
mangabeys and chimpanzees is a heightened state of chronic immune activation
throughout the course of the disease (22-24). Understanding the factors driving high levels
of immune activation is likely to provide new insights into the development of more
effective therapeutics.
The above findings offer considerable hope for millions of people in Africa and
other regions of the developing world where most individuals only become aware of their
infection status during the late stages of disease. The findings suggest that prevention of
immune activation during chronic infection may serve to prevent (or delay) the onset of
severe immune deficiency and AIDS. Thus, there is an urgent need to determine whether
recent SlY data can be directly extrapolated to HN-l and whether the suppression (or
elimination) of systemic immune activation, when used in conjunction with antiretroviral
therapy, can prevent AIDS. It is of note that previous immune-based treatment strategies,
including various protocols of structured treatment interruption (STI), focused on
activating rather than suppressing the host immune system (25-27). The rationale behind
STI, for example, was to allow for a transient re-expression of HN-l in latently infected
cells. The goal was to render the cryptic virus visible to immune recognition and
elimination. Another strategy was based on the administration of intermittent cycles of IL-
2. This approach was based on phase II trials showing that treatment with IL-2 led to
sustained and stable increases of peripheral CD4 T cell counts particularly in conjunction
with HAART (28-30). However, recent results from two lengthy phase III trials (SIILCAT
and ESPRIT) presented at CROI in Feb 2009 unequivocally demonstrated that HAART
plus IL-2 offered no additional protection from death and AIDS-defining events when
compared to HAART alone (see www.retroconference.org/2009).Todate.STland other
immune-enhancing strategies have met with only limited success (26,27), presumably due
to an insufficient body of basic knowledge relating to the complexity of HIY-llhost
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interactions, especially as it relates to the beneficial vs. harmful effects of immune
activation.
In order to develop strategies capable of suppressing the harmful effects of immune
activation, we first need to identify the factors driving chronic stimulation in HIV -1-
infected patients. Studies have repeatedly demonstrated that HIV-1 antigenic stimulation is
a major force fuelling immune activation and that antiretroviral therapy, by decreasing
viral load, can reduce immune activation (31,32). However, other recent studies have
suggested that increased translocation of bacterial products from the lumen of the GIT (due
to early HIV-l-related damage to epithelium barrier) into the circulation may also play a
critical role in activation (22,23). Elimination of microbial-driven activation will depend,
in large part, on whether the damage to the GIT is reversible and can be repaired.
Furthermore the involvement of bacterial microbes suggests that activation of innate
immune responses may play an important and pivotal role in mediating and amplifying the
pathogenic immune activation syndrome that accompanies and at least partial1y drives
HIV-I disease evolution.
Most studies of HIV-I and immune activation have focused on C04+ and COS+
lymphocytes. The reason for the disproportionate emphasis on T cel1s relates, in large
measure, to the fact that CD4+ T cells are the primary targets and the major site of virus
production, and that progressive CD4+ T cell depletion is a fundamental hallmark of HIV-
lIAIDS (33). Alternatively, CD8+ T cells are responsible for HIV-I-specific CTL
responses and contribute to the control of viral replication by releasing CCRS-binding
chemokines and other soluble antiviral factors (34, 35). However, cells of the MP lineage
also playa critical role both in the initial establishment of HIV-1 infection and throughout
the course of HIV-lIAIDS. This is not surprising given the HIV-I is a member of the
lentivirus subfamily of retroviruses. Indeed, animals infected with lentirviruses
demonstrate that cells of the MP system (including bone marrow precursor cells,
monocytes and fully differentiated tissue macrophages) are often the primary target of
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infection. For example, Maedi- Visna Virus (MVV), a virus that causes pulmonary disease
in sheep, infects only macrophages and DC and is accompanied by a wasting syndrome
similar to HN -1 enteropathy and a brain disease resembling AIDS deinentia (36,37).
Another reason that cells of the MP system have received less attention than T cell
is that they are difficult to study by non-invasive techniques (38). Cells of this MP lineage
exhibit a high level of heterogeneity, inter-donor variability and extreme plasticity. In
addition, tissue macrophages are easily activated during the course of cell isolation (39,
40). In vitro surrogate models (cell lines, primary MDM) have proven valuable for
unraveling the complexities of HN -1 entry and replication in macrophages and for
assessing the response of macrophages to antiretroviral therapy (38). However, there are
no guarantees that data obtained from in vitro studies will be representative of events
occurring at the patient level. Similarly, studies of SlY conducted in non-human primates
may not be a true reflection of HN-I pathogenesis in humans. Thus, a multi-faceted
approach involving both in vitro and ex vivo studies may provide the best chance for
obtaining critical new information on the role of macrophages in HIV-1 pathogenesis.
This thesis has used a multi-pronged in vitro and patient-based approach to address
questions relating to the relationships between HIV-I, macrophage activation/polarization
and microbial translocation. Chapters 2, 3 and 4 of the thesis examine the role of
macrophage polarization (MI vs. M2a) in the regulation of viral replication and the
establishment of productive vs. latent infection. To our knowledge this is one of the first
studies to demonstrate that HN -1 can be differentially modulated by cytokine-induced
changes in the phenotypic and functional properties of primary MDM. Importantly, it was
also observed that MI activation appears to protect macrophages from infection, whereas
M2a activation and polarization may drive the formation of viral reservoirs. M2a. but not
MI polarization, was also associated with an increased the capacity of macrophages to
transmit HN-I to CD4+ T cells. Based on these results, it seems reasonable to hypothesize
that strategies aimed at suppressing replication and driving the host immune system toward
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an Ml phenotype may be helpful in controlling HIV-l in macrophages and in preventing
macrophage-to- T cell transmission.
Chapters 5 and 6 describe ex vivo studies conducted on peripheral blood and
gastrointestinal biopsies obtained from antiretroviral-naive African patients with late-stage
HIV-l disease and no evidence of opportunistic co-infections such as tuberculosis, CMV
or enteric pathogens. Results from Chapter 5 revealed that Africans, both HIV-l-infected
and uninfected, have higher levels of immune activation than their North America and
European counterparts. Monocyte activation was higher in infected compared to
uninfected Africans and was associated with an increase in the plasma ratio ofIL-lO:IL-12
suggesting that, at least in this group of patients, HIV-I infection was associated with a
shift towards an alternative (M2) monocyte activation profile. Interestingly, some of these
monocyte activation markers were positively correlated with HIV-I viremia (CCL2,
CDl6) where as others (sCDI4, TNF) showed a strong positive correlation with plasma
LPS suggesting that HIV -l and microbial translocation contribute differentially to the
activation of monocytes. Thus, HAART, on its own, may not be sufficient to eliminate all
aspects of monocyte activation and consequent disease progression.
Finally, Chapter 6 reveals that, similar to inflammatory bowel disease (IBD), HIV-
1 infection is associated with increased recruitment of inflammatory macrophages into the
lamina propria of the intestine and that these cells appear to playa bi-functional role in
controlling viral replication and mediating bacterial translocation. Based on these findings,
it seems reasonable to hypothesize that approaches aimed at decreasing inflammation and
host responsiveness to bacterial products, and of promoting protection and repair of the
mucosal barrier of the GIT, may help reduce microbe-driven activation. The data also
suggests that approaches used to treat Crohn's disease, for example anti-TNF Ab, may also
prove useful in the treatment of HIV-L Alternative approaches aimed at limiting the
recruitment of inflammatory monocytes to the GIT (and tissues such as the brain) may also
prove effective in reducing HIV -I-associated disease pathogenesis.
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In summary, the prevention and treatment of HIV-lIAIDS has proven to be a
formidable task. Despite these daunting challenges, significant incremental progress has
been made through intense effort and dedication. I truly believe that an improved
understanding of monocyte-macrophages and innate immunity responses in HIV infection
may point the way to future advances in therapeutic intervention.
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